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1 
A comprehensive summary of the work to be incorporated in the thesis entitled 
“Development, validation and application of analytical methods for bioactive 
compounds” has been describe as under, 
  
PART - [A]:  HPLC METHOD DEVELOPMENT AND VALIDATION OF SOME  
PHARMACEUTICAL FORMULATIONS. 
PART - [B]:  UPLC METHOD DEVELOPMENT AND VALIDATION OF 
TICLOPIDINE HYDROCHLORIDE. 
PART - [C]:  SPECTROPHOTOMETRIC METHOD DEVELOPMENT AND 
VALIDATION OF TICLOPIDINE HYDROCHLORIDE. 
 
PART-[A]:  HPLC METHOD DEVELOPMENT AND VALIDATION OF SOME  
PHARMACEUTICAL FORMULATIONS. 
 
The research work undertaken in these studies mainly addresses analysis, 
development of stability indicating HPLC methods and validation protocol, according to 
ICH guidelines.  
Aim of work 
To develop stability indicating high performance liquid chromatographic method 
for the estimation of some active pharmaceutical ingredient from their single/combine 
pharmaceutical dosage forms by HPLC and to perform the validation procedure for same. 
 
EXPERIMENTAL WORK  
Development of analytical method   Validation of analytical method 
Selection of mobile phase   Specificity  
Selection of stationary phase     Linearity and range  
Choice of flow-mode and flow rate  Precision & Intermediate precision  
Wave-length    Accuracy  
Injection volume / Concentration  Robustness  
Selection of diluents    Solution stability  
Synopsis… 
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We have undertaken work on different bioactive compounds which are described 
as under the following section, 
Section-I: Studies on Ticlopidine hydrochloride 
Ticlopidine hydrochloride is an inhibitor of platelet aggregation used in the 
management and prevention of thromboembolic disorders. Ticlopidine hydrochloride is 
chemically 5-[(2-chlorophenyl) methyl]-4, 5, 6, 7-tetrahydrothieno [3, 2-c] pyridine 
hydrochloride [Fig.1]. Its molecular formula is C14H14ClNS.HCl having molecular weight 
300.25 g/mole. It is used as adenosine diphosphate [ADP] receptor antagonists in an 
antiplatelet therapy. It is also significantly reduces restenosis after endovascular therapy 
in femoropopliteal lesions.  
 
 
N
S
Cl
ClH.
 
[1] 
 
 
Developed chromatographic parameters are as under 
Mobile phase: -  Buffer: Metanol (20: 80, v/v) 
Buffer: 0.01 M ammonium acetate buffer, pH 5.0 with glacial 
acetic acid 
Column: -   Phenomenex luna C8, 4.6 x 250mm, 5µ  
Flow rate: -  1 ml/min 
Wavelength: -  235 nm 
Injection volume: - 20 µl       
Diluent: -   Methanol 
 The developed procedure has been evaluated over the specificity, linearity, 
accuracy, precision, limit of detection, limit of quantification and robustness in order to 
ascertain the stability of the analytical method. It has been proved that it was specific, 
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3 
linear, precise, accurate and robust and stability indicating. Hence, the method is 
recommended for routine quality control analysis and also stability sample analysis. 
 
Section-II: Studies on Spironolactone and Furosemide 
Spironolactone is chemically 7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17-
carbolactone [Fig.2]. Its molecular formula is C24H32O4S having molecular weight 416.58 
gm/mole. Spironolactone inhibits the effect of aldosterone by competing for intracellular 
aldosterone receptors in the distal tubule cells. Furosemide is chemically 4-Chloro-2-
(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid [Fig.3]. Its molecular formula is 
C12H11ClN2O5S  having molecular weight 330.74gm/mole. Furosemide, an anthranilic 
acid derivative, is a potent diuretic that inhibits the active reabsorption of chloride in the 
diluting segment of the loop of Henle, thus preventing the reabsorption of sodium, which 
passively follows chloride. This loop diuretic is commonly used for the treatment of renal 
diseases, congestive heart failure and hypertension. 
O
S
O CH3
O
O
Cl
S
O
NH2
O
O OH
NH
O
 
         [2]    [3] 
 
Developed chromatographic parameters are as under 
Mobile phase: -  Buffer: Acetonitrile: (50: 50, v/v) 
Buffer: 0.01M ammonium acetate buffer pH 3.9 with glacial acetic 
acid 
Column: -   Wakosil II 5C8RS 4.6 x 150mm, 5 μm  
Flow rate: -  1 ml/min 
Wavelength: -  254 nm 
Injection volume: - 20 µl       
Diluent: -   Water: Acetonitrile: Methanol (50: 20: 30, v/v)   
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The developed procedure has been evaluated over the specificity, linearity, 
accuracy, precision, limit of detection, limit of quantification and robustness in order to 
ascertain the stability of the analytical method. It has been proved that it was specific, 
linear, precise, accurate and robust and stability indicating. Hence, the method is 
recommended for routine quality control analysis and also stability sample analysis. 
 
Section-III: Studies on Lamotrigine  
Lamotrigine is chemically 6-(2, 3-Dichlorophenyl)-1, 2, 4-triazine-3, 5-diamine 
[Fig.4] and its molecular formula is C9H7N5Cl2, and molecular weight is 256.09 gm/mole. 
Lamotrigine, an antiepileptic drug (AED) of the phenyltriazine class, is chemically 
unrelated to existing antiepileptic drugs, has been used successfully to treat essential 
trigeminal neuralgia. 
 
N
N
N
Cl
Cl
NH2NH2  
[4] 
  
Chromatographic parameters 
  
Mobile phase: -  Buffer: Methanol (50: 50, v/v)  
         Buffer: 0.01M Ammonium acetate  
Column: -   Phenomenex luna C8, 4.6 x 250mm, 5µ  
Flow rate: -  0.8 ml/min 
Wavelength: -  225 nm 
Injection volume: - 20 µl       
Diluent: -   Water: Methanol (50: 50, v/v)   
 
The developed procedure has been evaluated over the specificity, linearity, 
accuracy, precision, limit of detection, limit of quantification and robustness in order to 
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ascertain the stability of the analytical method. It has been proved that it was specific, 
linear, precise, accurate and robust and stability indicating. Hence, the method is 
recommended for routine quality control analysis and also stability sample analysis. 
 
PART - [B]:  UPLC METHOD DEVELOPMENT AND VALIDATION OF 
TICLOPIDINE HYDROCHLORIDE. 
The research work undertaken in this study in the area of pharmaceuticals and 
mainly addresses method development for determination of ticlopidine hydrochloride in 
drug product by UPLC. Developed analytical method was validated for its intended 
application as per ICH guideline.  
 
Aim of work 
To develop stability indicating ultra performance liquid chromatographic method 
for the estimation of ticlopidine hydrochloride from their pharmaceutical dosage form by 
UPLC and to perform the validation procedure for same. 
 
Developed Chromatographic parameters are as under 
Mobile phase: -   Buffer: Methanol (20: 80, v/v) 
Buffer: 0.01 M ammonium acetate buffer, pH 5.0 with 10% 
glacial acetic acid 
Column: -    Zorbax SB C18 50 x 4.6 mm, 1.8μm  
Flow rate: -   0.8 ml/min 
Wavelength: -   235 nm 
Injection volume: -  4.0 µl       
Column ovan temp: -  35 °C 
Sample temp: -   15 °C 
Diluent: -    Methanol 
 The developed procedure has been evaluated over the specificity, linearity, 
accuracy, precision and robustness in order to ascertain the stability of the analytical 
method. It has been proved that it was specific, linear, precise, accurate and robust and 
stability indicating. Hence, the method is recommended for routine quality control 
analysis and also stability sample analysis. 
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PART - [C]:  SPECTROPHOTOMETRIC METHOD DEVELOPMENT AND 
VALIDATION OF TICLOPIDINE HYDROCHLORIDE. 
The research work undertaken in this study in the area of pharmaceuticals and 
mainly addresses method development for determination of ticlopidine hydrochloride in 
drug product by UV Visible spectrophotometer. Developed analytical method was 
validated for its intended application as per ICH guideline.  
 
Aim of work 
To develop spectrophotometric method for the estimation of ticlopidine 
hydrochloride from their pharmaceutical dosage form by UV Visible spectrophotometer 
and to perform the validation procedure for same. 
 
Developed spectrophotometric parameters are as under 
 
Detection: -  233 nm 
Cell pathlength: - 1 cm 
Diluent: -   Methanol: Water (70: 30, v/v) 
 
 The developed procedure has been evaluated over the specificity, linearity, 
accuracy, precision and robustness in order to ascertain the stability of the analytical 
method. It has been proved that it was specific, linear, precise, accurate and robust. 
Hence, the method is recommended for routine quality control analysis and also stability 
sample analysis. 
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1. NEED FOR DRUG ANALYSIS 
The number of drugs introduced into the market is increasing every year. These 
drugs may be either new entities or partial structural modification of the existing one [1]. 
Very often there is a time delay from the date of introduction of a drug into the market to 
the date of its inclusion in pharmacopoeias. This happens because of the possible 
uncertainties in the continuous and wider usage of these drugs, reports of new toxicities 
(resulting in their withdrawal from the market), development of long-suffering opposition 
and introduction of better drugs by competitors. Under these conditions, standards and 
analytical procedures for these drugs may not be available in the pharmacopoeias. It 
becomes necessary, therefore to develop newer analytical methods for such drugs. 
Also quality is important in every product or service but it is vital in medicines as 
it involves life. Quality control is a concept, which strives to produce a perfect product by 
series of measures designed to prevent and eliminate errors at different stage of 
production. The decision to release or reject a product is based on one or more type of 
control action. With the growth of pharmaceutical industry during last several years, there 
has been rapid progress in the field of pharmaceutical analysis involving complex 
instrumentation. Providing simple analytical procedure for complex formulation is a 
matter of most importance. 
In brief, the reasons for the development of newer methods of drug analysis are: 
 The drug or drug combination may not be official in any pharmacopoeias, 
 A proper analytical procedure for the drug may not be available in the literature due 
to patent regulations, 
 Analytical methods may not be available for the drug in the form of a formulation due 
to the interference caused by the formulation excipients, 
 Analytical methods for the quantitation of the drug in biological fluids may not be 
available, 
 Analytical methods for a drug in combination with other drugs may not be available, 
 The existing analytical procedures may require expensive reagents and solvents. It 
may also involve cumbersome extraction and separation procedures and these may 
not be reliable. 
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2. CHROMATOGRAPHIC METHODS [2,3] 
Modern pharmaceutical formulations are complex mixtures containing one or 
more therapeutically active ingredients, to a number of inert materials like excipients, 
disintegrates, colors and flavors. In order to ensure quality and stability of the final 
product, the pharmaceutical analyst must be able to separate the mixtures into individual 
components prior to quantitative analysis.  
Chromatography is the powerful techniques in which differential migration of 
components take place between two phases, one is stable which is known as stationary 
phase and another is movable which is known as a mobile phase. Species in the sample 
undergo repeated interactions (partitions) between the mobile phase and stationary phase. 
The stationary phase may be solid or a liquid (supported on a solid or a gel), and packed 
in a column, spread as a layer or film. The mobile phase may be gaseous or liquid. Those 
solutes, distributed preferentially in the mobile phase, will move rapidly through the 
system than those distributed preferentially in the stationary phase. This forms the basis 
of separation of component present in a sample [4]. The distribution of a solute between 
two phases results from the balance of forces between solute molecules and the molecule 
of each phase.  It reflects the relative attraction or repulsion that molecule or ions of the 
competing phase shown for the solute and for them.  These forces can be polar in nature 
arising from permanent on induced and dipole moment. In ion exchange chromatography, 
the forces on the solute molecules are substantially ionic in nature but include polar and 
non-polar forces as well. 
 
Chromatographic method must having essentially, 
 Stationary phase, 
 Mobile phase, 
 Sample injection system, 
 Solvent delivery system , 
 Column (support for stationary phase), 
 Detection by detecting agent. 
         All chromatographic methods involve modifications in these basic components.  
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Classification of Chromatographic Methods [5]
 
CHROMATOGRAPHY 
Gas Chromatography Liquid Chromatography
Gas liquid  
Chromatography (GLC)
Gas Solid 
           Chromatography (GSC)
Liquid-liquid  
Chromatography 
Liquid Soild  
Chromatography 
(LSC)
lon exchange 
Chromatography 
(IEC)
Exclusion 
Chromatography 
(EC)
 
 
Bonded 
phase 
Chromatography
Ion pair  
Chromatography
 
Chromatographic methods can be classified according to the nature of the stationary and 
mobile phases [6].   
The different types of chromatography are:  
1. Adsorption chromatography  
2. Partition chromatography   
3. Ion exchange chromatography  
4. Size exclusion or gel permeation chromatography.  
 The modern instrumental techniques of GLC and HPLC provide excellent 
separation and allow accurate assay of very low concentrations of wide variety of 
substance in complex mixtures. 
 
2.1 High Performance Liquid Chromatography (HPLC)[7-9] 
 This is a sophistication of the century-old technique and is the most widely used 
of all the analytical separation techniques. In high performance liquid chromatography 
(HPLC) the liquid mobile phase is forced through the stationary phase under pressure. A 
simple HPLC includes a solvent reservoir to hold the mobile phase, a pump to pressurize 
the mobile phase, and injector to allow injection of a small volume of the sample mixture 
under high pressure, a column containing the bed of stationary phase, a detector to detect 
the presence of components as they exit the column, and a recorder to record the detector 
signal [10]. 
Most of the drugs in dosage forms can be analyzed by HPLC method because of 
the several advantages like rapidity, specificity, accuracy, precision and ease of 
Introduction… 
 
 
 
10 
automation in this method. HPLC method eliminates tedious extraction and isolation 
procedures. Some of the advantages are [11]: 
 Speed (analysis can be accomplished in 20 minutes or less), 
 Greater sensitivity (various detectors can be employed), 
 Improved resolution (wide variety of stationary phases), 
 Reusable columns (expensive columns but can be used for many analysis), 
 Ideal for the substances of low volatility, 
 Easy sample recovery, handling and maintenance, 
 Instrumentation tends itself to automation and quantitation (less time and less   
labor), 
 Precise and reproducible, 
 Calculations are done by integrator itself, 
 Suitable for preparative liquid chromatography on a much larger scale. 
There are different modes of separation in HPLC. They are normal phase mode, 
reversed phase mode, reverse phase ion pair chromatography, affinity chromatography 
and size exclusion chromatography (gel permeation and gel filtration chromatography) 
[12]. 
In the normal phase mode, the stationary phase is polar and the mobile phase is 
nonpolar in nature. In this technique, nonpolar compounds travel faster and are eluted 
first. This is because of the lower affinity between the nonpolar compounds and the 
stationary phase. Polar compounds are retained for longer times because of their higher 
affinity with the stationary phase. These compounds, therefore take more times to elute. 
Normal phase mode of separation is therefore, not generally used for pharmaceutical 
applications because most of the drug molecules are polar in nature and hence take longer 
time to elute.  
Reversed phase mode is the most popular mode for analytical and preparative 
separations of compound of interest in chemical, biological, pharmaceutical, food and 
biomedical sciences. In this mode, the stationary phase is nonpolar hydrophobic packing 
with octyl or octa decyl functional group bonded to silica gel and the mobile phase is 
polar solvent. An aqueous mobile phase allows the use of secondary solute chemical 
equilibrium (such as ionization control, ion suppression, ion pairing and complexation) to 
control retention and selectivity. The polar compound gets eluted first in this mode and 
nonpolar compounds are retained for longer time. As most of the drugs and 
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pharmaceuticals are polar in nature, they are not retained for longer times and hence elute 
faster. The different columns used are octa decyl silane (ODS) or C18, C8, C4, etc., (in 
the order of increasing polarity of the stationary phase) [13]. 
In ion exchange chromatography, the stationary phase contains ionic groups 
like NR
3+
 or SO
3-
 , which interact with the ionic groups of the sample molecules. This is 
suitable for the separation of charged molecules only. Changing the pH and salt 
concentration can modulate the retention.  
Ion pair chromatography may be used for the separation of ionic compounds 
and this method can also substitute for ion exchange chromatography. Strong acidic and 
basic compounds may be separated by reversed phase mode by forming ion pairs 
(columbic association species formed between two ions of opposite electric charge) with 
suitable counter ions. This technique is referred to as reversed phase ion pair 
chromatography or soap chromatography.  
Affinity chromatography uses highly specific biochemical interactions for 
separation. The stationary phase contains specific groups of molecules which can adsorb 
the sample if certain steric and charge related conditions are satisfied. This technique can 
be used to isolate proteins, enzymes as well as antibodies from complex mixtures.  
Size exclusion chromatography separates molecules according to their molecular 
mass. Largest molecules are eluted first and the smallest molecules last. This method is 
generally used when a mixture contains compounds with a molecular mass difference of 
at least 10%. This mode can be further subdivided into gel permeation chromatography 
(with organic solvents) and gel filtration chromatography (with aqueous solvents). 
 
Fig: 1 A schematic diagram of HPLC equipment 
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Various components of HPLC are [14, 15]:
                             
 
(a) A solvent delivery system, including pump,   (b) Sample injection system, 
(C) A chromatographic column,   (d) A detector, 
(e)  A strip chart recorder,   (f) Data handling device and microprocessor control. 
    
a) Solvent delivery system [16,17] 
A mobile phase is pumped under pressure from one or several reservoir and flows 
through the column at a constant rate. For normal phase separation-eluting power 
increases with increasing polarity of the solvent but for reversed phase separation, eluting 
power decreases with increasing polarity. A degasser is needed to remove dissolved air 
and other gases from the solvent. Special grades of solvents are available for HPLC and 
these have been purified carefully in order to remove absorbing impurities and particulate 
matter to prevent these particles from damaging the pumping or injection system or 
clogging the column. 
 
Pumps 
The pump is one of the most important components of HPLC, since its 
performance directly affects retention time, reproducibility and detector sensitivity. Three 
main types of pumps are used in HPLC to propel the liquid mobile phase through the 
system. These are:  
I. Displacement pump 
 It produces a flow that tends to independent of viscosity and backpressure and also 
output is pulse free. But it possesses limited capacity (250 ml).  
II. Reciprocating pump 
It has small internal volume (35 to 400 µl), their high output pressure (up to 
10,000 psi) and their constant flow rates. But it produces a pulsed flow. 
III. Pneumatic or constant pressure pump 
They are pulse free; suffer from limited capacity as well as a dependence of flow 
rate on solvent viscosity and column backpressure. They are limited to pressure 
less than 2000 psi.  
 
b) Sample injection system 
Insertion of the sample onto the pressurized column must be as a narrow plug so 
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that the peak broadening attributable to this step is negligible. The injection system itself 
should have no dead (void) volume. 
There are three important ways of introducing the sample into injection port: 
 Loop injection: In which, a fixed amount of volume is introduced by making use of 
fixed volume loop injector. 
 Valve injection: In which, a variable volume is introduced by making use of an 
injection valve. 
 On column injection: In which, a variable volume is introduced by means of a 
syringe through a septum. 
 
c) Chromatographic column 
The column is usually made up of heavy glass or stainless steel tubing to 
withstand high pressure. The columns are usually 10-30 cm long and 4-10 mm inside 
diameter containing stationary phase at particle diameter of 25 µm or less. Columns with 
an internal diameter of 5 mm give good results because of compromise between 
efficiency, sample capacity, and the amount of packing and solvent required. 
 
Column packing 
The packing used in modern HPLC consists of small, rigid particles having a 
narrow particle size distribution. There are three main types of column packing in HPLC. 
1. Porous, polymeric beds  
Porous, polymeric beds based on styrene divinyl benzene co-polymers used in ion 
exchange and size exclusion chromatography. For analytical purpose these have now 
been replaced by silica based, packing which are more efficient and more stable. 
2. Porous layer beds 
Consisting of a thin shell (1-3 µm) of silica or modified silica on an spherical inert 
core (e.g. Glass). After the development of totally porous micro particulate packing, these 
have not been used in HPLC. 
3. Totally porous silica particles (dia. <10 µm) 
These packing have widely been used for analytical HPLC in recent years. 
Particles of diameter >20 µm are usually dry packed, while particles of diameter <20 µm 
are slurry packed in which particles are suspended on a suitable solvent and the slurry so 
obtained is driven into the column under pressure. 
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d) Detectors 
The function of the detector in HPLC is to monitor the mobile phase as it merges 
from the column. Detectors are usually of two types:  
1. Bulk property detectors 
It compares overall changes in a physical property of the mobile phase with and 
without an eluting solute. e.g. Refractive index, dielectric constant or density. 
2. Solute property detectors 
It responds to a physical property of the solute, which is not exhibited by the pure 
mobile phase. e.g. UV absorbance, fluorescence or diffusion current. Such 
detectors are about 1000 times more sensitive giving a detectable signal for a few 
nanograms of sample [18]. 
 
2.2 Quantitative analysis in HPLC [19, 20] 
Three methods are generally used for quantitative analysis. They are the external 
standard method, the internal standard method and the standard addition method. 
 
2.2.1 External standard method 
 The external standard method involves the use of a single standard or up to three 
solutions. The peak area or the height of the sample and the standard use are compared 
directly. One can also use the slope of the calibration curve based on standard that contain 
known concentrations of the compound of interest. 
 
2.2.2 Internal standard method 
A widely used technique of quantitation involves the addition of an internal 
standard to compensate for various analytical errors. In this approach, a known compound 
of a fixed concentration is added to the known amount of samples to give separate peaks 
in the chromatograms to compensate for the losses of the compounds of interest during 
sample pretreatment steps. Any loss of the component of interest will be accompanied by 
the loss of an equivalent fraction of the internal standard. The accuracy of this approach 
obviously dependence on the structural equivalence of the compounds of interest and the 
internal standard. The requirements for an internal standard are: 
 It must have a completely resolved peak with no interferences, 
 It must elute close to the compound of interest, 
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 It must behave equivalent to the compound of interest for analysis like 
pretreatments, derivative formations, etc., 
 It must be added at a concentration that will produce a peak area or peak height ratio 
of about unity with the compound, 
 It must not be present in the original sample, 
 It must be stable, unreactive with sample components, column packing and the 
mobile phase and 
 It is desirable that this compound is commercially available in high purity. 
  The internal standard should be added to the sample prior to sample preparation 
procedure and homogenized with it. To be able to recalculate the concentration of a 
sample component in the original sample, we have to demonstrate first the response 
factor. The response factor (RF) is the ratio of peak areas of sample component (Ax) and 
the internal standard (AISTD) obtained by injecting the same quantity. It can be calculated 
by using the formula, 
RF = Ax / AISTD 
On the basis of the response factor and strength of the internal standard (NISTD), the 
amount of the analyte in the original sample can be calculated using the formula,                               
X =AS / RF × AISTD ×    NISTD 
The calculations described above can be used after proving the linearity of the 
calibration curve for the internal standard and the analytical reference standard of the 
compound of interest. When more than one component is to be analyzed from the sample, 
the response factor of each component should be determined in the calculations using 
similar formula. 
 
2.2.3 Standard addition method 
   In the standard addition method, a known amount of the standard compound is 
added to the sample solution to be estimated. This method is suitable if sufficient amount 
of the sample is available and is more realistic in the sense that it allows calibration in the 
presence of excipients or other components. As gradient elution can be a source of 
additional error in quantitative analysis. It is also necessary to keep the flow rate and the 
mobile phase composition constant. The sample should be dissolved in the mobile phase. 
If the solvent used in the preparing the sample solution and the mobile phase are not 
identical, the analysis can become less accurate and it is also possible that the detector 
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response is more dependent on the sample. 
 
2.3 Method development and design of separation method [21,22] 
 Methods for analyzing drugs in multi component dosage forms can be developed, 
provided one has knowledge about the nature of the sample, namely, its molecular 
weight, polarity, ionic character and the solubility parameter. An exact recipe for HPLC, 
however, cannot be provided because method development involves considerable trial 
and error procedures. The most difficult problem usually is where to start, what type of 
column is worth trying with what kind of mobile phase. In general one begins with 
reversed phase chromatography, when the compounds are hydrophilic in nature with 
many polar groups and are water soluble.  
The organic phase concentration required for the mobile phase can be estimated 
by gradient elution method. For aqueous sample mixtures, the best way to start is with 
gradient reversed phase chromatography. Gradient can be started with 5-10% organic 
phase in the mobile phase and the organic phase concentration (methanol or acetonitrile) 
can be increased up to 100% within 30-45min. Separation can then be optimized by 
changing the initial mobile phase composition and the slope of the gradient according to 
the chromatogram obtained from the preliminary run. The initial mobile phase 
composition can be estimated on the basis of where the compounds of interest were 
eluted, namely, at what mobile phase composition.  
Changing the polarity of mobile phase can alter elution of drug molecules. The 
elution strength of a mobile phase depends upon its polarity, the stronger the polarity, 
higher is the elution. Ionic samples (acidic or basic) can be separated, if they are present 
in undissociated form. Dissociation of ionic samples may be suppressed by the proper 
selection of pH.  
The pH of the mobile phase [23] has to be selected in such a way that the 
compounds are not ionized. If the retention time is too short, the decrease of the organic 
phase concentration in the mobile phase can be in steps of 5%. If the retention time is too 
long, an increase of the organic phase concentration is needed.  
In UV detection, good analytical results are obtained only when the wavelength is 
selected carefully. This requires knowledge of the UV spectra of the individual 
components present in the sample. If analyte standards are available, their UV spectra can 
be measured prior to HPLC method development. 
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The molar absorbance at the detection wavelength is also an important parameter. 
When peaks are not detected in the chromatograms, it is possible that the sample quantity 
is not enough for the detection. An injection of volume of 20 µl from a solution of              
1 mg/ml concentration normally provides good signals for UV active compounds around 
220 nm. Even if the compounds exhibit higher max, they absorb strongly at lower 
wavelength. It is not always necessary to detect compounds at their maximum 
absorbance. It is, however, advantageous to avoid the detection at the sloppy part of the 
UV spectrum for precise quantitation. When acceptable peaks are detected on the 
chromatogram, the investigation of the peak shapes can help further method development.  
The addition of peak modifiers to the mobile phase can affect the separation of 
ionic samples. For examples, the retention of the basic compounds can be influenced by 
the addition of small amounts of triethylamine (a peak modifier) to the mobile phase. 
Similarly for acidic compounds small amounts of acids such as acetic acid can be used. 
This can lead to useful changes in selectivity.  
When tailing or fronting is observed, it means that the mobile phase is not totally 
compatible with the solutes. In most case the pH is not properly selected and hence partial 
dissociation or protonation takes place. When the peak shape does not improve by lower 
(1-2) or higher (8-9) pH, then ion-pair chromatography can be used. For acidic 
compounds, cationic ion pair molecules at higher pH and for basic compounds,anionic 
ion-pair molecules at lower pH can be used. For amphoteric solutes or a mixture of acidic 
and basic compounds, ion-pair chromatography is the method of choice. 
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Fig.2.3.1 Different peak shapes are observed during method development in HPLC 
 
 
 
The low solubility of the sample in the mobile phase can also cause bad peak 
shapes. It is always advisable to use the same solvents for the preparation of sample 
solution as the mobile phase to avoid precipitation of the compounds in the column or 
injector. Optimization can be started only after a reasonable chromatogram has been 
obtained.   
A reasonable chromatogram means that more or less symmetrical peaks on the 
chromatogram detect all the compounds. By slight change of the mobile phase 
composition, the position of the peaks can be predicted within the range of investigated 
changes. An optimized chromatogram is the one in which all the peaks are symmetrical 
and are well separated in less run time.  
The peak resolution can be increased by using a more efficient column (column 
with higher theoretical plate number, N), which can be achieved by using a column of 
smaller particle size, or a longer column. These factors, however, will increase the 
analysis time. Flow rate does not influence resolution, but it has a strong effect on the 
analysis time. 
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 The parameters that are affected by the changes in chromatographic conditions are 
[24]:
 
a. Resolution (Rs), 
b. Capacity factor (k'), 
c. Selectivity ( ), 
d. Column efficiency (N) and 
e. Peak asymmetry factor (As). 
 
a. Resolution (Rs) 
Resolution is the parameter describing the separation power of the complete 
chromatographic system relative to the particular components of the mixture. The 
resolution, Rs, of two neighboring peaks is defined as the ratio of the distance between 
two peak maxima. It is the difference between the retention times of two solutes divided 
by their average peak width. For baseline separation, the ideal value of Rs is 1.5. It is 
calculated by using the formula, 
Rs = Rt2 - Rt1 / 0.5 (W1 + W2) 
Where, Rt1 and Rt2 are the retention time of components 1 and 2 and 
W1 and W2 are peak width of components 1 and 2. 
There are three fundamental parameters that influence the resolution of a 
chromatographic separation: 
 Capacity factor 
 Selectivity 
 Column efficiency 
 
b. Capacity Factor (k') 
 Capacity factor is the ratio of the reduced retention volume to the dead volume. 
Capacity factor, k', is defined as the ratio of the number of molecules of solute in the 
stationary phase to the number of molecules of the same in the mobile phase. Capacity 
factor is a measure of how well the sample molecule is retained by a column during an 
isocratic separation. The ideal value of k' ranges from 2-10. Capacity factor can be 
determined by using the formula, 
k' =  V1 - V0 / V0 
Where, V1 = retention volume at the apex of the peak (solute) and  
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             V0 = void volume of the system. 
The values of k' of individual bands increase or decrease with changes in solvent 
strength. In reversed phase HPLC, solvent strength increases with the increase in the 
volume of organic phase in water/ organic mobile phase. Typically an increase in 
percentage of the organic phase by 10% by volume will decrease k' of the bands by a 
factor of 2-3. 
 
Adjusting capacity factor (k'): 
Good isocratic method usually have a capacity factor (k') in the range of 2 -10 
(typically 2 – 5). Lower values may give inadequate resolution. Higher values are usually 
associated with excessively broad peak and unacceptably long run time. If the shift in k' 
value is observed with both analyst and the column test solution, the problem is most 
likely due to change in column, temperature or mobile phase composition. This is true if 
the shift occurs gradually over series of run. 
Capacity factor (k') values are sensitive to: 
 Solvent strength 
 Composition 
 Purity 
 Temperature 
 Column chemistry 
 Sample 
 
c. Selectivity ( ) 
The selectivity (or separation factor), , is a measure of relative retention of two 
components in a mixture. Selectivity is the ratio of the capacity factors of both peaks, and 
the ratio of its adjusted retention times. Selectivity represents the separation power of 
particular adsorbent to the mixture of these particular components. 
This parameter is independent of the column efficiency; it only depends on the 
nature of the components, eluent type, and eluent composition, and adsorbent surface 
chemistry. In general, if the selectivity of two components is equal to 1, then there is no 
way to separate them by improving the column efficiency. 
       The ideal value of  is 2. It can be calculated by using formula, 
= V2 – V1 / V1 – V0     = k1'/ k2' 
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       Where,   V0 = the void volume of the column, 
   V1 and V2 = the retention volumes of the second and the first peak respectively. 
 
Adjusting selectivity (α) 
When troubleshooting changes in selectivity (α), the approach is similar to the 
approach used in the capacity factor. When selectivity (α) is affected, the corrective 
action depends on whether the problem is mobile phase or column related. Be sure to 
compare results obtained with the test solution to those observed when the column was 
new. 
Selectivity (α) values are sensitive to: 
 Changes in mobile phase composition (pH ionic strength) 
 Purity 
 Temperature 
 
d. Column efficiency/ Band broadening 
 Efficiency N, of a column is measured by the number of theoretical plates per 
meter. It is a measure of band spreading of a peak. Similar the band spread, higher is the 
number of theoretical plates, indicating good column and system performance. Column 
with N ranging from 5,000 to 1,00,000 plates/meter are ideal for a good system.  
 Efficiency is calculated using the formula, 
N = 16 Rt
2
 / W
2
 
  Where, Rt is the retention time and W is the peak width. 
 A decline in measured column efficiency may be due to: 
 Age and history of the column 
 Extra column band broadening (such as due to malfunctioning injector or 
improper tubing i.d.) 
 Inappropriate detector setting 
 Change in flow rate and solvent viscosity 
 
You can recognize problems in your separation due to a loss of column efficiency 
when the width or shapes of all peaks are affected. 
 
Methods of measuring column efficiency (N) 
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  Method used for the measurement and calculation of column include (in order to 
sensitivity to abnormal peak shape): 
 Asymmetry based (most sensitive to tailing or fronting) 
 5 sigma 
 4 sigma 
 Tangent 
 3 sigma 
 ½ height 
 2 sigma (least sensitive to tailing or fronting) 
 Chose the method that best suits your operating requirements. It is critical that the 
same method always be used and executed reproducibly. 
 
e. Peak asymmetry factor (As) 
 Peak asymmetry factor, As, can be used as a criterion of column performance. The 
peak half width, b, of a peak at 10% of the peak height, divided by the corresponding 
front half width, a, gives the asymmetry factor. 
As = b / a 
 For a well-packed column, an asymmetry factor of 0.9 to 1.1 should be 
achievable. 
2.3 Validation of analytical method [25-29] 
“Validation is an act of proving that any procedure, process, equipment, material, 
activity or system performs as expected under given set of conditions and also give the 
required accuracy, precision, sensitivity, ruggedness, etc.” 
When extended to an analytical procedure, depending upon the application, it 
means that a method works reproducibly, when carried out by same or different persons, 
in same or different laboratories, using different reagents, different equipments, etc. 
The various validation parameters are: 
a) Accuracy,  
b) Precision(repeatability and reproducibility), 
c) Linearity and Range, 
d) Limit of detection(LOD)/ Limit of quantitation (LOQ), 
e) Selectivity/ Specificity, 
f) Robustness/ Ruggedness and 
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g) Stability and System suitability studies. 
Advantages of Analytical method Validation 
 The biggest advantage of method validation is that it builds a degree of 
confidence, not only for the developer but also to the user. 
 Although the validation exercise may appear costly and time consuming, it results 
inexpensive, eliminates frustrating repetitions and leads to better time management in 
the end. 
 Minor changes in the conditions such as reagent supplier or grade, analytical setup 
are unavoidable due to obvious reasons but the method validation absorbs the shock 
of such conditions and pays for more than invested on the process. 
Method validation is required when 
1. A new method has been developed 
2. Revision of established method 
3. When established methods are used in different laboratories and different analysts etc. 
4. Comparison of methods required 
5. When quality control indicates method changes. 
Key parameters of the analytical method validation 
It is important for one to understand the parameters or characteristics involved in 
the validation process. The various performance parameters, which are addressed in a 
validation exercise, are grouped as follows. 
a) Accuracy 
The accuracy of an analytical method may be defined as the closeness of the test 
results obtained by the method to the true value. It is the measure of the exactness of the 
analytical method developed. Accuracy may often express as percent recovery by the 
assay of a known amount of analyte added. 
Accuracy may be determined by applying the method to samples or mixtures of 
excipients to which known amount of analyte have been added both above and below the 
normal levels expected in the samples. Accuracy is then calculated from the test results as 
the percentage of the analyte recovered by the assay. Dosage form assays commonly 
provide accuracy within 3-5% of the true value. 
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The ICH documents recommend that accuracy should be assessed using a 
minimum of nine determinations over a minimum of three concentration levels, covering 
the specified range (i.e. three concentrations and three replicated of each concentration). 
b) Precision 
The precision of an analytical method is the degree of agreement among 
individual test results when the method is applied repeatedly to multiple samplings of 
homogenous samples. This is usually expressed as the standard deviation or the relative 
standard deviation (coefficient of variation). Precision is a measure of the degree of 
reproducibility or of the repeatability of the analytical method under normal operating 
circumstances. 
Repeatability involves analysis of replicates by the analyst using the same 
equipment and method and conducting the precision study over short period of time while 
reproducibility involves precision study at 
 Different occasions, 
 Different laboratories, 
 Different batch of reagent, 
 Different analysts, 
 Different equipments. 
 
    1) Determination of repeatability 
Repeatability can be defined as the precision of the procedure when repeated by 
same analyst under the same operating conditions (same reagents, equipments, settings 
and laboratory) over a short interval of time. 
It is normally expected that at least six replicates be carried out and a table showing 
each individual result provided from which the mean, standard deviation and co-efficient 
of variation should be calculated for set of n value. The RSD values are important for 
showing degree of variation expected when the analytical procedure is repeated several 
time in a standard situation. (RSD below 2% for assays in finished product). 
The ICH documents recommend that repeatability should be assessed using a 
minimum of nine determinations covering the specified range for the procedure (i.e. three 
concentrations and three replicates of each concentration or using a minimum of six 
determinations at 100% of the test concentration). 
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    2) Determination of reproducibility 
Reproducibility means the precision of the procedure when it is carried out under 
different conditions-usually in different laboratories-on separate, identical samples taken 
from the same homogenous batch of material. Comparisons of results obtained by 
different analysts, by the use of different equipments, or by carrying out the analysis at 
different times can also provide valuable information. 
 
c) Linearity and range 
The linearity of an analytical method is its ability to draw out test results that are 
directly (or by a well defined mathematical transformation) proportional to the analyte 
concentration in samples within a given range. Linearity usually expressed in terms of the 
variance around the slope of regression line calculated according to an established 
mathematical relationship from test results obtained by the analysis of samples with 
varying concentrations of analyte. 
The linear range of detectability that obeys Beer’s law is dependent on the 
compound analyzed and the detector used. The working sample concentration and 
samples tested for accuracy should be in the linear range. The claim that the method is 
linear is to be justified with additional mention of zero intercept by processing data by 
linear least square regression. Data is processed by linear least square regression 
declaring the regression co-efficient and b of the linear equation y= ax + b together with 
the correlation coefficient of determination. For the method to be linear the r value should 
be close to1. 
The range of an analytical method is the interval between the upper and lower 
levels of the analyte (including these levels) that have been demonstrated to be 
determined with precision, accuracy and linearity using the method as written. 
 
d) Limit of Detection and Limit of Quantitation 
    1) Limit of detection 
  The limit of detection is the parameter of limit tests. It is the lowest level of 
analyte that can be detected, but not necessarily determined in a quantitative fashion, 
using a specific method under the required experimental conditions. The limit test thus 
merely substantiates that the analyte concentration is above or below a certain level. 
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The determination of the limit of detection of instrumental procedures is carried 
out by determining the signal-to-noise ratio by comparing test results from the samples 
with known concentration of analyte with those of blank samples and establishing the 
minimum level at which the analyte can be reliably detected. A signal-to-noise ratio of 
2:1 or 3:1 is generally accepted. 
The signal-to-noise ratio is determined by dividing the base peak by the standard 
deviation of all data points below a set threshold. Limit of detection is calculated by 
taking the concentration of the peak of interest divided by three times the signal-to-noise 
ratio. 
For spectroscopic techniques or other methods that rely upon a calibration curve 
for quantitative measurements, the IUPAC approach employs the standard deviation of 
the intercept (Sa) which may be related to LOD and the slope of the calibration curve, b, 
by 
LOD = 3.3 Sa / b 
    2) Limit of quantitation 
  Limit of quantitation is a parameter of quantitative assays for low levels of 
compounds in sample matrices such as impurities in bulk drugs and degradation products 
in finished pharmaceuticals. The limit of quantitation is the lowest concentration of 
analyte in a sample that may be determined with acceptable accuracy and precision when 
the required procedure is applied. 
It is measured by analyzing samples containing known quantities of the analyte 
and determining the lowest level at which acceptable degrees of accuracy and precision 
are attainable, Where the final assessment is based on an instrumental reading, the 
magnitude of background response by analyzing a number of blank samples and 
calculating the standard deviation of this response. The standard deviation multiplied by a 
factor (usually 10) provides an estimate of the limit of quantitation. In many cases, the 
limit of quantitation is approximately twice the limit of detection. 
 
e) Selectivity and Specificity 
The selectivity of an analytical method is its ability to measure accurately and 
specifically the analyte of interest in the presence of components that may be expected to 
be present in the sample matrix. 
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If an analytical procedure is able to separate and resolve the various components 
of a mixture and detect the analyte qualitatively the method is called selective. On the 
other hand, if the method determines or measures quantitatively the component of interest 
in the sample matrix without separation, it is said to be specific. 
Hence one basic difference in the selectivity and specificity is that, while the 
former is restricted to qualitative detection of the components of a sample, the latter 
means quantitative measurement of one or more analytes. 
Selectivity may be expressed in terms of the bias of the assay results obtained 
when the procedure is applied to the analyte in the presence of expected levels of other 
components, compared the results obtained when the procedure is applied to the analyte 
in the presence of expected levels of other components, compared to the results obtained 
on the same analyte without added substances. When the other components are all known 
and available, selectivity may be determined by comparing the test results obtained on the 
analyte with and without the addition of the potentially interfering materials. When such 
components are either unidentified or unavailable, a measure of selectivity can often be 
obtained by determining the recovery of a standard addition of pure analyte to a material 
containing a constant level of the other components. 
 
f) Robustness and Ruggedness 
1) Robustness 
The robustness of an analytical method is a measure of its capacity to remain 
unaffected by small but deliberate variation in method parameters and provides an 
indication of its reliability during normal usage. The determination of robustness requires 
that methods characteristic are assessed when one or more operating parameter varied. 
2) Ruggedness 
  The ruggedness of an analytical method is the degree of reproducibility of test 
results obtained by the analysis of the same samples under a variety of normal test  
conditions such as different laboratories, different analysts, using operational and 
environmental conditions that may differ but are still within the specified parameters of 
the assay. The testing of ruggedness is normally suggested when the method is to be used 
in more than one laboratory. Ruggedness is normally expressed as the lack of the 
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influence on the test results of operational and environmental variables of the analytical 
method. 
For the determination of ruggedness, the degree of reproducibility of test result is 
determined as function of the assay variable. This reproducibility may be compared to the 
precision of the assay under normal condition to obtain a measure of the ruggedness of 
the analytical method. 
 
g) Stability and System suitability tests 
Stability of the sample, standard and reagents is required for a reasonable time to 
generate reproducible and reliable results. For example, 24 hour stability is desired for 
solutions and reagents that need to be prepared for each analysis. 
System suitability test provide the added assurance that on a specific occasion the 
method is giving, accurate and precise results. System suitability test are run every time a 
method is used either before or during analysis. The results of each system suitability test 
are compared with defined acceptance criteria and if they pass, the method is deemed 
satisfactory on that occasion. The nature of the test and the acceptance criteria will be 
based upon data generated during method development optimization and validation 
experiments. 
 
Table1.1: Data elements required for assay validation 
Analytical 
Performance 
Characteristics 
Assay 
Category I 
Assay Category II Assay 
Category III 
Assay 
Category IV Quantitative 
tests 
Limit 
tests 
Accuracy X X May be May be  
Precision X X  X  
Specificity X X X May be X 
Limit of 
Detection 
  X May be  
Limit of 
Quantitation 
 X  May be  
Linearity X X  May be  
Range X X May be May be  
 
Where, X indicates the tests to be performed. 
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Category I: Analytical methods for quantitation of major components of bulk drug 
substances or active ingredients including preservatives in finished pharmaceutical 
products. 
Category II: Analytical methods for determination of impurities in bulk drugs or for 
determination of degradation compounds in finished pharmaceutical products. 
Category III: Analytical methods for determination of performance characteristics (e.g. 
dissolution, drug release). 
Category IV: Identification tests. 
 
3. OBJECTIVE OF THE WORK 
 
 The specific and main objectives of the work are:  
 Development and validation of a stability indicating HPLC assay method for 
determination of Ticlopidine Hydrochloride in tablet formulation. 
 Development and validation of HPLC assay method for determination of 
Furosemide and Spironolactone in combined dosage form in presence of degradation 
product formed under ICH recommended stress condition. 
 Development and validation of a stability indicating HPLC assay method for 
determination of Lamotrigine in tablet formulation. 
 
3.1 INSTRUMENT USE FOR WHOLE RESEARCH WORK 
3.1.1 Chromatographic system 
 The chromatographic system used to perform development and validation of this 
assay method was comprised of a LC-10ATvp binary pump, a SPD-M10Avp photo diode 
array detector and a rheodyne manual injector model 7725i with 20μl loop (Shimadzu, 
Kyoto, Japan) connected to a multi-instrument data acquisition and data processing 
system (Class-VP 6.13 SP2, Shimadzu) and the UPLC system of Waters Acquity with 
PDA was also used. 
 
3.1.2 Spectrophotometer system 
 The spectrophotometer system used to perform development and validation of this 
assay method was model Phamaspec-UV-1700, Shimadzu, Kyoto, Japan and data 
processing system (UV probe, Shimadzu). 
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3.1.3 Other instruments 
 Ultrasonic Bath (SONICA, Spincotech Pvt. Ltd., Mumbai). 
 pH-Meter (Li-610, Elico Ltd. India) 
 Hot Air Oven (Nova Instruments, India) 
 Digital Balance (Metller Toledo, Japan) 
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1. INTRODUCTION TO TICLOPIDINE HYDROCHLORIDE 
Ticlopidine hydrochloride is an inhibitor of platelet aggregation used in the 
management and prevention of thromboembolic disorders [1]. Ticlopidine hydrochloride 
is a white crystalline solid. It is freely soluble in water and self-buffers to a pH of 3.6. It 
also dissolves freely in methanol, is sparingly soluble in methylene chloride and ethanol, 
slightly soluble in acetone and insoluble in a buffer solution of pH 6.3. 
TICLID (Ticlopidine hydrochloride) tablets for oral administration are provided 
as white, oval, film-coated, blue-imprinted tablets containing 250 mg of ticlopidine 
hydrochloride. Each tablet also contains citric acid, magnesium stearate, microcrystalline 
cellulose, povidone, starch and stearic acid as inactive ingredients. The white film-coating 
contains hydroxypropylmethyl cellulose, polyethylene glycol and titanium dioxide. Each 
tablet is printed with blue ink, which includes FD&C Blue #1 aluminum lake as the 
colorant. The tablets are identified with Ticlid on one side and 250 on the reverse side. 
1.1 Description 
Ticlopidine hydrochloride is chemically 5-[(2-Chlorophenyl) methyl]-4, 5, 6, 7-
tetrahydrothieno [3, 2-c] pyridine hydrochloride (Fig.1). Its molecular formula is 
C14H14ClNS.HCl having molecular weight 300.25 g/mole. Its CAS Registry Number is 
55142-85-3. It is used as adenosine diphosphate [ADP] receptor antagonists in an 
antiplatelet therapy [2]. It is also significantly reduces restenosis after endovascular 
therapy in femoropopliteal lesions [3].  
 
N
S
Cl
ClH.
 
Figure: 1     5-[(2-Chlorophenyl) methyl]-4, 5, 6, 7-tetrahydrothieno [3, 2-c] 
pyridine hydrochloride                    
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1.2 Side Effects 
Adverse reactions in stroke patients were relatively frequent with over 50% of 
patients reporting at least one. Most (30% to 40%) involved the gastrointestinal tract. 
Most adverse effects are mild, but 21% of patients discontinued therapy because of an 
adverse event, principally diarrhea, rash, nausea, vomiting, GI pain and neutropenia. Most 
adverse effects occur early in the course of treatment, but a new onset of adverse effects 
can occur after several months. 
Hematological: Neutropenia/thrombocytopenia, TTP, aplastic anemia, leukemia, 
agranulocytosis, eosinophilia, pancytopenia, thrombocytosis and bone-marrow depression 
have been reported.  
Gastrointestinal: Ticlopidine hydrochloride therapy has been associated with a variety of 
gastrointestinal complaints including diarrhea and nausea. The majority of cases are mild, 
but about 13% of patients discontinued therapy because of these. They usually occur 
within 3 months of initiation of therapy and typically are resolved within 1 to 2 weeks 
without discontinuation of therapy. If the effect is severe or persistent, therapy should be 
discontinued. In some cases of severe or bloody diarrhea, colitis was later diagnosed. 
Hemorrhagic: TICLID has been associated with increased bleeding, spontaneous 
posttraumatic bleeding and perioperative bleeding including, but not limited to, 
gastrointestinal bleeding. It has also been associated with a number of bleeding 
complications such as ecchymosis, epistaxis, hematuria and conjunctival hemorrhage. 
Intracerebral bleeding was rare in clinical trials in stroke patients with TICLID, 
with an incidence no greater than that seen with comparator agents (ticlopidine 0.5%, 
aspirin 0.6%, placebo 0.75%). It has also been reported postmarketing. 
Rash: Ticlopidine has been associated with a maculopapular or urticarial rash (often with 
pruritus). Rash usually occurs within 3 months of initiation of therapy with a mean onset 
time of 11 days. If drug is discontinued, recovery occurs within several days. Many 
rashes do not recur on drug rechallenge. There have been rare reports of severe rashes, 
including Stevens-Johnson syndrome, erythema multiforme and exfoliative dermatitis. 
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1.3 Drug Interaction 
Therapeutic doses of TICLID caused a 30% increase in the plasma half-life of 
antipyrine and may cause analogous effects on similarly metabolized drugs. Therefore, 
the dose of drugs metabolized by hepatic microsomal enzymes with low therapeutic ratios 
or being given to patients with hepatic impairment may require adjustment to maintain 
optimal therapeutic blood levels when starting or stopping concomitant therapy with 
ticlopidine. Studies of specific drug interactions yielded the following results: 
Aspirin and Other NSAIDs: Ticlopidine potentiates the effect of aspirin or other NSAIDs 
on platelet aggregation. The safety of related use of ticlopidine and NSAIDs has not been 
established. The safety of concomitantuse of ticlopidine and aspirin beyond 30 days has 
not been established. Aspirin did not modify the ticlopidine-mediated inhibition of ADP-
induced platelet aggregation, but ticlopidine potentiated the effect of aspirin on collagen-
induced platelet aggregation. Caution should be exercised in patients who have lesions 
with a propensity to bleed, such as ulcers. Long-term concomitant use of aspirin and 
ticlopidine is not recommended . 
Antacids: Administration of TICLID after antacids resulted in an 18% decrease in plasma 
levels of ticlopidine. 
Cimetidine: Chronic administration of cimetidine reduced the clearance of a single dose 
of TICLID by 50%. 
Digoxin: Coadministration of TICLID with digoxin resulted in a slight decrease 
(approximately 15%) in digoxin plasma levels. Little or no change in therapeutic efficacy 
of digoxin would be expected. 
Theophylline: In normal volunteers, concomitant administration of TICLID resulted in a 
significant increase in the theophylline elimination half-life from 8.6 to 12.2 hours and a 
comparable reduction in total plasma clearance of theophylline. 
Phenobarbital: In 6 normal volunteers, the inhibitory effects of TICLID on platelet 
aggregation were not altered by chronic administration of phenobarbital.  
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Phenytoin: In vitro studies demonstrated that ticlopidine does not alter the plasma protein 
binding of phenytoin. However, the protein binding interactions of ticlopidine and its 
metabolites have not been studied in vivo. Several cases of elevated phenytoin plasma 
levels with associated somnolence and lethargy have been reported following 
coadministration with TICLID. Caution should be exercised in coadministering this drug 
with TICLID, and it may be useful to remeasure phenytoin blood concentrations. 
Propranolol: In vitro studies demonstrated that ticlopidine does not alter the plasma 
protein binding of propranolol. However, the protein binding interactions of ticlopidine 
and its metabolites have not been studied in vivo. Caution should be exercised in 
coadministering this drug with TICLID. 
Other Concomitant Therapy: Although specific interaction studies were not performed, 
in clinical studies TICLID was used concomitantly with beta blockers, calcium channel 
blockers and diuretics without evidence of clinically significant adverse interactions. 
Food Interaction: The oral bioavailability of ticlopidine is increased by 20% when taken 
after a meal. Administration of TICLID with food is recommended to maximize 
gastrointestinal tolerance. In controlled trials in stroke patients, TICLID was taken with 
meals. 
1.4 Precaution 
General: TICLID should be used with caution in patients who may be at risk of increased 
bleeding from trauma, surgery or pathological conditions. If it is desired to eliminate the 
antiplatelet effects of TICLID prior to elective surgery, the drug should be discontinued 
10 to 14 days prior to surgery. Several controlled clinical studies have found increased 
surgical blood loss in patients undergoing surgery during treatment with ticlopidine. In 
TASS and CATS it was recommended that patients have ticlopidine discontinued prior to 
elective surgery. Several hundred patients underwent surgery during the trials, and no 
excessive surgical bleeding was reported. 
Prolonged bleeding time is normalized within 2 hours after administration of 20 
mg methylprednisolone IV. Platelet transfusions may also be used to reverse the effect of  
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TICLID on bleeding. Because platelet transfusions may accelerate thrombosis in 
patients with TTP on ticlopidine, they should, if possible, be avoided. 
GI Bleeding: TICLID prolongs template bleeding time. The drug should be used with 
caution in patients who have lesions with a propensity to bleed (such as ulcers). Drugs 
that might induce such lesions should be used with caution in patients on TICLID. 
Use in Hepatically Impaired Patients: Since ticlopidine is metabolized by the liver, 
dosing of TICLID or other drugs metabolized in the liver may require adjustment upon 
starting or stopping concomitant therapy. Because of limited experience in patients with 
severe hepatic disease, who may have bleeding diatheses, the use of TICLID is not 
recommended in this population. 
Use in Renally Impaired Patients: There is limited experience in patients with renal 
impairment. Decreased plasma clearance, increased AUC values and prolonged bleeding 
time can occur in renally impaired patients. In controlled clinical trials no unexpected 
problems have been encountered in patients having mild renal impairment, and there is no 
experience with dosage adjustment in patients with greater degrees of renal impairment. 
Nevertheless, for renally impaired patients, it may be necessary to reduce the dosage of 
ticlopidine or discontinue it altogether if hemorrhagic or hematopoietic problems are 
encountered. 
1.5 Overdose 
One case of deliberate overdosage with TICLID has been reported by a foreign 
postmarketing surveillance program. A 38-year-old male took a single 6000-mg dose of 
TICLID (equivalent to 24 standard 250-mg tablets). The only abnormalities reported were 
increased bleeding time and increased SGPT. No special therapy was instituted and the 
patient recovered without sequelae. 
1.6 Contraindications 
The use of TICLID is contraindicated in the following conditions: 
 Hypersensitivity to the drug , 
Ticlopidine HCl…   Part-A (Section-I) 
 
37 
 Presence of hematopoietic disorders such as neutropenia and thrombocytopenia or 
a past history of either TTP or aplastic anemia , 
 Presence of a hemostatic disorder or active pathological bleeding (such as 
bleeding peptic ulcer or intracranial bleeding) , 
 Patients with severe liver impairment. 
1.7 Clinical Pharmacology 
Mechanism of Action: When taken orally, ticlopidine hydrochloride causes a time- and 
dose-dependent inhibition of both platelet aggregation and release of platelet granule 
constituents, as well as a prolongation of bleeding time. The intact drug has no significant 
in vitro activity at the concentrations attained in vivo; and, although analysis of urine and 
plasma indicates at least 20 metabolites, no metabolite which accounts for the activity of 
ticlopidine has been isolated. 
Ticlopidine hydrochloride, after oral ingestion, interferes with platelet membrane 
function by inhibiting ADP-induced platelet-fibrinogen binding and subsequent platelet-
platelet interactions. The effect on platelet function is irreversible for the life of the 
platelet, as shown both by persistent inhibition of fibrinogen binding after washing 
platelets ex vivo and by inhibition of platelet aggregation after resuspension of platelets in 
buffered medium. 
Pharmacokinetics and Metabolism: After oral administration of a single 250-mg dose, 
ticlopidine hydrochloride is rapidly absorbed with peak plasma levels occurring at 
approximately 2 hours after dosing and is extensively metabolized. Absorption is greater 
than 80%. Administration after meals results in a 20% increase in the AUC of ticlopidine. 
Ticlopidine hydrochloride displays nonlinear pharmacokinetics and clearance 
decreases markedly on repeated dosing. In older volunteers the apparent half-life of 
ticlopidine after a single 250-mg dose is about 12.6 hours; with repeat dosing at 250 mg 
bid, the terminal elimination half-life rises to 4 to 5 days and steady-state levels of 
ticlopidine hydrochloride in plasma are obtained after approximately 14 to 21 days. 
Ticlopidine hydrochloride binds reversibly (98%) to plasma proteins, mainly to 
serum albumin and lipoproteins. The binding to albumin and lipoproteins is nonsaturable 
over a wide concentration range. Ticlopidine also binds to alpha-1 acid glycoprotein. At 
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concentrations attained with the recommended dose, only 15% or less ticlopidine in 
plasma is bound to this protein. 
Ticlopidine hydrochloride is metabolized extensively by the liver; only trace 
amounts of intact drug are detected in the urine. Following an oral dose of radioactive 
ticlopidine hydrochloride administered in solution, 60% of the radioactivity is recovered 
in the urine and 23% in the feces. Approximately 1/3 of the dose excreted in the feces is 
intact ticlopidine hydrochloride, possibly excreted in the bile. Ticlopidine hydrochloride 
is a minor component in plasma (5%) after a single dose, but at steady-state is the major 
component (15%). Approximately 40% to 50% of the radioactive metabolites circulating 
in plasma are covalently bound to plasma proteins, probably by acylation. 
Clearance of ticlopidine decreases with age. Steady-state trough values in elderly 
patients (mean age 70 years) are about twice those in younger volunteer populations. 
Hepatically Impaired Patients: The effect of decreased hepatic function on the 
pharmacokinetics of TICLID was studied in 17 patients with advanced cirrhosis. The 
average plasma concentration of ticlopidine in these subjects was slightly higher than that 
seen in older subjects in a separate trial. 
Renally Impaired Patients: Patients with mildly (Ccr 50 to 80 mL/min) or moderately 
(Ccr 20 to 50 mL/min) impaired renal function were compared to normal subjects (Ccr 80 
to 150 mL/min) in a study of the pharmacokinetic and platelet pharmacodynamic effects 
of TICLID (250 mg bid) for 11 days. Concentrations of unchanged TICLID were 
measured after a single 250-mg dose and after the final 250-mg dose on Day 11. 
AUC values of ticlopidine increased by 28% and 60% in mild and moderately 
impaired patients, respectively, and plasma clearance decreased by 37% and 52%, 
respectively, but there were no statistically significant differences in ADP-induced 
platelet aggregation. In this small study (26 patients), bleeding times showed significant 
prolongation only in the moderately impaired patients. 
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Pharmacodynamics: In healthy volunteers over the age of 50, substantial inhibition (over 
50%) of ADP-induced platelet aggregation is detected within 4 days after administration 
of ticlopidine hydrochloride 250 mg bid, and maximum platelet aggregation inhibition 
(60% to 70%) is achieved after 8 to 11 days. Lower doses cause less, and more delayed, 
platelet aggregation inhibition, while doses above 250 mg bid give little additional effect 
on platelet aggregation but an increased rate of adverse effects. The dose of 250 mg bid is 
the only dose that has been evaluated in controlled clinical trials. 
After discontinuation of ticlopidine hydrochloride, bleeding time and other 
platelet function tests return to normal within 2 weeks, in the majority of patients. 
At the recommended therapeutic dose (250 mg bid), ticlopidine hydrochloride has 
no known significant pharmacological actions in man other than inhibition of platelet 
function and prolongation of the bleeding time. [4] 
2. LITERATURE REVIEW 
The literature reviews regarding ticlopidine hydrochloride suggest that various 
analytical methods were reported for its determination as drug, in pharmaceutical 
formulation and in various biological fluids. The literature reviews for analysis of 
ticlopidine hydrochloride are as under: 
2.1 C. K. Markopoulou, J. E. Koundourellis, M. G. Orkoula, C. G. Kontoyannis 
have developed quantitative nondestructive methods for the determination of ticlopidine 
in tablets using reflectance near-infrared and fourier transform raman spectroscopy.  The 
results were compared to those obtained by high-performance liquid chromatography 
(HPLC) [5].   
2.2   R. T. Sane, N. L. Chonkar, S. R. Surve, M. G. Gangrade, V. V. Bapat have 
developed extractive colorimetric determination of ticlopidine hydrochloride, buspirone 
hydrochloride, nefopam hydrochloride, and ketotifen fumarate in pharmaceutical 
preparations. The method involved simple, accurate, fast and precise extractive 
colorimetric technique for the determination of aforesaid compounds in pharmaceuticals 
with acid dyes like bromothymol blue, bromophenol blue, bromocresol purple and 
bromocresol green in presence of acidic buffers.  The colored complexes were extracted 
into chloroform and measured at the respective wavelengths of maximum absorption [6]. 
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2.3 R. T. Sane, M. G. Gangrade, V. V. Bapat, S. R. Surve, N. L. Chonkar have 
developed gas chromatographic determination of flutamide, nimodipine, and ticlopidine 
hydrochloride from their pharmaceutical preparations. The method involved simple, 
accurate, fast and precise techniques for the determination of flutamide, nimodipine and 
ticlopidine.  A 10% OV-1 column was used for all the 3 drugs.  The oven temprature was 
set at 225  for flutamide, 280  for nimodipine and 220  for ticlopidine.  The detection 
was done by using a flame ionization detector.  The analysis was carried out using an 
internal std. method.  The methods were further extended for the determination of these 
drugs in pharmaceuticals [7].  
2.4 Li, Weiyong, Pu Huang, Yong Han, Ying Zhang have reported study on 
pharmacokinetics and bioavailability of ticlopidine hydrochloride tablets. The relative 
bioavailability between two products of ticlopidine hydrochloride (tablet A and B) was 
evaluated. The plasma ticlopidine hydrochloride concentration was determined by HPLC 
method. The relative bioavailability of tablet A to tablet B was (105.6  30.4) %.                                    
There were no significant differences in the parameters of Cmax and AUC0  between 
two products [8]. 
2.5 Ebru Turkoz, A. Nur Onar have developed determination of ticlopidine in 
pharmaceutical products. The voltammetric behavior of ticlopidine-HCl was studied 
using square-wave, sampled d.c., and cyclic voltammetry.  The drug showed a cathodic 
peak at -0.01V vs. Ag/AgCl with hanging mercury drop electrode.  The current was 
investigated using cyclic voltammetry and characterized as diffusion controlled.  The 
calibration plot was linear over the concentration range of 1.96  10-6 - 1.13  10-4 M in 
0.5 M phosphate buffer of pH 5.0.  Limit of detection and limit of quantification were 
achieved as 5.17  10-7, 1.72  10-6 M, respectively. The proposed procedure was 
successfully applied for assay of ticlopidine in its pharmaceutical formulation as tablet 
without the necessity for sample pretreatment prior to assay of the drug [9]. 
2.6 Xiu-Ling Zhang has developed a detection method for HPLC of ticlopidine 
hydrochloride in capsules and tablets. It was determinate by HPLC on a TWG-C18H37 
column with Methanol-pH 3.0 sodium dihydrogen phosphate solution (70:30) as mobile 
phase, Ph benzoate as internal standard, and 268 nm as the detection wavelength.  The 
RSD of the replicate tests and the average recovery were not more than 0.5% [10]. 
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2.7 G. Furlan, N. Malusa, A, Strohmayer, F. B. Klugmann, G. Decorti, L. 
Candussio have developed optimised method for determination of ticlopidine in serum 
by HPLC. In this study they verified whether HPLC with UV detection (HPLC-UV) 
could be optimised and hence become a useful method for measuring ticlopidine 
concentrations in patient blood.  The extraction step was improved by adding isoamylic 
alcohol in the extraction mixture, resulting in a better recovery.  Moreover, the extraction 
efficiency was consistently ameliorated by evaporation to dryness of the organic extract; 
we could therefore utilise a lower (213 nm) wavelength, corresponding to the maximum 
of absorption, achieving a better sensitivity.  With these technical improvements, the limit 
of quantitation is 0.02 microgram/ml, and the limit of detection is 0.01 microgram/ml, 
hence comparable to levels obtained with gas-liquid chromatography with nitrogen 
detection (GC-NPD).  In addition, HPLC method, if compared with GC-NPD, is simpler 
and can be easily used for routine determinations of a lot of serum samples [11]. 
2.8 K. Rona, K. Ary, B. Gachalyi have developed validity of a liquid 
chromatographic (HPLC) method for the determination of ticlopidine in human plasma. 
In this study a simple HPLC method for determination of ticlopidine in human plasma 
using UV detection was developed.  The separation of the investigated compound and 
internal standard was achieved on "BST Rutin" 10, C18 BD column with a 0.01 M, (pH 
4) potassium dihydrogen phosphate buffer acetonitrile-methanol (20:40:40 v/v) mobile 
phase at the wavelenght of  215 nm. The compounds were isolated from plasma by Bond 
Elut C18 solid-phase extraction, the mean absolute recovery was 84.9%.  The limit of 
quantitation was 10 ng/ml, the limit of detection was 5 ng/ml [12]. 
2.9 Minhui Chen, Lige Jia have developed quantitative determination of ticlopidine 
hydrochloride capsules by high performance liquid chromatography. The HPLC method 
for determination of ticlopidine hydrochloride capsules was: ODS column, mobile phase: 
0.1% triethylamine (adjusted to pH 2.5 with 85% phosphoric acid)-methanol (60:40), 
detector wavelength: 233 nm, flow rate: 1.0 mL/min.  The results showed that the linear 
range was 10 ng-10 g, quantitation limit was l0 ng, and RSD within day was 0.50%, RSD 
between days was 0.46%.  The method was simple and reliable [13]. 
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3. AIM OF PRESENT WORK 
As per discussion in the literature review, reflectance near-infrared and Fourier 
transform Raman spectroscopy, Gas Chromatographic, Colorimetric, Volta metric and 
HPLC methods for the determination of ticlopidine hydrochloride in pharmaceutical 
dosage forms or in biological fluids are reported. HPLC methods applied to the 
pharmacokinetic studies of ticlopidine hydrochloride. So far to our present knowledge, no 
validated stability indicating HPLC assay method for the determination of ticlopidine 
hydrochloride in pharmaceutical formulation was available in literature. Our work deals 
with the forced degradation of ticlopidine hydrochloride under stress condition like acid 
hydrolysis, base hydrolysis, and oxidation, thermal and photolytic stress. This work also 
deals with the validation of the developed method for the assay of ticlopidine 
hydrochloride from its dosage form (tablets). Hence, the method is recommended for 
routine quality control analysis and also stability sample analysis. 
 
The aim and scope of the proposed work are as under: 
 To developed suitable HPLC method for ticlopidine hydrochloride. 
 Forced degradation study of ticlopidine hydrochloride under stress condition 
 To resolve all major impurities generated during the force degradation studies of 
ticlopidine hydrochloride. 
 Perform the validation for the developed method. 
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4. EXPERIMENTAL 
4.1 Materials  
Ticlopidine hydrochloride standard was provided by Aarti Drugs Ltd., Boisar 
(India). Ticlopidine hydrochloride tablets containing 250mg ticlopidine hydrochloride 
and the inactive ingredient used in drug matrix were obtained from market. Analytical 
grade ammonium acetate was purchased from Sisco Research Pvt. Ltd., Mumbai (India). 
HPLC grade methanol and water were obtained from Spectrochem Pvt. Ltd., Mumbai 
(India). Analytical grade hydrochloric acid, glacial acetic acid, sodium hydroxide pellets 
and 30% v/v hydrogen peroxide solution were obtained from Ranbaxy Fine Chemicals, 
New Delhi (India).  
 
4.2 Instrumentation 
The chromatographic system used to perform development and validation of this 
assay method was comprised of a LC-10ATvp binary pump, a SPD-M10Avp photodiode-
array detector and a rheodyne manual injector model 7725i with 20μl loop (Shimadzu, 
Kyoto, Japan) connected to a multi-instrument data acquisition and data processing 
system (Class-VP 6.13 SP2, Shimadzu).  
 
4.3 Mobile Phase preparation 
The mobile phase consisted of methanol – 0.01M ammonium acetate buffer pH 5.0 
(80: 20, v/v). To prepare the buffer solution, 0.7708 g ammonium acetate were weighed 
and dissolve in 1000 ml HPLC grade water and then adjusted to pH 5.0 with glacial acetic 
acid. Mobile phase was filtered through a 0.45 μm nylon membrane (Millipore Pvt. Ltd. 
Benglore, India) and degassed in an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai).  
4.4 Diluent Preparation  
Methanol used as diluents. 
 
4.5 Standard Preparation  
A Ticlopidine hydrochloride standard solution containing 250 μg/ml was prepared 
in a 100 ml volumetric flask by dissolving 25.00 mg of ticlopidine hydrochloride and then 
diluted to volume with methanol as diluents.  
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4.6 Test Preparation  
Twenty tablets were weighed and the average weight of tablet was determined. 
From these, five tablets were weighed and transfer into a 500 ml volumetric flask. About 
50 ml methanol was added and sonicated for a minimum 30 min. with intermittent 
shaking. Then content was brought back to room temperature and diluted to volume with 
methanol. The sample was filtered through 0.45μm nylon syringe filter. The 
concentration obtained was 250 μg/ml of ticlopidine hydrochloride.  
 
4.7 Chromatographic Conditions  
Chromatographic analysis was performed on a Phenomenex Luna C8 (2) (250mm 
x 4.6mm i.d., 5 μm particle size) column. The mobile phase consisted of methanol – 
0.01M ammonium acetate buffer pH 5.0 (80: 20, v/v). The flow rate of the mobile phase 
was adjusted to 1.0 ml/min and the injection volume was 20 μl. Detection was performed 
at 235nm.  
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5.  RESULT AND DISCUSSION 
5.1 Development and Optimization of the HPLC Method 
 Proper selection of the methods depends upon the nature of the sample (ionic or 
ionisable or neutral molecule) its molecular weight and solubility. Ticlopidine 
hydrochloride is dissolved in polar solvent hence RP-HPLC was selected to estimate 
them. To develop a rugged and suitable HPLC method for the quantitative determination 
of ticlopidine hydrochloride, the analytical condition were selected after testing the 
different parameters such as diluents, buffer, buffer concentration, organic solvent for 
mobile phase and mobile phase composition and other chromatographic conditions. Our 
preliminary trials using different composition of mobile phases consisting of water with 
methanol or acetonitrile, did not give good peak shape.  
 The mobile phase consisted of methanol – 0.01M ammonium acetate buffer pH 
5.0 (80: 20, v/v). To prepare the buffer solution, 0.7708 g ammonium acetate were 
weighed and dissolve in 1000 ml HPLC grade water and then adjusted to pH 5.0 with 
glacial acetic acid. Mobile phase was filtered through a 0.45 μm nylon membrane 
(Millipore Pvt. Ltd. Benglore, India) and degassed in an ultrasonic bath (Spincotech Pvt. 
Ltd., Mumbai).  
 By using 10 mM Ammonium acetate buffer in 1000 ml of buffer, adjusted to pH 
5.0 with glacial acetic acid and keeping mobile phase composition as methanol-
ammonium acetate buffer (80: 20, v/v), best peak shape was obtained. For the selection of 
organic constituent of mobile phase, methanol was chosen to reduce the longer retention 
time and to attain good peak shape. Figure 2 and Figure 3 represent the chromatograms of 
standard and test preparation respectively. 
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Figure 2: Chromatogram of standard preparation 
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Figure 3: Chromatogram of test preparation 
5.3.1 Degradation Study 
The degradation samples were prepared by transferring powdered tablets, 
equivalent to 250 mg ticlopidine hydrochloride into a 250 ml round bottom flask. Then 
prepared samples were employed for acidic, alkaline and oxidant media and also for 
thermal and photolytic conditions. After the degradation treatments were completed, the 
stress content solutions were allowed to equilibrate to room temperature and diluted with 
mobile phase to attain 250 μg/ml concentrations. Specific conditions were described as 
follows. 
5.2.1 Acidic condition 
Acidic degradation study was performed by heating the drug content in 0.1 N HCl 
at 80° C for 1.5 hours and mixture was neutralized. Ticlopidine hydrochloride was found 
stable in acidic condition. (Figure 4) 
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Figure 4: Chromatogram of acidic forced degradation study 
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5.2.2 Alkaline condition 
Alkaline degradation study was performed by heating the drug content in 1 N 
NaOH at 80° C for 2 hours and mixture was neutralized. In alkali degradation, it was 
found that around 5-6 % of the drug degraded. (Figure 5) 
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Figure 5: Chromatogram of alkali forced degradation study 
 
5.2.3 Oxidative condition 
Oxidation degradation study was performed by heating the drug content in 3% v/v 
H2O2 at 80° C for 1 hour. Major degradation was found in oxidative condition that 
product was degraded up to 7-8 %. The major impurity peaks was found at 3.49min.  
(Figure 6) 
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Figure 6: Chromatogram of oxidative forced degradation study 
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5.2.4 Thermal condition 
Thermal degradation was performed by exposing solid drug at 80° C for 72 hours. 
Ticlopidine hydrochloride is found to be stable under thermal degradation condition. 
There is no degradation observed in above specific thermal condition. Ticlopidine 
hydrochloride was found to be stable in thermal condition. (Figure 7) 
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Figure 7: Chromatogram of thermal degradation study 
5.2.5 Photolytic condition 
Photolytic degradation study was performed by exposing the drug content in UV-
light for 72 hours. In photolytic degradation, it was found that around 4-5% of the drug 
degraded. (Figure 8) 
Minutes
0 5 10 15 20 25 30 35 40 45 50 55 60
m
A
U
0
200
400
T
ic
lo
p
id
in
e
 H
C
l
 
Figure 8: Chromatogram of UV-light degradation study 
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5.3 Method Validation 
5.3.1 Specificity 
   The specificity of the method was determined by checking the interference of 
placebo with analyte and the proposed method was eluted by checking the peak purity of 
ticlopidine hydrochloride during the force degradation study. The peak purity of the 
ticlopidine hydrochloride was found satisfactory (0.9999) under different stress condition. 
There was no interference of any peak of degradation product with drug peak. 
 
5.3.2 Linearity 
Seven points calibration curve were obtained in a concentration range from 100-
400 μg/ml for ticlopidine hydrochloride. The response of the drug was found to be linear 
in the investigation concentration range and the linear regression equation was y 
=303758861.79x+76638.20 with correlation coefficient 0.9999. (Figure 9) Chromatogram 
obtain during linearity study were shown in figure 10-16. 
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Figure 9: Linearity curve for ticlopidine hydrochloride 
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Figure 10: Linearity study chromatogram of level-1 (40%) 
 
Minutes
0 1 2 3 4 5 6 7 8 9 10 11 12
m
A
U
0
100
200
300
 
T
ic
lo
p
id
in
e
 H
C
l
 
Figure 11: Linearity study chromatogram of level-2 (60%) 
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Figure 12: Linearity study chromatogram of level-3 (80%) 
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Figure 13: Linearity study chromatogram of level-4 (100%) 
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Figure 14: Linearity study chromatogram of level-5 (120%) 
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Figure 15: Linearity study chromatogram of level-6 (140%) 
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Figure 16: Linearity study chromatogram of level-7 (160%) 
 
5.3.3 LOD and LOQ 
 The limit of detection and limit of quantification were evaluated by serial dilutions 
of ticlopidine hydrochloride stock solution in order to obtain signal to noise ratio of 3:1 
for LOD and 10:1 fro LOQ. The LOD value for ticlopidine hydrochloride was found to be 
0.25 ppm and the LOQ value 0.5 ppm. Chromatogram of LOD and LOQ study were 
shown in Figure 17-18. 
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Figure 17: Chromatogram of LOD Study of ticlopidine hydrochloride  
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Figure 28: Chromatogram of LOQ study of ticlopidine hydrochloride 
 
5.3.4 Precision 
 The result of repeatability and intermediate precision study are shown in Table 1. 
The developed method was found to be precise as the %RSD values for the repeatability 
and intermediate precision studies were < 0.41 % and < 0.61 %, respectively, which 
confirm that method was precise. 
 
Table 1: Evaluation data of precision study 
Set Intraday (n = 6) Interday (n = 6) 
1 100.3 100.5 
2 100.8 101.6 
3 101.4 101.3 
4 101.3 101.7 
5 100.8 100.5 
6 100.6 100.3 
Mean 100.9 101.0 
Standard deviation 0.42 0.62 
% RSD 0.41 0.61 
 
 
Ticlopidine HCl…   Part-A (Section-I) 
 
54 
5.3.5 Accuracy  
  The HPLC area responses for accuracy determination are depicted in Table 2. The 
result shown that best recoveries (99.78-99.95 %) of the spiked drug were obtained at 
each added concentration, indicating that the method was accurate. Chromatogram obtain 
during accuracy study were shown in figure 17-19. 
Table 2: Evaluation data of accuracy study 
 
Level (%) 
 
Amount added 
concentration
 a
 
(mg/ml) 
Amount found 
concentration
 a
 
(mg/ml) 
% Recovery % RSD 
50 0.12700 0.12693 99.55 0.41 
100 0.25133 0.25089 98.83 0.23 
150 0.37133 0.37051 99.78 0.28 
 
a
 Each value corresponds to the mean of three determinations 
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Figure 17: Accuracy study chromatogram of level-1 (50%) 
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Figure 18: Accuracy study chromatogram of level-2 (100%) 
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Figure 19: Accuracy study chromatogram of level-3 (150%) 
 
5.3.6 Solution stability study 
  Table 3 shows the results obtain in the solution stability study at different time 
intervals for test preparation. It was concluded that the test preparation solution was found 
stable up to 48 h at 2 - 5˚ C and ambient temperature, as during this time the result was 
not decrease below the minimum percentage. 
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Table 3: Evaluation data of solution stability study 
Intervals 
% Assay for test 
preparation solution 
stored at 2-5 ˚C 
% Assay for test preparation 
solution stored at ambient 
temperature 
Initial 100.1 100.1 
12 h 100.2 100.0 
24 h 99.9 99.8 
36 h 99.9 99.9 
48 h 99.6 99.4 
 
5.3.7 Robustness 
  The result of robustness study of the developed assay method was established in 
Table 4. The result shown that during all variance conditions, assay value of the test 
preparation solution was not affected and it was in accordance with that of actual. System 
suitability parameters were also found satisfactory; hence the analytical method would be 
concluded as robust. Chromatogram obtain during robustness study were shown in figure 
20-26. 
 
Table 4: Evaluation data of robustness study 
 
Robust conditions % Assay 
System suitability parameters 
Theoretical plates Asymmetry 
Flow 0.9 ml/min 100.6 6662 1.12 
Flow 1.1 ml/min 101.2 6349 1.18 
Buffer pH 4.8 100.1 5201 1.14 
Buffer pH 5.2 100.2 5630 1.24 
Buffer-ACN (78: 22,v/v) 100.2 5882 1.12 
Buffer-ACN (82: 18,v/v) 100.0 5446 1.29 
Column change 99.7 5741 1.08 
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Figure 20: Standard chromatogram (0.9 ml/min flow rate) 
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Figure 21: Standard chromatogram (1.1 ml/min flow rate) 
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Figure 22: Standard chromatogram (Buffer-ACN (78: 22, v/v)) 
Ticlopidine HCl…   Part-A (Section-I) 
 
58 
Minutes
0 1 2 3 4 5 6 7 8 9 10 11 12
m
A
U
0
200
400
600
T
ic
lo
p
id
in
e
 H
C
l
 
Figure 23: Standard chromatogram (Buffer-ACN (82: 18, v/v)) 
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Figure 24: Standard chromatogram (pH 5.2) 
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Figure 25: Standard chromatogram (pH 4.8) 
Ticlopidine HCl…   Part-A (Section-I) 
 
59 
Minutes
0 1 2 3 4 5 6 7 8 9 10 11 12
m
A
U
0
200
400
T
ic
lo
p
id
in
e
 H
C
l
 
Figure 26: Standard chromatogram (Column change) 
 
5.3.8 System suitability 
  A system suitability test of the chromatographic system was performed before 
each validation run. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate and % RSD of peak area were determined for same. 
Acceptance criteria for system suitability, asymmetry not more than 2.0, theoretical plate 
not less then 5000 and % RSD of peak area not more then 2.0, were full fill during all 
validation parameter.  
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4. CALCULATION AND DATA 
 
Calculation formula used 
 
    
1. Calculation formula for % assay of ticlopidine hydrochloride 
 
 
WeightTest
Weight
AreaMean
AreaTestMean
Assay
500
100
Standard
Standard
%  
 
Standard
5
50
ofPotency
ClaimLable
WeightTestMean
 
 
 
2. Relative standard deviation 
 
100
sMeasurmentofValueMean
sMeasurmentofDeviationStandard
RSD%  
 
 
3. Recovery 
 
100
AddedAmount
foundAmount
erycovRe%  
 
 
4. Amount found  
 
ionConcentratStandard
AreaStandardMean
AreaTestMean
)ml/mg(FoundAmount  
 
 
5. Amount added 
 
Volume
Weight
)ml/mg(AddedAmount  
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Specificity Study for Analytical Method Validation of Ticlopidine hydrochloride 
Tablets 
 
Standard Weight (mg) 25.8     
Standard Dilution 100     
Standard Potency 100 %     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration 
(mg/ml) 
0.258     
      
Replicate 1 2 3 4 5 
Standard Area 7815695 7835444 7834388 7826797 7823805 
Mean Standard Area 7827226     
Stdev. 8119.13     
% RSD 0.10     
 
 
Replicate Test Area 
1 7575821 
2 7578063 
Mean Test Area 7576942 
Test Weight (mg) 1429.1 
Label claim (mg) 250 
Mean Test Weight 
(mg) 
288.8 
% Assay 100.9 % 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
1.1429
500
100
8.25
7827226
7576942
% Assay 100
250
8.288
5
50
 
 
              
     = 100.9 % 
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Linearity Study for Analytical Method Validation of Ticlopidine hydrochloride 
Tablets 
 
 
 
 
 
 
 
 
 
 
 
Standard Weight (mg) 25.8     
Standard Dilution 100     
Standard Potency 100.0 %     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration (mg/ml) 0.258     
Concentration of Linearity Stock 
Solution (mg/ml) 
1.25     
      
Replicate 1 2 3 4 5 
Standard Area 7654471 7657745 7663816 7805836 7648103 
Mean Standard Area 7685994     
Stdev 60135.2     
% RSD 0.78     
Concentration Level 
(%) 
Volume of 
Linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final Concentration 
(mg/ml) 
Mean Area 
40 4.0 50 0.1000 3112800 
60 6.0 50 0.1500 4629979 
80 8.0 50 0.2000 6157095 
100 10.0 50 0.2500 7666394 
120 12.0 50 0.3000 9213297 
140 14.0 50 0.3500 10675619 
160 16.0 50 0.4000 12239042 
  Correlation co-efficient 0.9999 
  Slope 30375861.79 
  Intercept 76638.20 
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Precision Study for Analytical Method Validation of Ticlopidine hydrochloride 
Tablets 
 
 
Standard Weight (mg) 25.6     
Standard Dilution 100     
Standard Potency 100.0 %     
Label Claim (mg) 250     
Mean Test Weight (mg) 288.8     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration (mg/ml) 0.256     
      
Replicate 1 2 3 4 5 
Standard Area 7683474 7675223 7683625 7700051 7674693 
Mean Standard Area 7683413     
Stdev. 10246.78     
% RSD 0.13     
 
 
 
Description Mean area Test Weight (mg) % Assay 
Set 1 7498765 1439.1 100.3 
Set 2 7676178 1466.1 100.8 
Set 3 7689818 1460.1 101.4 
Set 4 7694288 1461.1 101.3 
Set 5 7511344 1434.1 100.8 
Set 6 7538668 1442.1 100.6 
  Mean 100.9 
  Stdev 0.42 
  % RSD 0.41 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
1.1439
500
100
6.25
7683413
7498765
% Assay 100
250
8.288
5
50
 
     
    = 100.3 % 
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Intermediate precision study for Analytical Method Validation of Ticlopidine 
hydrochloride tablet 
 
Standard Weight (mg) 25.8     
Standard Dilution 100     
Standard Potency 100.0 %     
Label Claim (mg) 250     
Mean Test weight (mg) 288.8     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration (mg/ml) 0.2580     
      
Replicate 1 2 3 4 5 
Standard Area 7706106 7785156 7732609 7794420 7695462 
Mean Standard Area 7742751     
Stdev. 45138.22     
% RSD 0.58     
 
 
 
Description Mean area Test Weight (mg) % Assay 
Set 1 7514538 1438.5 100.5 
Set 2 7690843 1456.4 101.6 
Set 3 7702078 1462.8 101.3 
Set 4 7707515 1458.6 101.7 
Set 5 7514284 1439.0 100.5 
Set 6 7560891 1450.7 100.3 
  Mean 101.0 
  Stdev 0.62 
  % RSD 0.61 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
5.1438
500
100
8.25
7742751
7514538
% Assay 100
250
8.288
5
50
 
     
 
    = 100.5 % 
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Comparison for Precision and Intermediate Precision Study for 
Analytical Method Validation for Ticlopidine hydrochloride Tablets 
 
 
 Set %Asay 
Precision study 
1 100.3 
2 100.8 
3 101.4 
4 101.3 
5 100.8 
6 100.6 
Intermediate precision study
1 100.5 
2 101.6 
3 101.3 
4 101.7 
5 100.5 
6 100.3 
 Mean 100.9 
 Stdev 0.51 
 % RSD 0.50 
 
 
Accuracy study for Analytical Method Validation of Ticlopidine 
hydrochloride tablets 
 
Standard Weight (mg) 25.8 
Standard Dilution 100 
Standard Potency 100.0 % 
Factor 1 298.50 
Factor 2 298.50 
Standard Concentration (mg/ml) 0.2580 
 
Replicate 1 2 3 4 5 
Standard Area 7637999 7695284 7701211 7690517 7670908 
Mean Standard Area 7679184     
Stdev 25678.50     
% RSD 0.33     
 
Ticlopidine HCl…   Part-A (Section-I) 
 
66 
Accuracy Study for Analytical Method Validation of Ticlopidine hydrochloride Tablets 
 
Recover
y 
Level 
Set 
No. 
Mean 
area 
Wigh
t (mg) 
Volume 
(ml) 
Amount added Amount found 
% 
Recovery 
Mean % 
Recover
y 
Std 
Dev 
% RSD Concentration(mg/ml
) 
Concentration(mg/ml
) 
50% 
Set 1 3908368 12.7 100 0.12700 0.12724 100.19 
99.95 0.41 0.41 Set 2 3877524 12.6 100 0.12600 0.12623 100.18 
Set 3 3911147 12.8 100 0.12800 0.12733 99.48 
100% 
Set 1 7709566 25.1 100 0.25100 0.25099 100.00 
99.83 0.23 0.23 Set 2 7707274 25.2 100 0.25200 0.25091 99.57 
Set 3 7703213 25.1 100 0.25100 0.25078 99.91 
150% 
Set 1 11364292 37.2 100 0.37200 0.36997 99.45 
99.78 0.28 0.28 Set 2 11387681 37.1 100 0.37100 0.37073 99.93 
Set 3 11391136 37.1 100 0.37100 0.37084 99.96 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
100
12700.0
12724.0
covRe% ery  = 100.19 % 
 
2500.0
7679184
3908368
)/( mlmgFoundAmount  = 0.12724 mg/ml 
 
100
7.12
)/( mlmgAddedAmount  = 0.12700 mg/ml
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Solution Stability Study for Analytical Method Validation of Ticlopidine 
hydrochloride Tablets 
 
 
System suitability of standard preparation for solution stability 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 7757874 7518815 7609269 7683945 7622877 
2 7763281 7623545 7631760 7713623 7712111 
3 7762355 7597709 7661026 7699542 7713724 
4 7762355 7600418 7666737 7685978 7731233 
5 7767107 7605695 7635902 7685993 7739825 
Mean 7763046 7589236 7640939 7693816 7703954 
Stdev 3399.38 40632.35 23354.01 12700.14 46814.37 
%RSD 0.04 0.54 0.31 0.17 0.61 
 
 
 
 
Solution stability for standard preparation at 2 -8°C 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 7757874 7757874 7757874 7757874 
2 7763281 7763281 7763281 7763281 
3 7762355 7762355 7762355 7762355 
4 7764611 7764611 7764611 7764611 
5 7767107 7767107 7767107 7767107 
1 7893626 7985419 7956735 7986193 
2 8018401 8010614 7916853 7981698 
Mean 7818179 7830180 7812688 7826160 
Stdev 100851.20 114918.04 85603.69 107831.65 
%RSD 1.29 1.47 1.10 1.38 
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Solution stability for standard preparation at room temperature 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 7757874 7757874 7757874 7757874 
2 7763281 7763281 7763281 7763281 
3 7762355 7762355 7762355 7762355 
4 7764611 7764611 7764611 7764611 
5 7767107 7767107 7767107 7767107 
1 7919478 7721317 7950553 7960751 
2 7771401 7894634 7834308 7999420 
Mean 7786587 7775883 7800013 7825057 
Stdev 58747.83 54695.32 71551.39 106527.47 
%RSD 0.75 0.70 0.92 1.36 
Solution stability for test preparation at 2 -8°C 
 
Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 7757874 7518815 7609269 7683945 7622877 
2 7763281 7623545 7631760 7713623 7712111 
3 7762355 7597709 7661026 7699542 7713724 
4 7764611 7600418 7666737 7685978 7731233 
5 7767107 7605695 7635902 7685993 7739825 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 7571168 7597329 7595651 7641296 7763862 
2 7499446 7448025 7628511 7673534 7846607 
Mean 7535307 7522677 7612081 7657415 7805234 
% Assay 100.1 100.2 99.9 99.9 99.6 
Standard weight (mg) 25.8 25.3 25.1 25.1 24.6 
Test weight (mg) 1438.5 1456.4 1462.8 1458.6 1439.0 
% Difference compare 
to that of Initial 
 -0.1 0.2 0.3 0.5 
Ticlopidine HCl…   Part-A (Section-I) 
 
69 
 
 
Solution stability for test preparation at room temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 7757874 7518815 7609269 7683945 7622877 
2 7763281 7623545 7631760 7713623 7712111 
3 7762355 7597709 7661026 7699542 7713724 
4 7764611 7600418 7666737 7685978 7731233 
5 7767107 7605695 7635902 7685993 7739825 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 7571168 7511262 7577153 7796588 7728102 
2 7499446 7498458 7623123 7838562 7838562 
Mean 7535307 7504860 7600138 7817575 7783332 
% Assay 100.1 100.0 99.8 99.9 99.4 
Standard weight (mg) 25.8 25.3 25.1 24.6 24.6 
Test weight (mg) 1438.5 1456.4 1462.8 1458.6 1439.0 
% Difference 
compare to that of 
Initial 
 0.1 0.3 0.2 0.8 
 
 
Calculation: 
 
Prototype calculation for one set: 
4.1456
500
100
3.25
7535307
7504860
% Assay 100
250
8.288
5
50
 
 
        = 100.00 % 
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Robustness Study for Analytical Method Validation of Ticlopidine hydrochloride Tablets 
 
 
 
Flow Rate at 
0.9ml/min 
Flow Rate at 
1.1ml/min 
Buffer-ACN 
63: 37 
Buffer- ACN 
67: 33 
Buffer pH 3.7 Buffer pH 3.3 
Column 
Change 
Replicate Standard Area Standard Area Standard Area Standard Area Standard Area Standard Area Standard Area 
1 8596688 6739023 8147538 8089507 8173081 8060999 7813568 
2 8653087 6978525 8160682 8178315 8219316 8158109 7918043 
3 8648104 6993772 8169591 8237396 8220580 8157099 7932029 
4 8645123 7014467 8176126 8213920 8212410 8160787 7984272 
5 8635802 7005135 8171698 8218279 8227428 8165395 7963510 
Mean 8635761 6946184 8165127 8187483 8210563 8140478 7922284 
Stdev 22731.52 116580.47 11327.12 58783.43 21619.99 44545.86 66095.04 
% RSD 0.26 1.68 0.14 0.72 0.26 0.55 0.83 
Replicate Test Area Test Area Test Area Test Area Test Area Test Area Test Area 
1 8544471 6923737 8073854 8073390 8096468 8019541 7767073 
2 8552299 6912500 8027313 8050042 8100256 8015954 7787106 
Mean 8548385 6918119 8050584 8061716 8098362 8017748 7777090 
Standard 
Weight (mg) 
25.4 25.4 25.4 25.4 25.4 25.4 25.4 
Test Weight 
(mg) 
1444.2 1444.2 1444.2 1444.2 1444.2 1444.2 1444.2 
Label Claim 
(mg) 
250 250 250 250 250 250 250 
Mean Test 
Weight (mg) 
288.8 288.8 288.8 288.8 288.8 288.8 288.8 
% Assay 100.6 101.2 100.2 100.0 100.2 100.1 99.7 
Calculation: Prototype calculation for one set: 
2.1444
500
100
4.25
8548385
6918119
% Assay 100
250
8.288
5
50
 = 101.2 % 
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HPLC METHOD DEVELOPMENT AND VALIDATION OF COMBINE DOSAGE 
FORM OF FUROSEMIDE AND SPIRONOLACTONE 
 
1. INTRODUCTION OF DRUG 
1.1 Introduction of Furosemide 
 
Furosemide (INN) or Frusemide (former BAN) is a loop diuretic used in the 
treatment of congestive heart failure and edema. It is most commonly marketed by 
Sanofi-Aventis under the brand name Lasix. It has also been used to prevent 
thoroughbred and standardbred race horses from bleeding through the nose during races. 
Along with some other diuretics, furosemide is also included on the World Anti-
Doping Agency's banned drug list due to its alleged use as a masking agent for other 
drugs. 
1.1.1 Description 
Furosemide is chemically 4-Chloro-2-(furan-2-ylmethylamino)-5-sulfa 
moylbenzoic acid (Figure 1). Its CAS number is 54-31-9. Its molecular formula is 
C12H11ClN2O5S  having molecular weight 330.74gm/mole. Furosemide, an anthranilic 
acid derivative, is a potent diuretic that inhibits the active reabsorption of chloride in the 
diluting segment of the loop of Henle, thus preventing the reabsorption of sodium, which 
passively follows chloride [1]. This loop diuretic is commonly used for the treatment of 
renal diseases, congestive heart failure and hypertension [2]. 
 
Cl
S
O
NH2
O
O OH
NH
O
 
 
 
Figure: 1     4-Chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid 
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1.1.2 Mechanism of action 
The name of Lasix is derived from lasts six (hours) -- referring to its duration of 
action. Like other loop diuretics, furosemide acts by inhibiting the Na-K-2Cl symporter in 
the thick ascending limb of the loop of Henle. The action on the distal tubules is 
independent of any inhibitory effect on carbonic anhydrase or aldosterone; it also 
abolishes the corticomedullary osmotic gradient and blocks negative as well as positive 
free water clearance. 
Due to the large NaCl absorptive capacity of the loop of Henle and the fact that 
diuresis is not limited by development of acidosis, as it is with the carbonic anhydrase 
inhibitors. 
By inhibiting the transporter, the loop diuretics reduce the reabsorption of NaCl 
and also diminish the lumen-positive potential that derives from K+ recycling. This 
electrical potential normally drives divalent cation reabsorbtion in the loop, and by 
reducing this potential loop diuretics cause an increase in Mg
2+
 and Ca
2+
 excretion. 
Prolonged use can cause significant hypomagnesemia in some patients. Since Ca
2+
 is 
actively reabsorbed in the distal convoluted tubule, loop diuretics do not generally cause 
hypocalcemia. 
Additionally, furosemide is a noncompetitive subtype-specific blocker of GABA-
A receptors [3][4][5]. Furosemide has been reported to reversibly antagonize GABA-
evoked currents of α6 β2 γ2 receptors at micromole concentrations, but not alpha1 β2 γ2 
receptors [3][5]. During development, the alpha6 beta2 gamma2 receptor increases in 
expression in cerebellar granule neurons, corresponding to increased sensitivity to 
furosemide [4]. 
 
1.1.3 Clinical use in humans 
Furosemide, as a loop diuretic, is principally used in the following indications 
(Aventis, 1998): 
 Edema associated with heart failure, hepatic cirrhosis, renal impairment, nephrotic 
syndrome  
 Hypertension  
 Adjunct in cerebral/pulmonary edema where rapid diuresis is required (IV 
injection) 
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It is also sometimes used in the management of severe hypercalcemia in 
combination with adequate rehydration [6]. Although disputed,[7] it is considered 
ototoxic: "usually with large parenteral doses and rapid administration and in renal 
impairment"[8]. The tendency, as for all loop diuretics, to cause low potassium levels 
(hypokalaemia) has given rise to combination products, either with potassium itself (e.g. 
Lasix-K) or with the potassium sparing diuretic of amiloride (Co-amilofruse). 
 
1.1.4 Use in horses 
The diuretic-effects are put to use most commonly in horses to prevent "bleeding" 
during a race. Sometime in the early 1970s, furosemide's ability to prevent, or at least 
greatly reduce, the incidence of "bleeding" (EIPH) by horses during races was discovered 
accidentally. Pursuant to the racing rules of most states, horses that bleed from the nostrils 
three times are permanently barred from racing (for their own protection). Clinical trials 
followed, and by decade's end, racing commissions in some states began legalizing its use 
on race horses. On September 1, 1995, New York became the last state in the United 
States to approve such use, after years of refusing to consider doing so. Some states allow 
its use for all racehorses; some allow it only for confirmed "bleeders." However, its use 
for this purpose is still prohibited in many other countries, and veterinarians dispute its 
use for this problem. 
Furosemide is also used in horses for pulmonary edema, congestive heart failure 
(in combination with other drugs), and allergic reactions. Despite the fact that it increases 
circulation to the kidneys, it does not help kidney function, and is not recommended for 
kidney disease. 
 
1.1.5 Precautions, side-effects, and administration 
Furosemide is injected either intramuscularly (IM) or intravenously (IV), usually 
0.5-1.0 mg/kg 2x/day, although less before a horse is raced. As with many diuretics, it can 
cause dehydration and electrolyte imbalance, including loss of potassium, calcium, 
sodium, and magnesium. It is especially important to prevent potassium loss. Excessive 
use of Furosemide will most likely lead to a metabolic alkalosis due to hypochloremia 
and hypokalemia as well as retention of bicarbonate as a result of fluid volume loss. The 
drug should therefore not be used in horses that are dehydrated or experiencing kidney 
failure. It should be used with caution in horses with liver problems or electrolyte 
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abnormalities. Overdose may lead to dehydration, change in drinking patterns and 
urination, seizures, GI problems, kidney damage, lethargy, collapse, and coma. 
Furosemide should be used with caution when combined with corticosteroids (as this 
increases the risk of electrolyte imbalance), aminoglycoside antibiotics (increases risk of 
kidney or ear damage), and trimethoprim sulfa (causes decreased platelet count). It may 
also cause interactions with anesthesics, so its use should be related to the veterinarian if 
the animal is going into surgery, and it decreases the kidney's ability to excrete aspirin, so 
dosages will need to be adjusted if combined with that drug 
Furosemide may cause digoxin toxicity due to hypokalemia. 
The drug is best not used during pregnancy or in a lactating mare, as it has been shown to 
be passed through the placenta and milk in studies with other species. It should not be 
used in horses with pituitary pars intermedia dysfunction (Cushings). 
Furosemide is detectible in urine 36-72 hours following injection. Its use is prohibited by 
most equestrian organizations. 
 
1.1.6 Drug interactions 
Furosemide has potential interactions with the following medications:[9] 
 Aminoglycoside antibiotics such as Gentamicin  
 Aspirin and other salicylates  
 Other diuretics (e.g. ethacrynic acid, hydrochlorothiazide)  
 Indomethacin  
 Lithium  
 Synergistic effects with other antihypertensives (e.g. Doxazosin)  
 Sucralfate 
 
1.1.7 Brand names 
Some of the brand names under which furosemide is marketed include: Aisemide, 
Apo-Furosemide, Beronald, Desdemin, Discoid, Diural, Diurapid, Dryptal, Durafurid, 
Errolon, Eutensin, Frusetic, Frusid, Fulsix, Fuluvamide, Furesis, Furix, Furo-Puren, 
Furosedon, Hydro-rapid, Impugan, Katlex, Lasilix, Lasix, Lodix, Lowpston, Macasirool, 
Mirfat, Nicorol, Odemase, Oedemex, Profemin, Rosemide, Rusyde, Salix, Trofurit, Urex, 
Frudix, Fusid. 
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1.2 Introduction of Spironolactone 
Spironolactone (marketed under the trade names Aldactone, Novo-Spiroton, 
Aldactazide, Spiractin, Spirotone, Verospiron or Berlactone) is a diuretic and is used as 
an antiandrogen. 
It is a synthetic 17-lactone drug that is a renal competitive aldosterone antagonist 
in a class of pharmaceuticals called potassium-sparing diuretics, used primarily to treat 
heart failure, ascites in patients with liver disease, low-renin hypertension, hypokalemia 
and Conn's syndrome. On its own, spironolactone is only a weak diuretic, but it can be 
combined with other diuretics. About one person in one hundred with hypertension has 
elevated levels of aldosterone; in these persons the antihypertensive effect of 
spironolactone may exceed that of complex combined regimens of other 
antihypertensives. Due to its anti-androgen effect, it can also be used to treat hirsutism, 
and it is a common component in hormone therapy for male-to-female transsexual and 
transgender people. It is commonly used to treat symptoms of Polycystic Ovary 
Syndrome (PCOS) such as excess facial hair and acne. 
1.2.1 Description 
Spironolactone is chemically 7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17-
carbolactone (Figure 2). Its molecular formula is C24H32O4S having molecular weight 
416.58 gm/mole. Spironolactone inhibits the effect of aldosterone by competing for 
intracellular aldosterone receptors in the distal tubule cells (it actually works on 
aldosterone receptors in the collecting duct). This increases the excretion of water and 
sodium, while decreasing the excretion of potassium. Spironolactone has a fairly slow 
onset of action, taking several days to develop, and similarly the effect diminishes slowly. 
Spironolactone has anti-androgen activity by binding to the androgen receptor and 
preventing it from interacting with dihydro testosterone [10]. 
O
O
O
H
H
H
H
S
O CH3
H
 
Figure: 2      7α-Acetylthio-3-oxo-17α-pregn-4-ene-21,17-carbolactone 
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1.2.2 Mechanism of action 
Spironolactone inhibits the effect of aldosterone by competing for intracellular 
aldosterone receptors in the distal tubule cells (it actually works on aldosterone receptors 
in the collecting duct). This increases the excretion of water and sodium, while decreasing 
the excretion of potassium. Spironolactone has a fairly slow onset of action, taking 
several days to develop, and similarly the effect diminishes slowly. Spironolactone has 
anti-androgen activity by binding to the androgen receptor and preventing it from 
interacting with dihydrotestosterone.[10] 
1.2.3 Pharmacokinetics 
Spironolactone is a synthetic steroid that acts as a competitive antagonist to 
aldosterone. Its onset and duration of action are determined by the kinetics of the 
aldosterone response in the target tissue. Substantial inactivation of spironolactone occurs 
in the liver. Over all, spironolactone has a rather slow onset of action, requiring several 
days before full therapeutic effect is achieved. 
1.2.4 Mortality and morbidity benefit in severe heart failure 
Spironolactone was shown to have a significant mortality and morbidity benefit in 
the Randomized Aldactone Evaluation Study (RALES), which studied people with severe 
congestive heart failure (New York Heart Association functional class III or IV).[11] 
Patients in the study arm of the trial (those receiving spironolactone) had a relative risk of 
death (when compared to the placebo group) equal to 0.70 or a 30% relative risk 
reduction. Patients in the study arm also had fewer symptoms of CHF and were 
hospitalized less frequently. 
The mechanism of this effect is also mediated by inhibiting aldosterone, which in 
conjunction with heart failure leads to myocardial fibrosis, sodium retention, and vascular 
dysfunction. 
1.2.5 Adverse effects and interactions  
Spironolactone is associated with an increased risk of bleeding from the stomach 
and duodenum, but a causal relationship between the two has not been established.[12] 
Because it also affects androgen receptors and other steroid receptors, it can cause 
gynecomastia, menstrual irregularities and testicular atrophy. Other side effects include 
ataxia, erectile dysfunction, drowsiness and rashes. A carcinogenic effect has been 
demonstrated in rats. Spironolactone has been shown to be immunosuppressive in the 
treatment of sarcoidosis.[13] 
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Spironolactone often increases serum potassium levels and can cause 
hyperkalemia, a potentially serious condition. Therefore, it is recommended that people 
using this drug avoid potassium supplements and salt substitutes containing potassium. 
[14] Doctors usually recommend periodic screening of serum potassium levels and some 
patients may be advised to limit dietary consumption of potassium. 
Research has also shown that spironolactone can interfere with the effectiveness of 
antidepressant treatment. The drug is actually (among its other receptor interactions) a 
mineralocorticoid (MR) antagonist, and has been found to reduce the effectiveness of 
antidepressant drugs in the treatment of major depression, presumably by interfering with 
normalization of the hypothalamic-pituitary-adrenal axis in patients receiving 
antidepressant therapy. [15] 
1.2.6 Carcinogenicity  
Studies of spironolactone and the related compound potassium canrenoate (which, 
like spironolactone, metabolizes to canrenone) in rats for one to two year periods show an 
increase in carcinogenesis in the thyroid gland, testes, liver, breasts, and myelocytic 
leukocytes. Mammalian cells, depending on the presence of metabolic activation, show 
mixed results for mutagenicity in vitro.[16] Doses relative to body weight were 10 to 150 
mg per kg, which is ten to 500 times higher than normal doses for treating humans. In 
light of this research, Sandoz has recommended that unnecessary use of spironolactone be 
avoided. 
1.2.7 Other potential benefits  
It has been suggested that spironolactone can reduce the risk of Alzheimer's 
disease. In one study [17], researchers observed a reduction in the risk of Alzheimer's 
specifically associated with potassium-sparing diuretics. Unpublished findings from other 
studies, including the Gothenberg Study have suggested that higher potassium levels may 
be associated with a lower risk of dementia. 
It is widely reported that most American diets contain more sodium than is 
necessary and lack the optimal daily intake of potassium. Therefore, spironolactone could 
theoretically counter the effects of the typical American diet as it tends to promote 
sodium excretion and potassium retention. However, there is no proof that it is beneficial 
for persons whose serum potassium and sodium levels are within the normal range. Few 
if any doctors would recommend using spironolactone in the absence of conditions for 
which it is normally indicated. 
Furosemide and Spironolactone…   Part-A (Section-II) 
 
 
 
79 
 
Spironolactone has also been shown to help prevent certain types of acne in 
females when taken in combination with oral contraceptives. 
2. LITERATURE REVIEW 
2.1 Literature review of furosemide 
The literature reviews regarding furosemide suggest that various analytical 
methods were reported for its determination as drug, in pharmaceutical formulation and in 
various biological fluids. The literature reviews for analysis of furosemide are as under:  
 
2.1.1 Santini, Alberto O.; Pezza, Helena R.; Sequinel, Rodrigo; Rufino, Jose L.; 
Pezza, Leonardo have studied the use of potentiometric sensor for furosemide 
determination in pharmaceuticals, urine, blood serum and bovine milk. The construction, 
evaluation, and analytical application of a potentiometric sensor, namely, 
Pt|Hg|Hg2(Fur)2|Graphite, where Furosemide 4-chloro-N-furfuryl-5-sulphamoyl-
anthranilate ion, are described.  This electrode has a linear dynamic range between 5.0  
10-7-1.0  10-2 mol L
-1
 with a near-nernstian slope of (-58.4  0.9) mV decade-1 and a 
detection limit of 3.8  10-7 mol L
-1
.  The potentiometric response is independent of the 
pH of the solution in the pH range 7.0-9.0.  The electrode shows easy construction, low-
cost, fast response time (within 10-20 s), and can be used for 6 month without significant 
change in its performance characteristics. The proposed sensor displayed good 
selectivities over a variety of other anions (carboxylates and inorg. anions) [18].   
 
2.1.2 Dias, Iara Lucia Tescarollo; Martins, Jorge Luiz S.; de Oliveira Neto, 
Graciliano have developed Furosemide determination by first-derivative 
spectrophotometric method.  Furosemide was analyzed in tablet and liquid 
pharmaceutical preparations entirely and after photolytic degradation, by direct UV 1st 
derivative spectrophotometry 1D at 262 nm.  At this wavelength, it was possible to 
eliminate the decomposition product interference.  A linear response range between 1.0 
and 10.0 g mL
-1
 was obtained in optimized conditions.  The estimation of relative 
standard deviation was within the range 0.37-2.4% (n = 10).  The method was applied in 
pharmaceutical samples, and the results were compared with those obtained with normal 
spectrophotometric method to determine furosemide with advantages as high selective, 
accuracy, and precision [19]. 
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2.1.3 Salim, Edward F.; Haussler, A.; Vaughan, J. B.  have studied  qualitative and 
quantiative tests for furosemide. Physical properties, identity tests, purity tests, and assay 
procedure are described for furosemide [20]. 
2.1.4 Xie, Juan; Yang, Fang; Zhai, Yu; Yao, Jie; Zhang, Weiqun   have developed 
determination of the related substances in furosemide for injection by HPLC. The 
samples were separated on Hypersil ODS column.  The mobile phase was water-
tetrahydrofuran-acetic acid (70:30:1) at a flow rate of 1.0 mL/min
-1
 at the wavelength of 
254 nm and the injection volume was 20 L.  The contents of the related substances were 
computed by a self control method.  the linear range of furosemide was 50-2000 g/mL
-1
 
(r = 0.999 7).  The avrage content of the related substances in samples was 0.78%.  The 
method is simple, rapid, accurate and reproducible, and it can be used as the quality 
control of furosemide for injection [21]. 
2.1.5 Valladao, Denia Mendes de Sousa; Ionashiro, Massao; Zuanon Netto, Jose  
have developed the method for determination of diuretic drugs by thin layer 
chromatography and spectrophotometry. A rapid, sensitive, and reliable thin-layer 
chromatography (TLC) and spectrophotometric screening procedure was developed for 
quantitation determination of diuretics in 4 pharmaceutical formulations (furosemide / 
spironolactone, furosemide / amiloride HCl, hydrochlorothiazide / spironolactone, 
hydrochlorothiazide/amiloride HCl). The TLC method used microcrystalline cellulose 
plates and butanol/glacial acetic acid/water (4:1:1) or amyl alcohol/25% aqueous 
ammonium hydroxide (9:1) as mobile phases, and detection by UV light.  The TLC Rf 
values were detected and the drug spots were collected from the TLC plates and 
quantified by UV spectrophotometrically at 271, 273, 238 and 286 nm for furosemide, 
hydrochlorothiazide, spironolactone, amiloride HCl respectivly. The obtained results 
were 97.5-102.5% of the theoretically values and were similar to data obtained by 
conventional methods [22]. 
2.1.6 Wesley-Hadzija, B.; Mattocks, A. M. have developed thin-layer 
chromatographic determination of furosemide and 4-chloro-5-sulfamoylanthranilic acid 
in plasma and urine. A method is described for the assay of furosemide [54-31-9] based 
on thin-layer chromatography and measurement of fluorescence directly on the plates.  As 
little as 10 ng can be accurately measured and fluorescence is linear up to 160 ng.  The 
metabolite or decomposed product 4-chloro-5-sulfamoylanthranilic acid  [3086-91-7] is 
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well separated and measured quantity in the procedure.  Application of the method to the 
assay in human plasma and urine is demonstrated [23]. 
2.1.7 He, Shu-hua; Li, Chao-yin have developed flow injection chemiluminescence’s 
method for the determination of furosemide based on KMnO4-Na2S2O4 reaction.  A novel 
flow injection chemiluminescence (FI-CL) system for determination of furosemide was 
presented.  It was based on the chemiluminescence reaction of sodium hydrosulfite with 
potassium permanganate in the vitriol acid solution. The emission intensity can be 
enhanced greatly by furosemide.  The chemiluminescence intensity was proportional to 
furosemide concentration over the range 0.01-5.0 mg/L.  The detection limit is 5.7μg/L 
and the relative standard deviation is 3.7% for the furosemide concentration 0.5 mg/L 
(times measuring n = 11).  This method had been successfully applied to determination of 
furosemide in injections [24]. 
2.1.8 Semaan, Felipe Silva; Cavalheiro, Eder Tadeu Gomes have developed 
spectrophotometric determination of furosemide based on its complexation with Fe (III) 
in ethanolic medium using a flow injection procedure. The proposed method was applied 
to tablets and ampoules and urine sample spiked with the analyte without an effect from 
the other substances present in the formulation [25]. 
2.1.9 Mishra, Pradeep; Katrolia, D.; Agrawal, R. K.  have developed  Simple 
colorimetric estimation of furosemide in dosage forms, tablets and injections by treatment 
with Cu(OAc)2 and measurement of the Cu complex obtained at 742 and 730 nm in 
MeOH and Ethyl acetate respectively. The metal to ligand ratio in the complex was 1:2 
and the structure was proposed.  The recovery was 98-100% and the sensitivity was 1-5 
mg/mL [26]. 
2.1.10 Dreux, C.; Halter, D.    Serv. Biochim., Hop. St.-Louis, Paris, Fr.,  have 
developed spectrofluorimetric determination of furosemide in biological fluids and 
application to pharmaco- and biokinetic studies. The method is described for the 
determination of furosemide [54-31-9] in blood serum and urine.  For blood serum 
samples, first is extracted with a slightly acidic EtOA soln. followed by a second 
extraction with borate buffer (pH 10).  The pH of the second extracted is adjusted to 2 
with formic acid and first was determined fluorometrically at 345 and 413 nm.  The 
sensitivity of this method is 0.02 and 0.5 μg/ml for serum and urine, respectively [27].   
2.1.11 Guerello, Lilo O.; Dobrecky, Jose have developed spectrophotometric 
determination of triamterene and furosemide in pharmaceutical mixtures. Triamterene and 
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furosemide in tablets are determined by spectrophotometry at 275 and 370 nm., using 
50% EtOH as a solvent [28]. 
2.1.12 Goelcue, A.  has developed spectrophotometric method was developed for the 
assay of furosemide (FUR), which is based on the complexation of the drug with 
copper(II) at pH 3.2 using Mclivaine buffer solution to produce a green adduct.  The latter 
has maximum absorbance at 790 nm and obeys Beer's law within the concentration range 
5-30 μg/mL.  Regression analysis of the calibration data showed a good correlation coeff. 
(r = 0.9997) with min. detection limit of 0.23 μg/mL.  The proposed procedure was 
successfully applied to the determination of this drug in tablets [29]. 
2.1.13 Abdel-Hay, Mohamed H.  have developed stability-indicating derivative 
spectrophotometric determination of frusemide.  The development of a first- and second-
derivative spectrophotometric determination of frusemide in pharmaceutical formulations 
in the presence of its acid-hydrolysis product saluamine, is described. The procedure 
involves measurements of first-derivative amplitudes at 254 and 262 nm and second-
derivative amplitudes at 265 and 272 nm for the assay of frusemide and saluamine, 
respectively. Kinetic investigation of the acid degrdation rate of frusemide revealed that 
the proposed method is stability indicating [30]. 
2.1.14 Hanna, George M.; Lau-Cam, Cesar A.  have developed stability-indicating 
proton nuclear magnetic resonance spectroscopic assay method for furosemide in tablets 
and injections. This method was developed for the identification and assay for furosemide 
and its degradation product, 4-chloro-5-sulfamoylanthranilic acid (CSA), in tablets and 
injections. Dissolution of the sample in D2O-NaOD resulted in a solution yielding the 
required separation among the resonance signals of furosemide, CSA, and tert-BuOH, the 
internal standard.  The mean standard deviation recovery values of furosemide and CSA 
from 10 synthetic formulations were 99.6 and 98.9%, respectively [31]. 
 
2.2 LITERATURE REVIEW OF SPIRONOLACTONE 
The literature reviews regarding spironolactone suggest that various analytical 
methods were reported for its determination as drug, in pharmaceutical formulation and in 
various biological fluids. The literature reviews for analysis of spironolactone are as 
under  
2.2.1 Tang, Zhen; Liu, Fuqiang; Go, Yuhui; Guo, Ye; Ren, Yulin have developed 
nondestructive quantitative analysis method of spironolactone pharmaceutical powder by 
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artificial neural network and near- infrared spectrometry. An artificial neural network 
model to predict unknown samples was based on the data from near-IR diffuse 
reflectance spectra of spironolactone pharmaceutical powders [32]. 
2.2.2 Mahrous, Mohamed S.; Issa, Ahmed S.; Soliman, Nabil S. have developed 
colorimetric methods for the determination of spironolactone in tablets. Three different 
methods were developed for the colorimetric determination of spironolactone, either in its 
pure form or in tablets.  The methods utilize either the alkaline picrate reagent, 
isonicotinic acid hydrazide solution or hydroxamic acid formation for the evaluation of 
spironolactone.  The sensitivity of the proposed procedures was discussed and the results 
obtained were compared with the pharmacopeial methods [33]. 
2.2.3 Moussa, Bahia A.; El Kousy, Naglaa M., have developed colorimetric analysis 
method of some diuretic drugs: hydrochlorothiazide and spironolactone.  
Hydrochlorothiazide [58-93-5] and spironolactone [52-01-7] were determined inbulk and 
tablets by colorimetry.  Hydrochlorothiazide reacted with BuNH2 [109-73-9] and CoCl2 
in anhydride medium, giving a blue-violet color. The absorbance at 570 nm of 0.2-1.12 
mg/mL hydrochlorothiazide obeyed Beer's law. Spironolactone determination was 
dependent on the reaction with isoniazid [54-85-3].  The absorbance was measured at 450 
nm.  Beer's law was obeyed over the concentration range 4-20 µg/mL [34]. 
2.2.4 Shingbal, D. M.; Rao, V. Ramakrishna have developed colorimetric analysis 
method for spironolactone and its dosage forms. Spironolactone [52-01-7] was 
determined in tablets by a colorimetric method based on spironolactone dissolution in 
EtOH and mixing of an aliquot of this solution with p-dinitrobenzene [100-25-4] and 
NaOH solution and measurement of the absorbance of the yellow solution at 400 nm.  
The color was stable for 6 hour at room temperature. Common tablet excipients did not 
interfere in the determination. The recovery was 98.8-99.76% [35]. 
2.2.5 Nevrekar, Vinay has developed spectrophotometric estimation of spironolactone. 
Spironolactone [52-01-7] was determined in tablets by dissolving in EtOH, diluted with 
MeOH, mixing with 2,3,5-triphenyltetrazolium chloride [298-96-4] and Me4NOH in 
MeOH, heating the solution at 45°C for 55 min, and measuring the absorbance at 480 nm.  
Beer's law held for 10-70 g/mL, and recoveries were 99.9-100.1% [36].  
2.2.6 Shingbal, D. M.; Prabhudesai, J. S.  have developed a spectrophotometric 
estimation method for spironolactone in pharmaceutical dosage form, based on reaction 
with isoniazid  [54-85-3] in CHCl3 and MeOH in acid medium and measuring the 
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absorbance of the resulting yellow solution at 375 nm.  Beer's law was obeyed in the 
concentration range 5-40 g/mL. The standard deviation was 0.613-0.652 and the 
recovery 99% [37].   
2.2.7 Parimoo, P.; Bharathi, A.; Padma, K. have developed a method for 
simultaneous determination of spironolactone with hydroflumethiazide and 
spironolactone with frusemide in combination formulations by UV absorption method. 
The λ max for SPN was found at 238 nm, for HFT at 273 nm and for FRU at 276 for SPN 
was found at 238 nm, for HFT at 273 nm and for FRU at 276 nm resp.  There were no 
interferences in their estimations [38]. 
2.2.8 Salem, Hesham; El-Maamli, Magda; El-Sadek, Mohamed; Kheir, Afaf Aboul 
have developed UV and UV derivative spectrophotometric determination of two-
component mixtures. Two-component mixtures (spironolactone with hydrochlorothiazide, 
captopril with hydrochlorothiazide, and spironolactone with furosemide) were assayed by 
UV (A), first derivative (dA/dλ) and second derivative (d2A/dλ) spectrophotometric 
methods, applying "Zero-Crossing" technique of measurement. The methods were proved 
using laboratory prepared mixtures.  The utility of the methods in assay of dosage forms 
is also presented [39].                
2.2.9 Chamberlain, Joseph has developed, a gas chromatographic determination 
method for levels of aldadiene in human plasma and urine following therapeutic doses of 
spironolactone. Aldadiene was extracted from the samples into dichloroethane and 
dissolved in EtOH for electron-capture gas chromatography on a 2% OV
-1
/CQ column at 
250°with N carrier gas and with androst-4-ene-3, 6, 17-trione as the internal standard.  
The mean recovery was 96% with < 4% standard deviations, and the detector response 
(relative peak height) was linear for 15 mg aldadiene/1 ml urine and 150 μg 
aldadiene/100 ml. plasma. Aldadiene levels in plasma reached a maximum of 10-15 
g/100 ml. approximately 3 hour after administration of 100-mg spironolactone, and 
approximately 4 mg aldadiene was excreted 24-hr following the spironolactone dose [40]. 
2.2.10 Belal, Fathalla has studied polarographic behavior and determination of 
spironolactone. The polarogaphic behavior of spironolactone in Britton-Robinson buffers 
content 40% MeOH as a solubilizer was studied. Over the pH range 3-12 a cathodic wave 
was produced. The wave was characterized as irreversible, diffusion-controlled and 
partially affected by adsorption phenomena. The number of electrons involved in the 
reduction was found by coulometric measurements at a controlled potential [41].   
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2.2.11 Dyade, G. K.; Sharma, A. K. have developed two methods for simultaneous 
spectrophotometric determination of spironolactone and hydroflumethiazide in tablet 
formulations. The methods were multi-wavelength spectroscopy and the isoabsorptive 
point method.  Spironolactone and hydroflumethiazide had absorption maxima at 238.0 
and 273.0 nm, respectively in MeOH. Both the drugs obeyed Beer's law in the 
concentration ranges employed for these methods [42].  
2.2.12 Ma, Hong-Yan; Qi, Guang-Cai. have developed method for determination of 
spironolactone by micellar enhanced spectrofluorimetry. In the presence of sodium 
dodecyl sulfate (SDS), the detection limit is 1.2  10-9 mol L
-1
, the linear range of 1.4  
10-9 - 4.3  10-6 mol L
-1
 is obtained. This method was successfully applied to the 
determination of spironolactone in tablets with satisfactory results [43].  
2.2.13 Parimoo, P.; Bharathi, A.; Padma, K. have developed Fluorimetric 
determination of spironolactone in the presence of frusemide and hydroflumethiazide in 
drug formulations. Spironolactone was determined in pharmaceuticals from its strong 
fluorescence in 62% H2SO4 and ethanol (excitation 324 nm, emission 530 nm).  The 
presence of HFT did not affect the fluorescence of SPN, however FRU caused a slight 
decrease in fluorescence intensity.  The limit of detection for SPN was 8.3 g/mL [44]. 
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3. AIM OF PRESENT WORK 
In recent time, there is increased tendency towards the development of stability-
indicating assays [45-47], using the approach of stress testing as enshrined in the 
International Conference on Harmonization (ICH) guideline Q1A (R2) [48]. Even this 
approach is being extended to drug combinations [49, 50] to allow accurate and precise 
quantitation of multiple drugs in presence of their degradation products and interaction 
product if any. 
Various publications are available regarding determination method of 
Spironolactone and Furosemide but most of the methods are applicable to alone 
Spironolactone or Furosemide in pharmaceutical dosage form or in biological fluids. 
Potentiometric, colorimetric estimation, thin-layer chromatography, fluorometrically, 
complexation, first-derivative and spectrophotometric, flow injection chemiluminescence 
method, proton nuclear magnetic resonance spectroscopic and HPLC methods are 
reported. Only four methods are reported for the simultaneous determination of 
spironolactone and furosemide. One is thin-layer chromatography (TLC) and 
spectrophotometric screening procedure was developed for quantitative determaination of 
diuretics in four pharmaceutical formulations (furosemide / spironolactone, furosemide / 
amiloride hydrochloride, hydrochlorothiazide / spironolactone, hydrochlorothiazide / 
amiloride hydrochloride). Two methods are UV and UV derivative spectrophotometric 
determination of two-component mixtures (spironolactone with hydrochlorothiazide, 
captopril with hydrochlorothiazide, and spironolactone with furosemide, spironolactone 
with hydroflumethiazide), which is able to determine spironolactone and furosemide in 
combined dosage form and fourth fluorimetric determination of spironolactone in the 
presence of frusemide and hydroflumethiazide in drug formulations. As far as our 
knowledge is concern, no stability-indicating analytical method for the determination of 
spironolactone and furosemide in combine dosage forms has been published. The 
previous published methods are not directly applicable for this issue and need more 
investigation for method development and validation.  
Consequently, the focus in the present study was to develop a validated stability 
indicating HPLC method for the combination, by degrading the drugs together under 
various stress conditions like acid hydrolysis, base hydrolysis, oxidation, thermal and 
photolytic stress which is recommended by ICH guideline. 
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The aim and scope of the proposed work are as under: 
 To developed suitable HPLC method for simultaneous determination spironolactone 
and furosemide in tablet formulation. 
 Forced degradation study of spironolactone and furosemide under stress condition. 
 To resolve all major impurities generated during the force degradation studies of 
spironolactone and furosemide. 
 Perform the validation for the developed method. 
 
4. EXPERIMENTAL 
4.1 Materials 
Spironolactone and Furosemide standard of was provided by Aarti Drugs Ltd., 
Boisar (India). Spironolactone and Furosemide tablets containing 50mg Spironolactone 
and 20mg Furosemide and the inactive ingredient used in drug matrix were obtained from 
market. HPLC grade acetonitrile and water were obtained from Spectrochem Pvt. Ltd., 
Mumbai (India). Analytical grade ammonium acetate, hydrochloric acid, glacial acetic 
acid, sodium hydroxide pellets and 30% v/v hydrogen peroxide solution were obtained 
from Ranbaxy Fine Chemicals, New Delhi (India). 
4.2 Instrumentation 
The chromatographic system used to perform development and validation of this 
assay method was comprised of a LC-10ATvp binary pump, a SPD-M10Avp photo-diode 
array detector and a rheodyne manual injector model 7725i with 20μl loop (Shimadzu, 
Kyoto, Japan) connected to a multi-instrument data acquisition and data processing 
system (Class-VP 6.13 SP2, Shimadzu). 
4.3 Mobile phase preparation 
The mobile phase consisted of acetonitrile – 0.01M ammonium acetate buffer pH 
3.9 (50: 50, v/v). To prepare the buffer solution, 0.7708 g ammonium acetate were 
weighed and dissolve in 1000 ml HPLC grade water and then adjusted to pH 3.9 with 
glacial acetic acid. Mobile phase was filtered through a 0.45μm nylon membrane 
(Millipore Pvt. Ltd. Bangalore, India) and degassed in an ultrasonic bath (Spincotech Pvt. 
Ltd., Mumbai). 
4.4 Diluent preparation 
Use Water: Acetonitrile: Methanol (50: 20: 30 v/v) used as a diluent. 
 
Furosemide and Spironolactone…   Part-A (Section-II) 
 
 
 
88 
 
4.5 Standard preparation 
Spironolactone standard stock solution containing 500µg/ml was prepared in a 
100 ml volumetric flask by dissolving 50.00 mg of Spironolactone and then diluted to 
volume with diluent. Further take 10 ml of this stock solution in 50 ml volumetric flask 
and make up to mark with diluent (this standard solution of 100µg/ml). Furosemide 
standard stock solution containing 200µg/ml was prepared in a 100 ml volumetric flask 
by dissolving 20.00 mg of Furosemide and then diluted to volume with diluent. Further 
take 10 ml of this stock solution in 50 ml volumetric flask and make up to mark with 
diluent (this standard solution of 40µg/ml). 
4.6 Test Preparation 
 
Twenty tablets were weighed and the average weight of tablet was determined. 
From these, five tablets were weighed and transfer into a 500 ml volumetric flask. About 
50 ml of diluent was added and sonicated for a minimum 30 minute. with intermittent 
shaking. Then content was brought back to room temperature and diluted to volume with 
diluent. The sample was filtered through 0.45µm nylon syringe filter. Further take 10 ml 
of this stock solution in 50 ml of volumetric flask and make up to mark with diluent. The 
concentration obtained was 100 µg/ml of Spironolactone and 40 µg/ml of Furosemide. 
 
4.7 Chromatographic Conditions 
Chromatographic analysis was performed on a SGE make SS Wakosil II 5C8RS 
column (150mm  4.6mm i.d., 5 μm particle size) column. The flow rate of the mobile 
phase was adjusted to 1.0 ml/min and the injection volume was 20 μl. Detection was 
performed at 254nm. 
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5. RESULT AND DISCUSSION 
5.1 Development and Optimization of the HPLC Method 
In the present work, an analytical method based on LC using UV detection was 
developed and validated for assay determination of Spironolactone and Furosemide in 
tablet formulation. The analytical conditions were selected, keeping in mind the different 
chemical nature of Spironolactone and Furosemide. The development trials were taken by 
using the degraded sample of each component was done, by keeping them in various 
extreme conditions. 
The column selection has been done on the basis of backpressure, resolution, peak 
shape, theoretical plates and day-to-day reproducibility of the retention time and 
resolution between Spironolactone and Furosemide peak. After evaluating all these 
factors, SGE make SS Wakosil II (150mm  4.6mm i.d., 5 μm particle size) column was 
found to be giving satisfactory results. The selection of buffer based on chemical structure 
of both the drugs. The acidic pH range was found suitable for solubility, resolution, 
stability, theoretical plates and peak shape of both components. Best results were obtained 
with 0.01M ammonium acetate buffer pH 3.9 with glacial acetic acid solution improved 
the peak shape of Spironolactone and Furosemide. Finally, by fixing    0.01M ammonium 
acetate buffer pH 3.9 and mobile phase composition consisting of a mixture of 0.01M 
ammonium acetate buffer pH 3.9 (v/v)-acetonitrile (50:50, v/v). Optimize mobile phase 
proportion was provide good resolution between Spironolactone and Furosemide and also 
for degradation product which is generated during force degradation study. For the 
selection of organic constituent of mobile phase, acetonitrile was chosen to reduce the 
longer retention time and to attain good peak shape. Figure 3 and Figure 4 represent the 
chromatograms of standard and test preparation respectively. 
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   Figure 3: Chromatogram of standard preparation 
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Figure 4: Chromatogram of test preparation 
5.2 Degradation Study 
In order to determine the analytical method and assay for the study of stability 
indicating method in tablets of Spironolactone combined with Furosemide studies under 
various stressed conditions to conduct forced degradation studies. Regulatory guidance in 
ICH Q2A, Q2B, Q3B and FDA 21CFR section 211 all require the development and 
validation of stability-indicating potency assays. Unfortunately, the current guidance 
documents do not indicate detailed degradation conditions in stress testing. However, the 
used forced degradation conditions, stress agent concentration and times of stress, were 
found to effect degradation, preferably not less than 10% and not complete degradation of 
active materials. The discovery of such conditions was based on trial and error. 
The degradation samples were prepared by transferring powdered tablets, 
equivalent to 50 mg Spironolactone and 20 mg Furosemide into a 250 ml round bottom 
flask. Then prepared samples were employed for acidic, alkaline and oxidant media and 
also for thermal and photolytic stress conditions. After the degradation treatments were 
completed, the stress content solutions were allowed to equilibrate to room temperature 
and diluted with mobile phase to attain 0.100 mg/ml of Spironolactone and 0.040 mg/ml
 
of Furosemide concentration. Specific degradation conditions were described as follows. 
 
5.2.1 Acidic condition 
Acidic degradation study was performed by taking the drug content in 0.01 N HCl 
at room temperature for 3.0 hour and mixture was neutralized. 
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The drug content was found to be degrading up to 8-9 % in acidic condition (Figure 5).   
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Figure 5: Chromatogram of acidic forced degradation study 
 
5.2.2 Alkaline condition 
Alkaline degradation study was performed by taking the drug content in 0.05 N 
NaOH at room temperature for 3.0 hour and mixture was neutralized. In alkali 
degradation, it was found that around 5-6 % of the drug degraded (Figure 6).  
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Figure 6: Chromatogram of alkali forced degradation study 
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5.2.3 Oxidative condition 
Oxidation degradation study was performed by taking the drug content in 30% v/v 
H2O2 at room temperature for 3 hour. In oxidative degradation, it was found that around 
0.1-0.3 % of the drug degraded (Figure 7). 
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Figure 7: Chromatogram of oxidative forced degradation study 
 
5.2.4 Thermal condition 
Thermal degradation was performed by exposing solid drug at 80˚ C for 72 hour. 
Resultant chromatogram of thermal degradation study indicate that spironolactone and 
furosemide is found to be stable under thermal degradation condition. (Figure 8) 
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Figure 8: Chromatogram of thermal degradation study 
Furosemide and Spironolactone…   Part-A (Section-II) 
 
 
 
93 
 
5.2.5 Photolytic condition 
Photolytic degradation study was performed by exposing the drug content in UV-
light for 72 h. There is slightly degradation observed in above specific photolytic 
condition. (Figure 9) 
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Figure 9: Chromatogram of UV-light degradation study 
 
5. Method Validation 
 
5.3.1 Specificity 
 
The specificity of the method was determined by checking the interference of 
placebo with analyte and the proposed method were eluted by checking the peak purity of 
Spironolactone and Furosemide during the force degradation study. The peak purity of 
the Spironolactone and Furosemide were found satisfactory under different stress 
condition. There was no interference of any peak of degradation product with drug peak. 
 
5.3.2 Linearity 
 
For linearity seven points calibration curve were obtained in a concentration range 
from 0.040-0.160 mg/ml for Spironolactone and 0.016-0.064 mg/ml for Furosemide. The 
response of the drug was found to be linear in the investigation concentration range and 
the linear regression equation for Spironolactone was y = 33130251.79x + 134505.25 
with correlation coefficient 0.9954(Figure 10) and for Furosemide was y = 22340420.21x 
+ 89280.80 with correlation coefficient 0.9964 (Figure 11). Where x is the concentration 
in mg/ml and y is the peak area in absorbance unit. Chromatogram obtain during linearity 
study were shown in Figure 12-18. 
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Linearity study for Spironolactone
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Figure 10: Linearity curve for Spironolactone 
Linearity study for Furosemide
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Figure 11: Linearity curve for Furosemide 
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Figure 12: Linearity study chromatogram of level-1 (40%) 
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Figure13: Linearity study chromatogram of level-2 (60%) 
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Figure14: Linearity study chromatogram of level-3 (80%) 
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Figure 15: Linearity study chromatogram of level-4 (100%) 
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Figure 16: Linearity study chromatogram of level-5 (120%) 
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Figure 17: Linearity study chromatogram of level-6 (140%) 
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Figure 18: Linearity study chromatogram of level-7 (140%) 
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5.3.3 LOD and LOQ 
The limit of detection and limit of quantification were evaluated by serial dilutions 
of Spironolactone and Furosemide stock solution in order to obtain signal to noise ratio of 
3:1 for LOD and 10:1 fro LOQ. The LOD value for Spironolactone and Furosemide were 
found to be 0.09 ppm and 0.06 ppm, respectively and the LOQ value 0.15  ppm and 0.15 
ppm, respectively. Chromatogram of LOD and LOQ study were shown in Figure 19-22. 
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Figure 19: Chromatogram of LOD Study of Spironolactone  
 
Minutes
0 1 2 3 4 5 6 7 8 9 10 11 12
m
A
U
-4
-2
0
2
F
u
r
o
s
e
m
id
e
(
S
p
ir
o
n
o
la
c
to
n
e
)
 
Figure 20: Chromatogram of LOD study of Furosemide 
 
Furosemide and Spironolactone…   Part-A (Section-II) 
 
 
 
98 
 
Minutes
0 1 2 3 4 5 6 7 8 9 10 11 12
m
A
U
-2
0
2
(F
u
ro
s
e
m
id
e
)
S
p
ir
o
n
o
la
c
to
n
e
 
Figure 21: Chromatogram of LOQ study of Spironolactone  
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Figure 22: Chromatogram of LOQ study of Furosemide  
 
5.3.4 Precision 
Data obtain from precision experiments are given in Table 1 for intraday and 
interday precision study for both Spironolactone and Furosemide. The RSD values for 
intra day precision study and interday precision study was < 2.0 % for Spironolactone and 
Furosemide. Which confirm that the method was precise. 
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Table 1: Results of precision study  
Set 
Spironolactone (%Assay) Furosemide (%Assay) 
Intraday 
(n = 6) 
Interday 
(n = 6) 
Intraday 
(n = 6) 
Intraday 
(n = 6) 
1 100.7 100.7 100.4 98.9 
2 101.1 100.9 100.5 98.9 
3 99.0 100.3 98.4 98.7 
4 100.7 99.7 98.0 98.5 
5 100.2 100.8 99.3 98.5 
6 101.6 100.3 100.9 98.4 
Mean 100.5 100.4 99.6 98.6 
Standard deviation 0.87 0.46 1.18 0.20 
% RSD
a
 0.87 0.46 1.19 0.20 
 
5.3.5 Accuracy 
Recovery of Spironolactone and Furosemide were determined at three different 
concentration levels. The mean recovery for Spironolactone was 99.12-99.83 % and 98.20-
100.35 % for Furosemide (Table 2). The result indicating that the method was accurate. 
Chromatogram obtain during accuracy study were shown in Figure 23-25. 
 
Table 2: Results of accuracy study 
 
 
Level 
(%) 
 
Theoretical 
Concentration
a
 
(µg/ml) 
Observed 
Concentration
a
 
(µg/ml) 
% 
Recovery 
% RSD 
Spironolactone 
50 50.34 50.42 100.17 0.49 
100 99.40 97.58 98.17 1.68 
150 148.73 145.83 98.05 1.38 
Furosemide 
50 20.85 20.73 100.58 0.32 
100 40.03 40.00 100.08 1.23 
150 59.64 60.20 99.07 1.37 
a
 Each value corresponds to the mean of three determinations 
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Figure 23: Accuracy study chromatogram of level-1 (50%) 
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 Figure 24: Accuracy study chromatogram of level-2 (100%) 
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 Figure 25: Accuracy study chromatogram of level-3 (150%) 
5.3.6 Solution stability study 
Table 3 shows the results obtain in the solution stability study at different time 
intervals for test preparation. It was concluded that the test preparation solution was found 
stable up to 48 h at 2 - 5˚ C and 36 h at ambient temperature with the consideration of      
< 2.0 % in %assay value difference against interval value. 
 
Table 3: Evaluation data of solution stability study 
 
Intervals 
% Assay for test solution 
stored at 2 -8˚ C 
% Assay for test solution 
stored at ambient 
temperature 
Spironolactone Furosemide Spironolactone Furosemide 
Initial 98.6 98.8 98.2 98.3 
12 h 99.9 99.7 98.9 101.0 
24 h 100.7 99.9 99.4 101.1 
36 h 99.4 100.5 100.5 101.4 
48 h 99.5 102.4 101.6 102.1 
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5.3.7 Robustness:  
The result of robustness study of the developed assay method was established in 
Table 4 and Table 5. The result shown that during all variance conditions, assay value of 
the test preparation solution was not affected and it was in accordance with that of actual. 
System suitability parameters were also found satisfactory, hence the analytical method 
would be concluded as robust. Chromatogram obtain during robustness study were shown 
in Figure 26-32. 
 
Table 4: Evaluation data of robustness study of Spironolactone  
 
Robust conditions % Assay 
System suitability parameters 
Theoretical plates Asymmetry 
Flow 0.9 ml/min 101.8 6332 1.55 
Flow 1.1 ml/min 102.0 6025 1.37 
Buffer pH 3.7 97.9 5987 1.35 
Buffer pH 4.1 98.5 6101 1.34 
Buffer-ACN (48:52,v/v) 99.9 6157 1.37 
Buffer-ACN (52:48,v/v) 98.8 5967 1.33 
Column change 100.0 6012 1.39 
 
Table 5: Evaluation data of robustness study for Furosemide  
 
Robust conditions % Assay 
System suitability parameters 
Theoretical plates Asymmetry 
Flow 0.9 ml/min 101.9 3391 1.55 
Flow 1.1 ml/min 102.1 2907 1.49 
Buffer pH 3.7 99.9 3001 1.46 
Buffer pH 4.1 99.4 2775 1.63 
Buffer-ACN (48:52,v/v) 100.5 3172 1.66 
Buffer-ACN (52:48,v/v) 99.7 3081 1.48 
Column change 100.9 2997 1.53 
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Figure 26:  Standard chromatogram (0.9 ml/min flow rate) 
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Figure 27: Standard chromatogram (1.1 ml/min flow rate) 
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Figure 28: Standard chromatogram (Buffer: ACN: 48: 52) 
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Figure 29: Standard chromatogram (Buffer: ACN: 52: 48) 
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Figure 30: Standard chromatogram (pH 4.1) 
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Figure 31: Standard chromatogram (pH 3.7) 
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Figure 32: Standard chromatogram (Column change) 
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5.3.8 System suitability:  
A system suitability test of the chromatographic system was performed before 
each validation run. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate, resolution and % RSD of peak area were determined for 
same. Acceptance criteria for system suitability, Asymmetry not more than 2.0, 
theoretical plate not less then 5000 for Spironolactone and 2000 for Furosemide and  % 
RSD of peak area not more then 2.0, were full fill during all validation parameter.  
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6. CALCULATION AND DATA 
 
Calculation formula used: 
 
1. Calculation formula for spironolactone 
 
 
WeightTest
Weight
AreaMean
AreaTestMean
Assay
500
50
10
100
Standard
Standard
%  
 
Standard
10
50
ofPotency
ClaimLable
WeightTestMean
 
 
2.  Calculation formula for furosemide 
 
 
50
10
100
Standard
Standard
%
Weight
AreaMean
AreaTestMean
Assay  
 
Standard
10
50500
ofPotency
ClaimLable
WeightTestMean
WeightTest
 
 
3. Relative standard deviation  
 
100
 tsMeasuremenofValueMean
 tsMeasuremenofDeviationStandard
RSD%  
 
4. Recovery  
 
100
AddedAmount
FoundAmount
erycovRe%  
 
5. Amount Found  
 
ionConcentratStandard
AreaStandardMean
AreaTestMean
)ml/mg(FoundAmount  
 
6. Amount added 
 
Volume
Weight
)ml/mg(AddedAmount  
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Specificity Study for Analytical Method Validation of Spironolactone Furosemide 
Tablets 
 
For Spironolactone 
 
Standard Weight (mg) 50.7     
Standard Dilution 100 10 50   
Standard Potency 100.00 %     
Factor 1 1     
Factor 2 1     
Standard Concentration 
(mg/ml) 0.1014     
      
Replicate 1 2 3 4 5 
Standard Area 3434665 3564491 3445427 3530658 3510034
Mean Standard Area 3497055     
Stdev 55684.81     
% RSD 1.59     
 
 
 
Replicate Test Area 
1 3339222 
2 3359414 
Mean Test Area 3349318 
Test Weight (mg) 1071.3 
Label Claim (mg) 50  
Average Test Weight (mg) 217.8 
% Assay 98.7 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
3.1071
500
50
10
100
7.50
3497055
3349318% ×××=Assay 100
50
8.217
10
50 ×××  
 
     = 98.7% 
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For Furosemide 
 
Standard Weight (mg) 20.5      
Standard Dilution 100 10 50   
Standard Potency 100.00 %     
Factor 1 1     
Factor 2 1     
Standard Concentration 
(mg/ml) 0.0410     
      
Replicate 1 2 3 4 5 
Standard Area 1169668 1211285 1171280 1191568 1189446
Mean Standard Area 1186649     
Stdev. 17055.15     
% RSD 1.44     
 
 
 
Replicate Test Area 
1 1115649 
2 1118716 
Mean Test Area  1117183 
Test Weight (mg) 1071.3 
Label Claim (mg) 20 
Mean Test weight (mg) 217.8 
% Assay 98.1 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
3.1071
500
50
10
100
5.20
1186649
1117183% ×××=Assay 100
20
8.217
10
50 ×××  
 
     = 98.1 % 
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Linearity Study for Analytical Method Validation of Spironolactone Furosemide 
Tablets 
 
For Spironolactone 
 
 
 
 
Standard Weight (mg) 100    
Standard Dilution 100 5 50  
Standard Potency 100.00 %     
Factor 1 1     
Factor 2 1     
Standard Concentration (mg/ml) 0.1000     
Concentration of Linearity Stock 
Solution (mg/ml) 1.0000     
      
 Replicate 1 2 3 4 5 
Standard Area 3358047 3327487 3242463 3248372 3326242 
Mean Standard Area 3300522     
Stdev 51933.19     
% RSD 1.57     
Concentration Level 
(%) 
Volume of 
Linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final Concentration 
(mg/ml) Mean Area 
40 2.0 50 0.0400 1472382 
60 3.0 50 0.0600 2198842 
80 4.0 50 0.0600 2834923 
100 5.0 50 0.0800 3249713 
120 6.0 50 0.1000 4077397 
140 7.0 50 0.1400 4773071 
160 8.0 50 0.1600 5526385 
  Correlation co-efficient 0.9977 
  Slope 33130251.79 
  Intercept 134504.96 
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For Furosemide 
 
 
 
Standard Weight (mg) 40.0    
Standard Dilution 100 10 50  
Standard Potency 100.00%    
Factor 1 1     
Factor 2 1     
Standard Concentration (mg/ml) 0.0400     
Concentration of Linearity Stock 
Solution (mg/ml) 0.4000     
      
Replicate 1 2 3 4 5 
Standard Area 955907 978747 981115 999690 971299 
Mean Standard Area 977352     
Stdev 15902.98     
% RSD 1.63     
Concentration Level 
(%) 
Volume of 
Linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final Concentration 
(mg/ml) Mean Area 
40 2.0 50 0.0160 425980 
60 3.0 50 0.0240 635952 
80 4.0 50 0.0320 827192 
100 5.0 50 0.0400 958738 
120 6.0 50 0.0480 1194404 
140 7.0 50 0.0560 1403349 
160 8.0 50 0.0640 1624030 
  Correlation co-efficient 0.9953 
  Slope 23551999.11 
  Intercept 54410.96 
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Precision Study for Analytical Method Validation of Spironolactone and Furosemide 
Tablets 
 
For Spironolactone 
 
 
Standard Weight (mg) 49.6     
Standard Dilution 100 10 100   
Standard Potency 100.00 %     
Label Claim (mg) 50     
Mean Test Weight (mg) 1071.3     
Factor 1 1     
Factor 2 1     
Standard Concentration (mg/ml) 0.0498     
      
Replicate 1 2 3 4 5 
Standard Area 3422949 3398387 3494888 3463082 3404464 
Mean Standard Area 3436754     
Stdev 41164.23     
% RSD 1.19     
 
 
 
 
Description Mean area Test Weight (mg) % Assay 
Set 1 3366197 1071.5 100.6 
Set 2 3379481 1070.5 101.1 
Set 3 3311436 1071.3 99.0 
Set 4 3366585 1070.4 100.7 
Set 5 3351654 1071.4 100.2 
Set 6 3397057 1073 101.4 
  Mean 100.5 
  Stdev 0.85 
  % RSD 0.84 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
5.1071
500
50
10
100
6.49
3436754
3366197% ×××=Assay 100
50
8.217
10
50 ×××  
 
       = 100.6 % 
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For Furosemide 
 
Standard Weight (mg) 19.8     
Standard Dilution 100 10 100   
Standard Potency 100.00 %     
Label claim (mg) 20     
Mean Test Weight (mg) 1071.3     
Factor 1 1     
Factor 2 1     
Standard Concentration (mg/ml) 0.0198     
      
Replicate 1 2 3 4 5 
Standard Area 996415 1002313 1027860 1015754 1024923 
Mean Standard Area 1013453     
Stdev 13773.25     
% RSD 1.35     
 
Description Mean area Test weight (mg) % Assay 
Set 1 998819 1071.5 101.0 
Set 2 999963 1070.5 101.1 
Set 3 978857 1071.3 98.9 
Set 4 975578 1070.3 98.6 
Set 5 987644 1071.4 99.8 
Set 6 1003532 1072 101.4 
  Mean 100.1 
  Stdev 1.19 
  % RSD 1.19 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
5.1071
500
50
10
100
8.19
1013453
998819% ×××=Assay 100
20
8.217
10
50 ×××  
 
       = 101.0 % 
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Intermediate Precision Study for Analytical Method Validation of Spironolactone 
and Furosemide Tablet 
 
For Spironolactone 
 
 
Standard Weight (mg) 50.7     
Standard Dilution 100 10 100   
Standard Potency 100.00 %     
Label Claim (mg) 50     
Mean Test Weight (mg) 1071.3     
Factor 1 1     
Factor 2 1     
Standard Concentration (mg/ml) 0.0507     
      
Replicate 1 2 3 4 5 
Standard Area 3607847 3534395 3602177 3569508 3575830
Mean Standard Area 3577951     
Stdev 29383.57     
% RSD 0.82     
 
 
Description Mean area Test Weight (mg) % Assay 
Set 1 3496814 1071.5 100.7 
Set 2 3500878 1070.5 100.9 
Set 3 3480761 1071.3 100.3 
Set 4 3459055 1070.3 99.7 
Set 5 3497922 1071.4 100.8 
Set 6 3480035 1072 100.3 
  Mean 100.4 
  Stdev 0.46 
  % RSD 0.46 
 
Calculation: 
 
Prototype calculation for one set: 
 
5.1071
500
50
10
100
7.50
3577951
3496814% ×××=Assay 100
50
8.217
10
50 ×××  
 
       = 100.7 % 
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For Furosemide 
 
Standard Weight (mg) 20.4     
Standard Dilution 100 10 100   
Standard Potency 100.00 %     
Label Claim (mg) 20     
Mean Test Weight (mg) 1071.3     
Factor 1 1     
Factor 2 1     
Standard Concentration (mg/ml) 0.0204     
      
Replicate 1 2 3 4 5 
Standard Area 1057052 1048022 1056219 1051455 1051195 
Mean Standard Area 1052789     
Stdev 3774.35     
% RSD 0.35     
 
 
Description Mean area Test Weight (mg) % Assay 
Set 1 1003949 1071.5 98.9 
Set 2 1004029 1070.5 98.9 
Set 3 1001844 1071.3 98.7 
Set 4 1000111 1070.3 98.5 
Set 5 1000388 1071.4 98.5 
Set 6 999289 1072 98.4 
  Mean 98.6 
  Stdev 0.20 
  % RSD 0.20 
 
Calculation: 
 
Prototype calculation for one set: 
 
5.1071
500
50
10
100
4.20
1052789
1003949% ×××=Assay 100
20
8.217
10
50 ×××  
 
       = 98.9 % 
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Comparison for Precision and Intermediate Precision Study for Analytical Method 
Validation for Spironolactone Furosemide Tablets 
 
For Spironolactone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For Furosemide  
 
 
  
   
 
 
 
 
 
 
 Set %Assay 
Precision study 
1 100.6 
2 101.1 
3 99.0 
4 100.7 
5 100.2 
6 101.4 
Intermediate precision 
study 
1 100.7 
2 100.9 
3 100.3 
4 99.7 
5 100.8 
6 100.3 
 Mean 100.5 
 Stdev 0.64 
 % RSD 0.64 
 Set % Assay 
Precision study 
1 101.0 
2 101.1 
3 98.9 
4 98.6 
5 99.8 
6 101.3 
Intermediate precision study 
1 98.9 
2 98.9 
3 98.7 
4 98.5 
5 98.5 
6 98.4 
 Mean 99.4 
 Stdev 1.12 
 % RSD 1.12 
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Accuracy Study for Analytical Method Validation of Spironolactone Furosemide 
Tablets 
 
For Spironolactone  
 
 
Standard Weight (mg) 50.1     
Standard Dilution 100 10 50   
Standard Potency 100.0 %     
Factor 1 1     
Factor 2 1     
Standard Concentration 
(mg/ml) 0.0501     
      
Replicate 1 2 3 4 5 
Standard Area 3450152 3391468 3494337 3519238 3571250 
Mean Standard Area 3485289     
Stdev 68302.05     
% RSD 1.96     
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Calculation: 
 
Prototype calculation for one set: 
 
100
04960.0
0.05007covRe% ×=ery  = 100.95 % 
 
0.1000
3485289
1745230)/( ×=mlmgFoundAmount = 0.05007 mg/ml 
 
50
10
100
24.8)/( ×=mlmgAddedAmount  = 0.04960 mg/ml 
Recovery 
Level Set No. 
Mean 
area 
Wt. 
(mg) 
Volume 
(ml) 
Value added Value found % 
Recovery 
Mean % 
Recovery
Std 
Dev 
% 
RSD Concentration(mg/ml) Concentration(mg/ml)
50% 
Set 1 1745230 24.8 100 0.04960 0.05007 100.95 
100.85 0.30 0.29 Set 2 1751617 25 100 0.05000 0.05026 100.52 
Set 3 1775875 25.2 100 0.05040 0.05095 101.09 
100% 
Set 1 3416855 50.1 100 0.10020 0.09804 97.84 
98.28 0.88 0.89 Set 2 3419150 50.2 100 0.10040 0.0981 97.71 
Set 3 3467489 50.1 100 0.10020 0.09949 99.29 
150% 
Set 1 5086446 75 100 0.15000 0.14594 97.29 
98.74 1.85 1.87 Set 2 5115728 74.8 100 0.14960 0.14678 98.11 
Set 3 5270956 75 100 0.15000 0.15123 100.82 
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For Furosemide 
 
Standard Weight (mg) 20.0     
Standard Dilution 100 10 50   
Standard Potency 100.00 %     
Factor 1 1     
Factor 2 1     
Standard Concentration 
(mg/ml) 0.0200     
      
Replicate 1 2 3 4 5 
Standard Area 1032216 993347 991806 1022863 1011881 
Mean Standard Area 1010422.6     
Stdev 17818.51     
% RSD 1.76     
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Recovery 
Level 
Set No. 
Mean 
area 
Wt. 
(mg) 
Volume 
(ml) 
Value added Value found % 
Recovery 
Mean % 
Recovery 
Std 
Dev 
% 
RSD Concentration(mg/ml) Concentration(mg/ml) 
50% 
Set 1 521772 10.1 100 0.02020 0.02066 102.28 
101.24 0.92 0.91 Set 2 525045 10.3 100 0.02060 0.02079 100.92 
Set 3 533203 10.5 100 0.02100 0.02111 100.52 
100% 
Set 1 987013 19.8 100 0.03960 0.03907 98.66 
100.24 1.38 1.37 Set 2 1019447 20 100 0.04000 0.04036 100.90 
Set 3 1027426 20.1 100 0.04020 0.04067 101.17 
150% 
Set 1 1509906 
1484600 
1530606 
30 100 0.06000 0.05977 99.62 
99.74 1.19 1.20 Set 2 29.8 100 0.05960 0.05877 98.61 
Set 3 30 100 0.06000 0.06059 100.98 
 
Calculation: 
 
Prototype calculation for one set: 
100
02020.0
0.02066
covRe% ery  = 102.28 % 
 
0400.0
1010423
521772
)/( mlmgFoundAmount  = 0.02066 mg/ml 
 
50
10
100
10.1
)/( mlmgAddedAmount  = 0.02020 mg/ml 
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Solution Stability Study for Analytical Method Validation of Spironolactone 
Furosemide Tablets 
 
For Spironolactone 
 
System suitability of standard preparation for solution stability 
 
Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours After 48 hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 3525659 3411851 3345671 3414991 3513918 
2 3506215 3373068 3360744 3362291 3488186 
3 3521712 3306061 3414441 3450124 3415377 
4 3481247 3446621 3382720 3450478 3462041 
5 3501201 3362608 3333020 3424563 3594032 
Mean 3507207 3380042 3367319 3420489 3494711 
Stdev 17761.26 53080.94 32194.57 36095.03 66402.86 
%RSD 0.51 1.57 0.96 1.06 1.90 
 
 
 
 
 
 
Solution stability for standard preparation at 2-8°C 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 3411851 3345671 3414991 3513918 
2 3373068 3310744 3362291 3488186 
3 3306061 3414441 3450124 3415377 
4 3446621 3382720 3450478 3462041 
5 3362608 3333020 3424563 3594032 
1 3314054 3356620 3402914 3354205 
2 3280379 3295503 3415413 3431034 
Mean 3356377 3348388 3417253 3465542 
Stdev 60051.91 40961.17 30201.46 76896.23 
%RSD 1.79 1.22 0.88 2.22 
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Solution stability for test preparation at 2-8°C 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 3525659 3411851 3345671 3414991 3513918 
2 3506215 3373068 3360744 3362291 3488186 
3 3521712 3306061 3414441 3450124 3415377 
4 3481247 3446621 3382720 3450478 3462041 
5 3501201 3362608 3333020 3424563 3594032 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 3405183 3392125 3356620 3391772 3392359 
2 3423649 3360191 3295503 3299577 3410809 
Mean 3414416 3376158 3326062 3345675 3401584 
% Assay 99.16 101.13 100.41 99.43 99.54 
Standard weight (mg) 50.1 49.8 50 50 50.3 
Test weight (mg) 1071.5 1070.5 1071.3 1070.4 1071.4 
% Difference compare 
to that of Initial 
 -1.97 -1.25 -0.27 -0.38 
 
 
 
 
Solution stability for test preparation at room temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 3525659 3411851 3345671 3414991 3513918 
2 3506215 3373068 3360744 3362291 3488186 
3 3521712 3306061 3414441 3450124 3415377 
4 3481247 3446621 3382720 3450478 3462041 
5 3501201 3362608 3333020 3424563 3594032 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 3405183 3239051 3268654 3319474 3474067 
2 3423649 3315343 3353971 3446251 3467102 
Mean 3414416 3277197 3311313 3382863 3470585 
% Assay 99.16 98.95 99.96 101.56 101.56 
Standard weight 
(mg) 
50.1 50.2 50 50.3 50.3 
Test weight (mg) 1071.5 1070.5 1071.3 1070.4 1071.4 
% Difference 
compare to that of 
Initial 
 0.21 -0.80 -1.37 -2.40 
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Calculation: 
 
Prototype calculation for one set: 
 
5.1070
500
50
10
100
5.20
1186649
1117183
% Assay 100
50
8.217
10
50
 
 
       = 98.9 % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Solution stability for standard preparation at room temperature 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 3411851 3345671 3414991 3513918 
2 3373068 3310744 3362291 3488186 
3 3306061 3414441 3450124 3415377 
4 3446621 3382720 3450478 3462041 
5 3362608 3333020 3424563 3594032 
1 3361898 3466189 3410165 3712552 
2 3451174 3390475 3350446 3600192 
Mean 3387612 3377609 3409008 3540900 
Stdev 52054.81 53031.14 39372.93 101064.76 
%RSD 1.54 1.57 1.15 2.85 
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For Furosemide 
 
 
System suitability of standard preparation for solution stability 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1048331 1010899 1008119 998235 1010610 
2 1048871 996520 993634 989691 1007649 
3 1053257 995405 1005471 1010631 999640 
4 1036581 1018127 1018657 1004096 996152 
5 1042941 1000193 998760 999268 1001175 
Mean 1045996 1004229 1004928 1000384 1003045 
Stdev 6411.22 9889.69 9546.75 7729.55 5937.81 
%RSD 0.61 0.98 0.95 0.77 0.59 
Solution stability for standard preparation at 2 -8°C 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1010899 1008119 998235 1000610 
2 996520 993634 989691 987649 
3 995405 1005471 1000631 989640 
4 1018127 1038657 1004096 986152 
5 1000193 991760 999268 1001175 
1 996628 1008030 1005403 995163 
2 989619 996377 995530 1034090 
Mean 1001056 1006007 998979 999211 
Stdev 9932.86 15935.64 5306.92 16505.39 
%RSD 0.99 1.58 0.53 1.65 
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Solution stability for test preparation at 2-8°C 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1048331 1000899 1008119 998235 1010610 
2 1048871 996520 993634 989691 1007649 
3 1053257 995405 1005471 1010631 999640 
4 1036581 1018127 1018657 1004096 996152 
5 1042941 1000193 998760 999268 1001175 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 1023050 1002086 1008030 996713 1004486 
2 1030439 995625 996377 975585 1019092 
Mean 1026745 998855.5 1002204 986149 1011789 
% Assay 99.78 100.30 101.38 100.71 102.54 
Standard weight (mg) 20 19.8 20 20.1 20 
Test weight (mg) 1071.5 1070.5 1071.3 1070.4 1071.4 
% Difference compare 
to that of Initial 
 -0.52 -1.60 -0.93 -2.76 
Solution stability for standard preparation at room temperature 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1010899 1008119 998235 1010610 
2 996520 993634 989691 987649 
3 995405 1005471 1010631 989640 
4 1018127 1028657 1004096 986152 
5 1000193 991760 999268 1001175 
1 993542 1023075 1019939 1042858 
2 1018958 1034299 994032 1034149 
Mean 1004806 1012145 1002270 1007462 
Stdev 10954.81 16841.75 10302.29 23017.40 
%RSD 1.09 1.66 1.03 2.28 
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Calculation: 
 
Prototype calculation for one set: 
 
5.1071
500
50
10
100
1.20
1026745
1002202
% Assay 100
20
8.217
10
50
 
 
       = 100.4 % 
Solution stability for test preparation at room temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1048331 1010899 1008119 998235 1010610 
2 1048871 996520 993634 989691 1007649 
3 1053257 995405 1005471 1010631 999640 
4 1036581 1018127 1018657 1004096 996152 
5 1042941 1000193 998760 999268 1001175 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 1023050 1007667 1018936 997219 1011072 
2 1030439 996737 1009267 1012044 1009445 
Mean 1026745 1002202 1014102 1004632 1010259 
% Assay 100.0 100.43 101.55 100.55 102.90 
Standard weight 
(mg) 
20.0 19.8 19.8 19.7 19.7 
Test weight (mg) 1071.5 1070.5 1071.3 1070.4 1071.4 
% Difference 
compare to that of 
Initial 
 -0.65 -1.77 -0.77 -3.12 
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Robustness Study for Analytical Method Validation of Spironolactone and Furosemide Tablets (Spironolactone) 
 
 
Flow Rate at 
0.9ml/min 
Flow Rate at 
1.1ml/min 
Buffer-ACN 
63: 37 
Buffer-ACN 
67: 33 
Buffer (2.8ml 
H3PO4/1000ml 
Water) 
Buffer (3.2ml 
H3PO4/1000ml 
Water) 
Column 
Change 
Replicate Standard Area Standard Area Standard Area Standard Area Standard Area Standard Area Standard Area 
1 3689245 3206633 3618178 3720294 3626939 3700285 3595942 
2 3787482 3209181 3640034 3728108 3742577 3754790 3671540 
3 3861800 3312580 3679052 3725628 3678611 3737570 3733938 
4 3819055 3322020 3702796 3796641 3712511 3740479 3805384 
5 3788216 3337606 3686992 3904388 3716452 3724136 3688574 
Mean 3789160 3277604 3665410 3775012 3695418 3731452 3699076 
Stdev 63555.08 64255.22 35087.05 78801.63 44526.45 20545.59 77494.99 
% RSD 1.68 1.96 0.96 2.09 1.20 0.55 2.09 
Replicate Test Area Test Area Test Area Test Area Test Area Test Area Test Area 
1 3727715 3309744 3526958 3656223 3651960 3620741 3684200 
2 3655753 3255163 3522067 3647441 3595328 3615275 3582560 
Mean 3691734 3282454 3524513 3651832 3623644 3618008 3633380 
Standard weight 
(mg) 
50.1 49.8 50.1 50.1 50.1 50.1 50.1 
Test weight (mg) 1071.3 1071.3 1071.3 1071.3 1071.3 1071.3 1071.3 
Label claim (mg) 50 50 50 50 50 50 50 
Average test 
weight (mg) 
217.8 217.8 217.8 217.8 217.8 217.8 217.8 
% Assay 99.2 101.4 97.9 98.5 99.9 98.8 100.0 
 
Calculation: Prototype calculation for one set: 
5.1071
500
50
10
100
1.20
3691734
3789160
% Assay 100
50
8.217
10
50
 = 99.2 % 
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Robustness Study for Analytical Method Validation of Spironolactone and Furosemide Tablets (Furosemide) 
 
 
Flow Rate at 
0.9ml/min 
Flow Rate at 
1.1ml/min 
Buffer-ACN 
63: 37 
Buffer-ACN 
67: 33 
Buffer (2.8ml 
H3PO4/1000ml 
Water) 
Buffer (3.2ml 
H3PO4/1000ml 
Water) 
Column 
Change 
Replicate Standard Area Standard Area Standard Area Standard Area Standard Area Standard Area Standard Area 
1 1072804 924712 1027386 1038876 999951 1044459 994402 
2 1113245 943216 1031757 1039291 1021403 1056350 1014522 
3 1107829 934665 1041048 1040555 1015532 1050354 1022732 
4 1082076 913243 1040101 1053434 1022412 1051359 1028236 
5 1107127 939371 1036755 1061533 1024537 1047274 1017992 
Mean 1096616 931041 1035409 1046738 1016767 1049959 1015577 
Stdev 17966.35 12120.00 5773.44 10237.51 9975.40 4483.86 12910.95 
% RSD 1.64 1.30 0.56 0.98 0.98 0.43 1.27 
Replicate Test Area Test Area Test Area Test Area Test Area Test Area Test Area 
1 1131654 963693 1053532 1060811 1041930 1068729 1048600 
2 1126211 957833 1055265 1059968 1042243 1066431 1041652 
Mean 1128933 960763 1054399 1060390 1042087 1067580 1045126 
Standard weight 
(mg) 
19.3 19.3 19.5 19.5 19.3 19.3 19.3 
Test weight (mg) 1071.3 1071.3 1071.3 1071.3 1071.3 1071.3 1071.3 
Label claim (mg) 20 20 20 20 20 20 20 
Average test 
weight (mg) 
217.8 217.8 217.8 217.8 217.8 217.8 217.8 
% Assay 101.0 101.2 100.9 100.4 100.5 99.7 100.9 
 
Calculation: 
Prototype calculation for one set: 
3.1071
500
50
10
100
0.20
1096616
1128933
% Assay 100
20
8.217
10
50
 = 101.0 % 
Furosemide and Spironolactone…   Part-A (Section-II) 
 
 
 
127 
 
References 
 
1. E. Berardesca, P. Gabba, G. Ucci, G. Borroni, G. Rabbiosi, Int. J. Tissue React. 10(2) 
(1988) 115. 
2. H. R. Jacobson ,  J. P. Kokko, Annu. Rev. Pharmacol. Toxicol., 16 (1976) 201. 
D. C. Brater, Drugs, 41 (1991) 14. 
3. E. R. Korpi, T. Kuner, P. H. Seeburg, H. Luddens, Mol. Pharmacology, 47 (2) (1995) 
283–289.  
4. S Tia, J.F. Wang, N. Kotchabhakdi, S. Vicini  J. Neurosci. 16 (11) (1996), 3630–
3640.  
5. K.A. Wafford, S.A. Thompson, D. Thomas, J. Sikela, A.S. Wilcox, P.J. Whiting, Mol. 
Pharmacol. 50 (3) (1996), 670–678.  
6. S Rossi, Australian Medicines Handbook (2004),  
7. K. Rais-Bahrami, M.Majd, E. Veszelovszky, B.Short , Am J Perinatol 21 (6) (2004), 
329–332.   
8. BNF, March 45 (2003).  
9. www.sanofi-aventis.com 
10. Berardesca, E; Gabba P, Ucci G, Borroni G, Rabbiosi G. ". Int J Tissue React. 10 (2) 
(1988), 115–119.  
11. Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. N 
,Engl J Med 341 (10) (1999), 709–717.  
12. Verhamme KMC, Mosis G, Dieleman JP, et al.,Brit Med J. 333 (2006), 330–333.  
13. Wandelt-Freerksen E. JZ Erkr Atmungsorgane. 149(1) (1977), 156–9.  
14.  www.losalt.com(2007). 
15. Holsboer, F.  J. Psychiatr. Res. 33(1999), 181–214. 
16. "Spironolactone RX Monograph".Sandoz Inc. dailymed.nlm.nih.gov. Retrieved 
(2007). 
17. www.archneur.ama-assn.org . 
18. Alberto O. Santini, Helena R. Pezza, Rodrigo Sequinel, Jose L. Rufino, Leonardo 
Pezza,  Journal of the Brazilian Chemical Society. 20(1) (2009), 64-73. 
19. Iara Lucia Tescarollo Dias, Jorge Luiz S. Martins, Graciliano de Oliveira Neto,     
Analytical Letters. 38(7) (2005), 1159-1166. 
Furosemide and Spironolactone…   Part-A (Section-II) 
 
 
 
128 
 
20. Edward F. Salim, A. Haussler, J. B. Vaughan, Journal of Pharmaceutical Sciences.  
57(4) (1968), 640-641. 
21. Juan Xie, Fang Yang, Yu Zhai, Jie Yao, Weiqun Zhang, Zhongguo Yaofang.  18(31) 
(2007), 2454-2455. 
22. Denia Mendes de Sousa Valladao, Massao Ionashiro, Jose Zuanon Netto, Quimica 
Nova  31(1) (2008), 44-46.  
23. B Wesley-Hadzija, A M Mattocks, Journal of chromatography.  229(2) (1982), 425-
32. 
24. Shu-hua He, Chao-yin Li, Sichuan Shifan Daxue Xuebao, Ziran Kexueban  30(6) 
(2007), 787-789. 
25. Felipe Silva Semaan, Paulo Alberto Nogueira, Eder Tadeu Gomes Cavalheiro,    
Analytical Letters.  41(1) (2008), 66-79. 
26. Pradeep Mishra, D. Katrolia, R. K. Agrawal, Current Science 58(9) (1989), 503-505. 
27. C. Dreux, D. Halter,    Hop. Serv. Biochim., Annales de Biologie Clinique  34(2) 
(1976), 113-120. 
28. Lilo O. Guerello, Jose Dobrecky, Revista Farmaceutica (Buenos Aires). 111(1-2) 
(1969), 13-16. 
29. A. Goelcue, Journal of Analytical Chemistry.  61(8) (2006), 748-754. 
30. H. Mohamed Abdel-Hay, International Journal of Pharmaceutics. 99(2-3) (1993), 
333-336.  
31. G M Hanna, C A. Lau-Cam, Journal of AOAC International. 76(3) (1993), 526-530. 
32. Zhen Tang, Fuqiang Liu, Yuhui Go, Ye Guo, Yulin Ren,  Fenxi Ceshi Xuebao.  20(3) 
(2001), 62-64.  
33. S. Mohamed Mahrous, S. Ahmed Issa, S. Nabil Soliman, Alexandria Journal of 
Pharmaceutical Sciences. 1(1) (1987), 25-27. 
34. B A Moussa, N M  Kousy, Scientific edition.  7(2) (1985), 79-82. 
35. D. M. Shingbal, V. Ramakrishna Rao, Indian Drugs.  23(4) (1986), 232-233. 
36. Vinay  Nevrekar, Indian Drugs.  21(8) (1984), 349-350. 
37. D. M. Shingbal, J. S. Prabhudesai, Indian Drugs. 21(7) (1984), 306-307. 
38. P. Parimoo, A. Bharathi, K. Padma, Indian Journal of Pharmaceutical Sciences  57(3) 
(1995), 126-129. 
39. Hesham Salem, Magda El-Maamli, Mohamed El-Sadek, Afaf Aboul Kheir,   
Spectroscopy Letters. 24(3) (1991), 451-470. 
Furosemide and Spironolactone…   Part-A (Section-II) 
 
 
 
129 
 
40. Joseph Chamberlain, Journal of Chromatography.  55(2) (1971), 249-253.  
41. Fathalla  Belal, Mikrochimica Acta  107(1-2) (1992), 11-17. 
42. G. K. Dyade, A. K. Sharma, Indian Drugs  38(2) (2001), 75-78.  
43. Hong-Yan Ma, Guang-Cai Qi, Guangpu Shiyanshi  16(3) (1999), 309-312. 
44. P. Parimoo, A. Bharathi, K. Padma, Indian Drugs 33(4) (1996), 160-162.   
45. S. Singh, B. Singh, R. Bahuguna, L. Wadhwa, R. Saxena, J. Pharm. Biomed. Anal. 41 
(2006) 1037-1040. 
46. A. Mohammadi, I. Haririan, N. Rezanour, L. Ghiasi, R. B. Walker, J. Chromatogr. A 
1116 (2006) 153-157. 
47. I. Ivana, Z. Ljiljana, Z. Mira, J. Chromatogr. A 1119 (2006) 209-215. 
48. ICH, Q1A (R2) Stability testing of new drug substances and products, in: 
International Conference on Harmonization, IFPMA, Geneva, (2003). 
49. G. Grosa, E. D. Grosso, R. Russo, G. Allegrone, J. Pharm. Biomed. Anal. 41 (2006) 
798-803. 
50. A. Mishal, D. Sober, J. Pharm. Biomed. Anal. 39 (2005) 819-823  
Lamotrigine…   Part-A (Section-III) 
 
 
130 
 
1. INTRODUCTION TO LAMOTRIGINE 
Lamotrigine is currently available in about 60 countries. The drug is currently 
only approved for the treatment of people with seizures. There are no systematic studies 
that establish the safety or efficacy of lamotrigine as a treatment for people with mood 
disorders. While such studies are in the planning stages, what is currently known about 
the use of lamotrigine for the control of mood disorders comes from uncontrolled case 
reports.  
Lamotrigine is an anticonvulsant that is chemically unrelated to any other 
anticonvulsant or mood regulating medication. Lamotrigine received final approval for 
marketing in the USDA on 27 December 1994 and is labeled for use as an anticonvulsant. 
It has full patent protection and a generic version is not available yet.  
The two major differences between lamotrigine and other mood regulating drugs are:  
 Lamotrigine's frequent effectiveness for patients who have failed to respond to 
antidepressants or mood stabilizers;  
 Lamotrigine's relatively benign side-effect profile 
Lamotrigine has been successful in controlling rapid cycling and mixed bipolar 
states in people who have not received adequate relief from carbamazepine and/or 
valproate. It also appears that lamotrigine has significantly more antidepressant potency 
than either carbamazepine or valproate. 
The initial use of lamotrigine was to treat depressed, manic and mixed states that 
did not respond to existing medications. Some patients are now being maintained on 
lamotrigine on a long term basis in an attempt to prevent future episodes. The 
effectiveness of lamotrigine as a long-term prophylactic agent is currently being 
established.  
 
1.1 Description 
Lamotrigine is chemically 6-(2, 3-Dichlorophenyl)-1, 2, 4-triazine-3, 5-diamine 
and its molecular formula is C9H7N5Cl2, and molecular weight is 256.09 gm/mole. 
Lamotrigine, an antiepileptic drug (AED) of the phenyltriazine class, is chemically 
unrelated to existing antiepileptic drugs, has been used successfully to treat essential 
trigeminal neuralgia (TN)  [1-4].  
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N
N
N
Cl
Cl
NH2NH2  
Figure: 1   6-(2, 3-Dichlorophenyl)-1, 2, 4-triazine-3, 5-diamine 
LAMICTAL tablets are supplied for oral administration as 25-mg (white), 100-mg 
(peach), 150-mg (cream), and 200-mg (blue) tablets. Each tablet contains the labeled 
amount of lamotrigine and the following inactive ingredients: lactose; magnesium 
stearate; microcrystalline cellulose; povidone; sodium starch glycolate; FD&C Yellow 
No. 6 Lake (100-mg tablet only); ferric oxide, yellow (150-mg tablet only); and FD&C 
Blue No. 2 Lake (200-mg tablet only).  
LAMICTAL chewable dispersible tablets are supplied for oral administration. The 
tablets contain 2 mg (white), 5 mg (white), or 25 mg (white) of lamotrigine and the 
following inactive ingredients: blackcurrant flavor, calcium carbonate, low-substituted 
hydroxypropylcellulose, magnesium aluminum silicate, magnesium stearate, povidone, 
saccharin sodium, and sodium starch glycolate.  
1.2 Indication and use 
Lamotrigine was first approved by the US FDA in 1994, for the treatment of 
partial seizures, and in 2003 for long-term management of bipolar I disorder [5]. 
Lamotrigine was the first FDA-approved therapy for maintenance treatment of bipolar I 
disorder since lithium pharmacology study [6].  
While traditional anticonvulsant drugs are mostly antimanics, lamotrigine is most 
effective in the treatment and prophylaxis of bipolar depression. Lamotrigine treats 
bipolar depression without triggering mania, hypomania, mixed states, or rapid-cycling, 
and the 2002 American Psychiatric Association guidelines recommended lamotrigine as a 
first-line treatment for acute depression in bipolar disorder as well as a maintenance 
therapy. 
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However, lamotrigine is not indicated on label for the treatment of acute bipolar 
symptoms. Because the dosage must be slowly increased from a sub-therapeutic level to 
the therapeutic level, the drug's utility in the management of acute manic symptoms is 
debatable; typically benzodiazepines or another anticonvulsant will be used to manage the 
acute mania until the lamotrigine reaches therapeutic blood concentration. 
For the doses considered sub-therapeutic, lamotrigine is thought to have a mild 
anti-depressant effect, leading some to question its safety for use in bipolar disorder, as 
partial remediation of cyclically depressed individuals (especially teens and young adults) 
has an elevated corelation to suicide until remission attains therapeutically acceptable 
levels. If lamotrigine's mechanism of action involves an increase in serotonin levels, this 
may potentially increase the risk of Serotonin syndrome. 
In addition to treating bipolar Lamotrigine is one of a small number of FDA-
approved therapies for seizures associated with Lennox-Gastaut syndrome, a severe form 
of epilepsy. Typically developing before four years of age, LGS is associated with 
developmental delays. There is no cure, treatment is often complicated, and complete 
recovery is rare. Symptoms include the atonic seizure (also known as a "drop attack"), 
during which brief loss of muscle tone and consciousness cause abrupt falls. Lamotrigine 
significantly reduces the frequency of LGS seizures, and is one of two medications 
known to decrease the severity of drop attacks [7]. Combination with valproate is 
common, but this increases the risk of lamotrigine-induced rash, and necessitates reduced 
dosing due to the interaction of these drugs [8].  
Off-label uses include the treatment of peripheral neuropathy, trigeminal 
neuralgia, cluster headaches, migraines, and reducing neuropathic pain [9]. Off-label 
psychiatric usage includes the treatment of depersonalization disorder, bipolar II 
disorders, schizoaffective disorder, borderline personality disorder, post traumatic stress 
disorder, and as adjunctive therapy for "treatment-resistant" unipolar depression [10].  
1.3 Mechanism of action 
One proposed mechanism of action for lamotrigine involves an effect on sodium 
channels, although this remains to be established in humans. In vitro pharmacological 
studies suggest that lamotrigine inhibits voltage-sensitive sodium channels, thereby 
Lamotrigine…   Part-A (Section-III) 
 
 
133 
 
stabilizing neuronal membranes and consequently modulating presynaptic transmitter 
release of excitatory amino acids (for example glutamate and aspartate) [11].  
1.4 Pharmacokinetics 
The pharmacokinetics of lamotrigine is quite complicated, with highly varying 
half-life and blood plasma levels. Lamotrigine has fewer drug interactions than many 
anticonvulsant drugs, although pharmacokinetic interactions with sodium valproate in 
particular is an indication for blood monitoring. 
1.5 Side Effects 
Lamotrigine prescribing information has a black box warning about life 
threatening skin reactions, including Stevens-Johnson Syndrome and Toxic Epidermal 
Necrolysis [11]. The manufacturer states that nearly all cases appear in the first 2 to 8 
weeks of therapy and if medication is suddenly stopped then resumed at the normal 
dosage. Patients should seek medical attention for any unexpected skin rash as its 
presence is an indication of a possible serious or even deadly side effect of the drug. Not 
all rashes that occur while taking lamotrigine progress to Stevens-Johnson Syndrome or 
Toxic Epidermal Necrolysis 
Cognitive side effects are common with doses over 50mg qid (quarter in die - four 
times daily), as shown in the 2001-2003 Glaxo-sponsored Clinical Trials comparing 
quality of life between Topiramate and Lamotrigine in healthy volunteers 
(unpublished).[citation needed] Common side effects include headaches, dizziness and 
insomnia. Other side effects may include acne and skin irritation, vivid dreams or 
nightmares, night sweats, body aches and cramps, muscle aches, dry mouth, fatigue, 
memory and cognitive problems, irritability, weight changes, hair loss, changes in libido, 
frequent urination, nausea, and other side effects. In very rare cases, Lamotrigine has 
been known to cause the development of a dangerous rash called Stevens-Johnson 
syndrome (or SJS). The rash is more common in children, so this medication is often 
reserved for adults. There is also an increased incidence of this rash in patients who are 
currently on, or recently discontinued a valproate-type anticonvulsant drug, as these 
medications interact in such a way that the clearance of both is decreased and the 
effective dose of lamotrigine is increased. . 
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In clinical trials women were more likely than men to have side effects. This is the 
opposite of most other anticonvulsants and antipsychotics. It has been suggested that 
genetic background makes a difference in dosages, with those of non-Caucasian 
background typically needing lower doses.[citation needed] 
Lamotrigine binds to melanin-containing tissues such as the iris of the eye. The 
long-term consequences of this are unknown [12].  
Use during pregnancy is recommended only if benefits outweigh potential risks. It 
was also reported on CNN in September 2006 that taking Lamictal during the first 
trimester of pregnancy can lead to a cleft palate in babies. Lamotrigine is found in breast 
milk; breastfeeding is not recommended during treatment. 
Some patients have reported experiencing a loss of concentration, even with very 
small doses, while some others have actually reported an increase in alertness and 
concentration. In general, however, it tends to have less of an impact on concentration 
relative to other mood stabilizers.[citation needed] GlaxoSmithKline investigated 
lamotrigine for the treatment of ADHD. The results were inconclusive. No detrimental 
effects on cognitive function were observed, however, the only statistical improvement in 
core ADHD symptoms was an improvement on a test, PASAT (Paced Auditory Serial 
Addition Test), that measures auditory processing speed and calculation ability [13].  
1.6 Availability 
GlaxoSmithKline's trademarked brand of Lamotrigine, Lamictal, is manufactured 
in scored tablets (25 mg, 100 mg, 150 mg and 200 mg) and chewable dispersible tablets 
(2 mg, 5 mg and 25 mg). Five-week sample kits are also available; these include titration 
instructions and scored tablets (25 mg for patients taking valproate, 25 mg and 100 mg for 
patients not taking valproate). Lamotrigine is also available in un-scored tablet form. In 
2005, Teva Pharmaceutical Industries Ltd. began selling generic Lamotrigine in the 
United States, but only in 5 mg and 25 mg chewable dispersible tablets [14]. On 23 July 
2008 Teva began offering the full line of generic Lamotrigine in the US [15]. Lamotrigine 
is also available in generic form [16] in the United States, the United Kingdom and 
Canada. 
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2. LITERATURE REVIEW 
The literature reviews regarding lamotrigine suggest that various analytical 
methods were reported for its determination as drug, in pharmaceutical formulation and in 
various biological fluids. The literature reviews for analysis of lamotrigine are as under  
 
2.1 Bartoli, Anna; Marchiselli, Roberto; Gatti, Giuliana have developed a rapid 
and specific assay for the determination of lamotrigine in human plasma by normal-phase 
HPLC.  Lamotrigine is extracted with dichloromethane from buffered plasma to which an 
internal std. has been added.  The solvent is directly injected into a 250 × 4.6-mm 
Spherisorb Silica column and the drug is eluted by using a mixture of methanol, n-
heptane, dichloromethane, and 28-30% ammonium hydroxide (20:40:40:0.3 vol/vol) at a 
flow rate of 1 mL/min.  The eluates are detected at 240 nm.  The assay requires 250 μl of 
sample, and concentrations as low as 0.4 µg/mL can be measured accurately.  The method 
is linear in the range of 0.4-16 µg/mL, with a mean coefficient of correlation (r)  0.997.  
Within- and between-day relative std. deviations at three different concentration levels (1, 
4, and 8 µg/mL) are 8.6% [17]. 
2.2 Gasgupta, Amitava; Hart, Amy P. developed a method for Lamotrigine analysis 
in plasma by gas chromatography-mass spectrometry after conversion to a tert-
butyldimethylsilyl derivative. Lamotrigine was extracted from alkaline serum with CHCl3 
and derivatized with N-methyl-N-(tert-butyldimethylsilyl) trifluoroacetamide content 2% 
tert-butyldimethylchlorosilane.  Oxazepam-d5 was used as an internal standard. The assay 
was linear for serum lamotrigine concns. of 0.5=2.0 µg/mL.  The detection limit was 0.25 
µg/mL [18]. 
2.3 Fraser, Albert D.; MacNeil, Wallace; Isner, Arthur F.; Camfield, Peter R. 
have developed Lamotrigine analysis in serum by high-performance liquid 
chromatography. Lamotrigine was extracted from serum at alkaline pH into Ethyl acetate 
after addition of the internal standard (BW725C78). After mixing, the organic layer was 
evaporated to dryness before dissolving the residue in methanol for isocratic separation 
on a RP-8 column (5 µm) with a mobile phase of H2O-pH 6.5 0.5M phosphate buffer-
MeCN (790:10:200) with eluant monitoring at 306 nm. Interference studies were 
performed on serum specimens content commonly monitored drugs. The only potentially 
interfering drug was carbamazepine, which elutes longer than lamotrigine [19]. 
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2.4 Sinz, Michael W.; Remmel, Rory P. have developed a method for analysis of 
lamotrigine and lamotrigine 2-N-glucuronide in guinea pig blood and urine by reserved-
phase ion-pairing liquid chromatography. The extraction procedure and reversed-phase 
high-performance liquid chromatography (HPLC) assay employed sodium dodecylsulfate 
(SDS) as an ion-pairing reagent to selectively separation. lamotrigine and lamotrigine 2-
N-glucuronide from endogenous blood components, other anticonvulsant drugs, and their 
metabolites.  The mobile phase was composed of acetonitrile-50 mM phosphoric acid (pH 
2.2) content 10 mM SDS (33:67, vol./vol.), and components were detected at 277 nm 
[20]. 
2.5 Patil Kuldeep M; Bodhankar Subhash L. have developed high-performance 
thin-layer chromatographic determination of lamotrigine in serum. The method involves 
extraction of the drug by ethyl acetate followed by separation on TLC silica plates using a 
mixture of toluene-acetone-ammonia (7:3:0.5), as eluting solvent. Densitometric analysis 
was carried out at 312 nm with lamotrigine being detected at Rf of 0.54. The analytical 
method has excellent linearity (r=0.998) in the range of 20-300 ng/spot. The limit of 
detection and limit of quantification were found to be 6.4 and 10.2 ng, respectively. Good 
accuracy is reported in the range of 92.06-97.12% and high precision with %CV in range 
of 0.53-2.59.  The method was applied for determination of serum lamotrigine levels in 
epileptic patients and in pharmacokinetic study of lamotrigine administered orally to 
rabbits [21]. 
2.6 Wyszomirska E; Czerwinska K  have developed method for identification and 
assay of lamotrigine in human milk with gas chromatography and densitometry.  
Conditions necessary for isolation and assay of lamotrigine in the human milk with gas 
chromatography in the range of concentrations 2-20 micrograms/ml, and densitometry in 
the range of 2-10 micrograms/ml are discussed.  Lamotrigine was extracted with 
methylene chloride from the alkaline solution.  In gas chromatography capillary column 
DB-17, flame-ionizing detector, and octacozanole as the internal standard have been used.  
Densitometric measurements have been performed at 217 nm [22]. 
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3. AIM OF PRESENT WORK 
As per discussion in the literature review, specific assay for the determination of 
lamotrigine in human plasma by normal-phase HPLC, gas chromatography-mass 
spectrometry, reserved-phase ion-pairing liquid chromatography, high-performance thin-
layer chromatographic, gas chromatography and densitometry methods for the 
determination of lamotrigine in pharmaceutical dosage forms or in biological fluids are 
reported. GC, HPLC and HPTLC methods simply used for estimation of lamotrigine from 
pharmaceutical formulation and GC-MS methods applied to the pharmacokinetic studies 
of lamotrigine. So far to our present knowledge, no validated stability indicating HPLC 
assay method for the determination of lamotrigine in pharmaceutical formulation was 
available in literature. Our work deals with the forced degradation of lamotrigine under 
stress condition like acid hydrolysis, base hydrolysis, oxidation, thermal and photolytic 
stress. This work also deals with the validation of the developed method for the assay of 
lamotrigine from its dosage form (tablets). Hence, the method is recommended for routine 
quality control analysis and also stability sample analysis. 
 
The aim and scope of the proposed work are as under: 
 To developed suitable HPLC method for lamotrigine, 
 Forced degradation study of lamotrigine under stress condition, 
 To resolve all major impurities generated during the force degradation studies of 
lamotrigine, 
 Perform the validation for the developed method. 
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4. EXPERIMENTAL 
4.1 Materials  
Lamotrigine standard of was provided by Alembic Pharmaceuticals Ltd., Baroda 
(India). Lamotrigine tablets containing 25mg Lamotrigine and the inactive ingredient 
used in drug matrix were obtained from market. Analytical grade ammonium acetate was 
purchased from Sisco Research Pvt. Ltd., Mumbai (India). HPLC grade methanol and 
water were obtained from Spectrochem Pvt. Ltd., Mumbai (India). Analytical grade 
hydrochloric acid, glacial acetic acid, sodium hydroxide pellets and 30% v/v hydrogen 
peroxide solution were obtained from Ranbaxy Fine Chemical, New Delhi (India). 
4.2 Instrumentation 
The chromatographic system used to perform development and validation of this 
assay method was comprised of a LC-10ATvp binary pump, a SPD-M10Avp photodiode-
array detector and a rheodyne manual injector model 7725i with 20μl loop (Shimadzu, 
Kyoto, Japan) connected to a multi-instrument data acquisition and data processing 
system (Class-VP 6.13 SP2, Shimadzu). 
4.3 Mobile Phase Preparation 
The mobile phase consisted of methanol – 0.01M ammonium acetate buffer pH 
4.3 (50: 50, v/v). To prepare the buffer solution, 0.7708 g ammonium acetate were 
weighed and dissolve in 1000 ml HPLC grade water and then adjusted to pH 4.3 with 
glacial acetic acid. Mobile phase was filtered through a 0.45 μm nylon membrane 
(Millipore Pvt. Ltd. Bangalore, India) and degassed in an ultrasonic bath (Spincotech Pvt. 
Ltd., Mumbai). 
 
4.4 Diluent Preparation  
Water: Methanol (50:50, v/v) used as a diluent. 
 
4.5 Standard Preparation  
A lamotrigine standard stock solution containing 250µg/ml was prepared in a 200 
ml volumetric flask by dissolving 50.00 mg of lamotrigine and then diluted to volume 
with methanol as a diluent and further takes 10 ml this stock solution in 50 ml volumetric 
flask and make up to mark methanol as a diluent. The concentration obtained was 50 
µg/ml of lamotrigine. 
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4.6 Test Preparation  
Twenty tablets were weighed and the average weight of tablet was determined. 
From these, five tablets were weighed and transfer into a 500 ml volumetric flask. About 
50 ml methanol was added and sonicated for a minimum 30 minute. with intermittent 
shaking. Then content was brought back to room temperature and diluted to volume with 
methanol. The sample was filtered through 0.45µm nylon syringe filter. Take 10 ml this 
filtrate solution in 50 ml volumetric flask and make up to mark methanol as a diluent. The 
concentration obtained was 50 µg/ml of lamotrigine. 
 
4.7 Chromatographic Conditions  
Chromatographic analysis was performed on a Phenomenex Luna C8 (2) (250mm 
 4.6mm i.d., 5 μm particle size) column. The mobile phase consisted of methanol – 
0.01M ammonium acetate buffer pH 4.3 (50: 50, v/v). The flow rate of the mobile phase 
was adjusted to 0.8 ml/min and the injection volume was 20 μl. Detection was performed 
at 225nm. 
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5. RESULT AND DISCUSSION 
5.1 Development and Optimization of the HPLC Method 
Proper selection of the methods depends upon the nature of the sample (ionic or 
ionisable or neutral molecule) its molecular weight and solubility. Lamotrigine is 
dissolved in polar solvent hence RP-HPLC was selected to estimate them. To develop a 
rugged and suitable HPLC method for the quantitative determination of lamotrigine, the 
analytical condition were selected after testing the different parameters such as diluents, 
buffer, buffer concentration, organic solvent for mobile phase and mobile phase 
composition and other chromatographic conditions. Our preliminary trials using different 
composition of mobile phases consisting of water with methanol or acetonitrile, did not 
give good peak shape. By using 10 mM ammonium acetate buffer with 1000 ml of buffer, 
adjusted to pH 4.3 with glacial acetic acid and keeping mobile phase composition as 
acetonitrile-phosphate buffer (50: 50, v/v), best peak shape was obtained. For the 
selection of organic constituent of mobile phase, methanol was chosen to reduce the 
longer retention time and to attain good peak shape. Figure 2 and Figure 3 represent the 
chromatograms of standard and test preparation respectively. 
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Figure 2: Chromatogram of standard preparation 
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Figure 3: Chromatogram of test preparation 
5.2 Degradation Study 
The degradation samples were prepared by transferring powdered tablets, 
equivalent to 25 mg lamotrigine into a 250 ml round bottom flask. Then prepared samples 
were employed for acidic, alkaline and oxidant media and also for thermal and photolytic 
conditions. After the degradation treatments were completed, the stress content solutions 
were allowed to equilibrate to room temperature and diluted with mobile phase to attain 
50 µg/ml concentrations. Specific conditions were described as follows.  
 
5.2.1 Acidic condition 
Acidic degradation study was performed by heating the drug content in 20 ml 0.1 
N HCl and 10 ml diluent at 80˚ C for 3.0 hr and mixture was neutralized. Lamotrigine 
was found to be degrading up to 3-5 % in acidic condition. The major impurity peaks was 
found at 10.6 min. (Figure 4) 
Minutes
0 5 10 15 20 25 30 35 40 45 50 55 60
m
A
U
-20
0
20
40
L
a
m
o
tr
ig
in
e
 
 
  
Figure 4: Chromatogram of acidic forced degradation study 
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5.2.2 Alkaline condition 
Alkaline degradation study was performed by heating the drug content in 5 N 
NaOH at 80˚ C for 3 h and mixture was neutralized with 5 N HCl solutions. In alkali 
degradation, it was found that around 12-14 % of the drug degraded. The major impurity 
peaks was found at 10.8 min. (Figure 5) 
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Figure 5: Chromatogram of alkali forced degradation study 
5.2.3 Oxidative condition 
Oxidation degradation study was performed by heating the drug content in 3% v/v 
H2O2 at 80˚ C for 3 h. Lamotrigine is found to be stable under oxidative degradation 
condition.  (Figure 6) 
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Figure 6: Chromatogram of oxidative forced degradation study 
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5.2.4 Thermal condition 
Thermal degradation was performed by exposing solid drug at 80˚ C for 72 h. 
Lamotrigine is found to be stable under thermal degradation condition. (Figure 7) 
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Figure 7: Chromatogram of thermal degradation study 
 
5.2.5 Photolytic condition 
Photolytic degradation study was performed by exposing the drug content in UV-
light for 72 h. There is slightly degradation observed in above specific photolitic 
condition.  (Figure 8) 
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Figure 8: Chromatogram of UV-light degradation study 
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5.3 Method Validation 
5.3.1 Specificity 
The specificity of the method was determined by checking the interference of 
placebo with analyte and the proposed method was eluted by checking the peak purity of 
lamotrigine during the force degradation study. The peak purity of the lamotrigine was 
found satisfactory (0.9999) under different stress condition. There was no interference of 
any peak of degradation product with drug peak. 
 
5.3.2 Linearity 
  Seven points calibration curve were obtained in a concentration range from 0.02-
0.08 mg/ml for lamotrigine. The response of the drug was found to be linear in the 
investigation concentration range and the linear regression equation was y 
=132036853.57143x -76472.46 with correlation coefficient 0.9976. (Figure 9) 
Chromatogram obtain during linearity study were shown in figure 10-16. 
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Figure 9: Linearity curve for lamotrigine 
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Figure 10: Linearity study chromatogram of level-1 (40%) 
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Figure 11: Linearity study chromatogram of level-2 (60%) 
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Figure 12: Linearity study chromatogram of level-3 (80%) 
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Figure 13: Linearity study chromatogram of level-4 (100%) 
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Figure 14: Linearity study chromatogram of level-5 (120%) 
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Figure 15: Linearity study chromatogram of level-6 (140%) 
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Figure 16: Linearity study chromatogram of level-7 (160%) 
 
5.3.3 Precision 
  The result of repeatability and intermediate precision study are shown in Table 1. 
The developed method was found to be precise as the %RSD values for the repeatability 
and intermediate precision studies were < 1.05 % and < 0.85 %, respectively, which 
confirm that method was precise 
 
Table 1: Evaluation data of precision study 
 
Set Intraday (n = 6) Interday (n = 6) 
1 98.8 98.2 
2 98.1 99.4 
3 99.4 100.3 
4 98.8 98.8 
5 98.1 98.5 
6 99.8 98.1 
Mean 98.8 98.9 
Standard deviation 1.03 0.84 
% RSD 1.05 0.85 
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5.3.4 Accuracy 
  The HPLC area responses for accuracy determination are depicted in Table 2. The 
result shown that best recovery (98.02-100.86 %) of the spiked drug was obtained at each 
added concentration, indicating that the method was accurate. Chromatogram obtain 
during accuracy study were shown in figure 17-19. 
 
Table 2: Evaluation data of accuracy study 
Level (%) 
 
Amount Added 
Concentration
 a
 
(μg /ml) 
Amount Found 
Concentration
 a
 
(μg /ml) 
% Recovery % RSD 
50 25.20 25.54 101.35 0.40 
100 49.80 50.26 100.98 0.10 
150 75.00 75.27 100.32 0.49 
a
 Each value corresponds to the mean of three determinations 
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Figure 17: Accuracy study chromatogram of level-1 (50%) 
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Figure 18: Accuracy study chromatogram of level-2 (100%) 
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Figure 19: Accuracy study chromatogram of level-3 (150%) 
 
5.3.5 Solution stability study 
  Table 3 shows the results obtain in the solution stability study at different time 
intervals for test preparation. It was concluded that the test preparation solution was found 
stable up to 48 h at 2 - 5˚ C and ambient temperature, as during this time the result was 
not decrease below the minimum percentage. 
Table 3: Evaluation data of solution stability study 
 
Intervals 
% Assay for Test 
Preparation Solution 
Stored at 2-5 ˚C 
% Assay for Test Preparation 
Solution Stored at Ambient 
Temperature 
Initial 98.6 98.6 
12 h 98.4 100.6 
24 h 98.7 100.7 
36 h 100.7 100.6 
48 h 99.4 101.5 
 
5.3.6 Robustness 
  The result of robustness study of the developed assay method was established in 
Table 4. The result shown that during all variance conditions, assay value of the test 
preparation solution was not affected and it was in accordance with that of actual. System 
suitability parameters were also found satisfactory, hence the analytical method would be 
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concluded as robust. Chromatogram obtain during robustness study were shown in figure  
20-16. 
 
Table 4: Evaluation data of robustness study 
 
Robust conditions % Assay 
System suitability parameters 
Theoretical plates Asymmetry 
Flow 0.7 ml/min 99.5 3930 1.50 
Flow 0.9 ml/min 99.6 3945 1.18 
Buffer pH 4.1 100.7 3250 1.14 
Buffer pH 4.5 100.5 4196 1.24 
Buffer-Methanol (38:42,v/v) 100.6 3915 1.12 
Buffer-Methanol (42:38,v/v) 99.4 3713 1.29 
Column change 99.2 3730 1.28 
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Figure 20: Standard chromatogram (0.7 ml/min flow rate) 
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Figure 21: Standard chromatogram (0.9 ml/min flow rate) 
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Figure 22: Standard chromatogram (Buffer-Methanol (38: 42, v/v)) 
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Figure 23: Standard chromatogram (Buffer-methanol (42: 38, v/v)) 
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Figure 24: Standard chromatogram (pH 4.1) 
Minutes
0 2 4 6 8 10 12
m
A
U
0
100
200
300
L
a
m
o
tr
ig
in
e
  
Figure 25: Standard chromatogram (pH 4.5) 
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Figure 26: Standard chromatogram (Column change) 
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5.3.7 System suitability  
  A system suitability test of the chromatographic system was performed before 
each validation run. Five replicate injections of standard preparation were injected and 
asymmetry, theoretical plate and % RSD of peak area were determined for same. 
Acceptance criteria for system suitability, Asymmetry not more than 2.0, theoretical plate 
not less then 3000 and % RSD of peak area not more then 2.0, were full fill during all 
validation parameter.  
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6. Calculation and data 
 
Calculation formula used: 
 
     
1. Calculation formula for % assay of lamotrigine 
 
 
WeightTest
Weight
AreaMean
AreaTestMean
Assay
500
100
Standard
Standard
%  
 
Standard
5
50
ofPotency
ClaimLable
WeightTestMean
 
 
 
2. Relative standard deviation 
 
100
sMeasurmentofValueMean
sMeasurmentofDeviationStandard
RSD%  
 
 
3. Recovery 
 
100
AddedAmount
foundAmount
erycovRe%  
 
 
4. Amount found  
 
ionConcentratStandard
AreaStandardMean
AreaTestMean
)ml/mg(FoundAmount  
 
 
5. Amount added 
 
Volume
Weight
)ml/mg(AddedAmount  
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Specificity Study for Analytical Method Validation of Lamotrigine Tablets 
Standard Weight (mg) 50.3      
Standard Dilution 200 10 50   
Standard Potency 100 %     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration 
(mg/ml) 
0.0503     
      
Replicate 1 2 3 4 5 
Standard Area 5527400 5356225 5546203 5556072 5365947 
Mean Standard Area 5470369     
Stdev. 100350.81     
% RSD 1.83     
 
 
Replicate Test Area 
1 5328712 
2 5425240 
Mean Test Area 5376976 
Test Weight (mg) 502.5  
Label claim (mg) 25 
Mean Test Weight (mg) 100.5 
% Assay 98.9 
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
50
10
200
3.50
5470369
5328712
% Assay 100
25
5.100
10
25
5.502
1000
 
 
              
     = 98.9 % 
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Linearity Study for Analytical Method Validation of Lamotrigine Tablets 
 
 
Standard Weight (mg) 50    
Standard Dilution 200 10 50  
Standard Potency 100.0 %    
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration (mg/ml) 0.05     
Concentration of Linearity Stock 
Solution (mg/ml) 
0.25     
      
Replicate 1 2 3 4 5 
Standard Area 6336584 6509307 6356584 6436584 6301442 
Mean Standard Area 6388100     
Stdev 75098.07     
% RSD 1.18     
Concentration Level 
(%) 
Volume of 
Linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final Concentration 
(mg/ml) 
Mean Area 
40 4.0 50 0.020 2655401 
60 6.0 50 0.030 4025163 
80 8.0 50 0.040 4950305 
100 10.0 50 0.050 6492386 
120 12.0 50 0.060 7803991 
140 14.0 50 0.070 9117878 
160 16.0 50 0.080 10632469 
  Correlation co-efficient 0.9976 
  Slope 132036853.57 
  Intercept -76472.46 
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Precision Study for Analytical Method Validation of Lamotrigine Tablets 
 
Standard Weight (mg) 50.4     
Standard Dilution 200 10 50   
Standard Potency 100.0 %     
Label Claim (mg) 25     
Mean Test Weight (mg) 288.8     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration (mg/ml) 0.0504     
      
Replicate 1 2 3 4 5 
Standard Area 5414910 5321336 5281955 5319734 5487855 
Mean Standard Area 5365158     
Stdev. 84315.27     
% RSD 1.57     
 
 
 
Description Mean area Test Weight (mg) % Assay 
Set 1 5300125 100.5 99.6 
Set 2 5184371 99.6 98.3 
Set 3 5296275 99.8 100.2 
Set 4 5258605 99.7 99.6 
Set 5 5215345 100.4 98.1 
Set 6 5330076 100 100.6 
  Mean 99.4 
  Stdev 1.01 
  % RSD 1.01 
    
 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
50
10
200
4.50
5365158
5300125
% Assay 100
25
0.100
10
50
5.100
100
 
 
    = 99.6 % 
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Intermediate precision study for Analytical Method Validation of Lamotrigine 
tablet 
 
Standard Weight (mg) 50.6     
Standard Dilution 200 10 50   
Standard Potency 100.0 %     
Label Claim (mg) 250     
Mean Test weight (mg) 288.8     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration (mg/ml) 0.0506     
      
Replicate 1 2 3 4 5 
Standard Area 5584018 5517376 5659789 5489476 5752024 
Mean Standard Area 5600537     
Stdev. 107217.40     
% RSD 1.91     
 
 
 
 
Description Mean area Test Weight (mg) % Assay 
Set 1 5417074 100.2 98.2 
Set 2 5451210 99.6 99.4 
Set 3 5510611 99.8 100.3 
Set 4 5425879 99.7 98.8 
Set 5 5402754 99.6 98.5 
Set 6 5399812 99.2 98.9 
  Mean 99 
  Stdev 0.75 
  % RSD 0.75 
    
 
Calculation: 
 
Prototype calculation for one set: 
 
50
10
200
6.50
5600537
5417074
% Assay 100
25
7.99
10
50
2.100
100
 
 
 
     = 98.2 % 
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Comparison for Precision and Intermediate Precision Study for Analytical Method 
Validation for Lamotrigine Tablets 
 
 
 Set %Assay 
Precision study 
1 99.6 
2 98.3 
3 100.2 
4 99.6 
5 98.1 
6 100.6 
Intermediate precision study 
1 98.2 
2 99.4 
3 100.3 
4 98.8 
5 98.5 
6 98.9 
 Mean 99.2 
 Stdev 0.87 
 % RSD 0.50 
 
 
 
Accuracy study for Analytical Method Validation of Lamotrigine tablets 
 
Standard Weight (mg) 49.8     
Standard Dilution 200 10 50   
Standard Potency 100.0 %     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration 
(mg/ml) 
0.0498     
      
Replicate 1 2 3 4 5 
Standard Area 5359736 5265777 5284942 5407490 5382929 
Mean Standard Area 5340175     
Stdev 61902.3     
% RSD 1.16     
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Accuracy Study for Analytical Method Validation of Lamotrigine Tablets 
Recovery 
Level 
Set No. 
Mean 
area 
Wt. 
(mg) 
Volume 
(ml) 
Value added Value found % 
Recovery 
Mean % 
Recovery 
Std 
Dev 
% 
RSD Concentration(mg/ml) Concentration(mg/ml) 
50% 
Set 1 2727934 25.2 200 0.02520 0.02544 100.95 
101.08 0.22 0.22 Set 2 2717285 25.1 200 0.02510 0.02534 100.96 
Set 3 2771405 25.5 200 0.02550 0.02584 101.33 
100% 
Set 1 5396274 49.8 200 0.04980 0.05032 101.04 
100.98 0.10 0.10 Set 2 5375651 49.7 200 0.04970 0.05013 100.87 
Set 3 5395705 49.8 200 0.04980 0.05032 101.04 
150% 
Set 1 8041876 75.1 200 0.07510 0.07499 99.85 
100.32 0.50 0.49 Set 2 8062917 75.0 200 0.07500 0.07519 100.25 
Set 3 8109547 75.0 200 0.07500 0.07563 100.84 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
100
02520.0
02544.0
covRe% ery  = 100.95 % 
 
0498.0
5340175
2727934
)/( mlmgFoundAmount  = 0.02544 mg/ml 
 
50
10
200
2.25
)/( mlmgAddedAmount   = 0.02520 mg/ml 
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Solution Stability Study for Analytical Method Validation of Lamotrigine Tablets 
 
System suitability of standard preparation for solution stability 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 6922586 6660362 5462959 5575230 5564557 
2 6844501 6684817 5501228 5378478 5341653 
3 6843378 6663369 5449584 5405457 5441873 
4 6919779 6728986 5479532 5374255 5398936 
5 6894250 6751158 5556266 5467820 5495234 
Mean 6884899 6697738 5489914 5440248 5448451 
Stdev 38988.32 40544.05 41807.48 84204.18 85979.75 
%RSD 0.57 0.61 0.76 1.55 1.58 
 
 
 
 
Solution stability for standard preparation at 2 -8°C 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 6660362 5462959 5575230 5564557 
2 6684817 5501228 5378478 5341653 
3 6663369 5449584 5405457 5441873 
4 6728986 5479532 5374255 5398936 
5 6751158 5556266 5467820 5495234 
1 6531182 5606348 5390149 5604497 
2 6505612 5699801 5446749 5563255 
Mean 6646498 5536531 5434020 5487144 
Stdev 93852.56 90727.42 71463.29 97143.00 
%RSD 1.41 1.64 1.32 1.77 
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Solution stability for standard preparation at room temperature 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 6660362 5462959 5575230 5564557 
2 6684817 5501228 5378478 5341653 
3 6663369 5449584 5405457 5441873 
4 6728986 5479532 5374255 5398936 
5 6751158 5556266 5467820 5495234 
1 6544838 5627708 5465149 5605263 
2 6561785 5604192 5361264 5657018 
Mean 6656474 5525924 5432522 5500648 
Stdev 78014.57 70664.70 76159.98 114447.07 
%RSD 1.17 1.28 1.40 2.08 
Solution stability for test preparation at 2 -8°C 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 6922586 6660362 5462959 5575230 5564557 
2 6844501 6684817 5501228 5378478 5341653 
3 6843378 6663369 5449584 5405457 5441873 
4 6919779 6728986 5479532 5374255 5398936 
5 6894250 6751158 5556266 5467820 5495234 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 6685376 6622722 5380534 5425628 5484071 
2 6703533 6329743 5414317 5464891 5334027 
Mean 6694455 6476233 5397426 5445260 5409049 
% Assay 98.9 97.8 99.0 99.8 100.6 
Standard weight (mg) 50.5 50.2 50 49.5 50.3 
Test weight (mg) 100.5 99.6 99.8 99.7 100.4 
% Difference compare 
to that of Initial 
 1.1 -0.1 -0.9 -1.7 
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Calculation: 
 
Prototype calculation for one set: 
 
50
10
200
2.50
6594455
6679494
% Assay 100
25
7.99
10
50
8.100
100
 
 
     = 99. 6 
Solution stability for test preparation at room temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 6444838 6660362 5462959 5575230 5564557 
2 6861785 6684817 5501228 5378478 5341653 
3 6622722 6663369 5449584 5405457 5441873 
4 6329743 6728986 5479532 5374255 5398936 
5 6701829 6751158 5556266 5467820 5495234 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 6685376 6701829 5503039 5379526 5257257 
2 6503533 6657159 5490427 5495918 5549417 
Mean 6594455 6679494 5496733 5473322 5403337 
% Assay 101.7 100.8 100.8 99.7 100.5 
Standard weight 
(mg) 
50.5 50.2 50 49.5 50.3 
Test weight (mg) 100.5 99.6 99.8 99.7 100.4 
% Difference 
compare to that of 
Initial 
 0.9 0.9 2.1 1.3 
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Robustness Study for Analytical Method Validation of Lamotrigine Tablets 
 
 
 
Flow Rate at 
0.9ml/min 
Flow Rate at 
1.1ml/min 
Buffer-ACN 
63: 37 
Buffer- ACN 
67: 33 
Buffer pH 3.7 Buffer pH 3.3 
Column 
Change 
Replicate Standard Area Standard Area Standard Area Standard Area Standard Area Standard Area Standard Area 
1 5453365 5529242 5737807 5348262 5737547 5467956 5750711 
2 5679887 5456342 5708162 5483858 5657141 5507968 5575427 
3 5503324 5586865 5591209 5395346 5587579 5499661 5796950 
4 5442554 5673108 5623858 5350008 5683036 5352893 5706438 
5 5513853 5605426 5555869 5508410 5559033 5291506 5659485 
Mean 5518597 5570197 5643381 5417177 5644867 5423997 5697802 
Stdev 95273.27 81776.91 77256.49 75012.27 72191.58 96589.61 85364.08 
% RSD 1.73 5529242 1.37 1.38 1.28 1.78 1.50 
Replicate Test Area Test Area Test Area Test Area Test Area Test Area Test Area 
1 5718608 5527677 5786442 5506257 5628473 5465175 5788571 
2 5605336 5830343 5685921 5486760 5894439 5523841 5512992 
Mean 5661972 5679010 5736182 5496509 5761456 5494508 5650782 
Standard 
Weight (mg) 
49.5 49.6 49.8 50.1 49.7 49.6 50.1 
Test Weight 
(mg) 
502.5 502.5 502.5 502.5 502.5 502.5 502.5 
Label Claim 
(mg) 
25 25 25 25 25 25 25 
Mean Test 
Weight (mg) 
100.2 100.3 100.3 100.3 100.3 100.3 100.3 
% Assay 101.3 100.9 101.0 101.5 101.3 100.3 99.2 
Calculation: Prototype calculation for one set: 
50
10
200
5.49
5518597
5661972
% Assay 100
25
3.100
10
50
2.100
100
 = 101.3 % 
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1. INTRODUCTION TO UPLC 
History of chromatography can give an idea about improvement in technology from 
conventional column chromatography to high performance liquid chromatography and finally 
at this stage an ultra performance liquid chromatography or in other way a combination of 
pressurized chromatographic technology and sub 2 (two) micron particle size of stationary 
phase technology leads to advance Ultra Performance Liquid Chromatography (UPLC) or 
Rapid Resolution Liquid Chromatography (RRLC) technology. 
 
Technology of sub 2 (two) micron particle size leads many modifications in hardware 
part of the system like reduction of system volume, higher pump pressure capacity, injector 
and needle part, and cell volume of detector as well as in software area, data acquisition rate 
or capacity was increased for sufficient data collection. 
 
In brief detail, small particle size columns leads to increase in pump pressure so that 
area was improved and for accurate and precise injection volume needle in needle technology 
with teflon material was came into the picture. Detector cell volume was reduced for better 
signals and resolution. 
 
Smaller particle size of 2 micron technology altered the machine and its application 
for faster way of analysis in current scenario of separation science. Requirement of this 
technology can be explained by van deemter equation [1,4] and plot as shown in fig 1. From 
this plot it reveals that there is minimum HETP against the linear velocity with the almost 
constant relation or maximum the theoretical plates can be achieved with particle size less 
than 2 micron. Finally as a known fact increasing in N leads to increase in Resolution as 
shown in formula; 
 
 
 
Rs  =  
N 
 4 
(  -1    ) 
      k 
    k+1 (     ) 
Retentivity Selectivity System 
Efficiency 
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Fig.1: Van Deemter plots-influence of particle size 
 
Now, for method conversion from HPLC to UPLC or for comparison of both the technology 
following aspects needs to take in consideration [2-3]. 
 
 Ratio of column length to particle size (L/dp) needs to keep constant. 
i.e. 150 mm/5 µm = 30,000 is closest to 50mm/1.7 µm = 29,500 
 
 Column selection should be based on same basic column chemistry 
i.e. C18 column should be replaced by C18 column 
 
 5 µm to 1.7 µm particle size leads to increase in speed of 9X along with 9X pressure 
 3 µm to 1.7 µm particle size leads to increase in speed of 3X along with 3X pressure 
 5 µm to 1.7 µm particle size leads to increase in peak height of 1.7X 
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 3 µm to 1.7 µm particle size leads to increase in peak height of 1.3X 
 
 5 µm to 1.7 µm particle size leads to decrease in peak width of 0.6X 
 3 µm to 1.7 µm particle size leads to decrease in peak width of 0.8X 
 
 Column efficiency (N) is inversely proportional to dp 
 
 
 
i.e. 5 µm to 1.7 µm particle size leads to increase in column efficiency (N) 3X but 
  
 
So, resolution also increase by 1.7X 
Based on above fact practically an example for chromatogram comparison against column 
dimension for rune time and resolution is shown in fig 2. 
 
Remark 
Here, X is used to express the mathematical relation in multi fold. 
e.g. pressure increased by 3X i.e. pressure increase by three times 
 
Method Development 
 
Method development in UPLC remains same as of HPLC but few areas of 
chromatographic conditions are different e.g. for gradient elution column equilibration time is 
very less as compare to HPLC due to lower column volume. 
 
Advance technology in column filled material for HPLC as well as UPLC allows 
higher pH and temperature stability for column for wider choice of mobile phase for different 
applications. e.g. pH of mobile phase or its buffer can selected based on compound chemical 
nature and that can be explain by fig.3 for reversed phase retention plot. 
 
 
dp
N
1
NRs
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Fig.2 Chromatogram comparison against column dimension 
 
Fig.3 Reversed phase retention plot  
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From the above plot and fundamental theory of solvent gives following information 
for development consideration. 
 
Facts for basic compound  
Alkaline pH increases retention of basic analytes 
Methanol increases retention of all components compared to acetonitrile 
Similar basic analytes differ little in selectivity, respective to one another, when they are 
either fully charged or uncharged 
Largest selectivity differences between bonded phases occur with methanol and analytes 
in their unionized state 
 
Facts for acid compound  
1. Acidic pH increases retention of acidic analytes 
Methanol increases retention of all components compared to acetonitrile 
Large differences in selectivity are observed when change in pH alters charge state 
Largest selectivity differences between bonded phases occur with methanol and analytes 
in their unionized state 
Column chemistry for known columns UPLC are shown in fig 4. 
 
Fig.4: Column chemistry of UPLC column 
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 By many recent research and development, UPLC presents the ability to extend and 
expand the utility of separation science at a time when many scientists have reached 
separation barriers, pushing the limits of conventional HPLC. New chemistry and 
instrumentation technology can provide more information per unit of work as UPLC begins 
to fulfil the promise of increased speed, resolution, and sensitivity predicted for liquid 
chromatography. As this is the concept for the scientist many of industries may take time to 
use in routine but it can be the future of the liquid chromatography. Hence present research 
work includes the extended area of HPLC to UPLC as a part of technology updating or a 
balance form of present HPLC and improved LC or UPLC for future scope for separation 
science. 
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2. LITERATURE REVIEW 
Literature review for methods developed for Ticlopidine hydrochloride is mentioned 
in the section 1, page number 39. 
 
3. AIM OF PRESENT WORK 
As per discussion in the literature review, reflectance near-infrared and fourier 
transform Raman spectroscopy, Gas Chromatographic, colorimetric, Voltammetric and 
HPLC methods for the determination of ticlopidine hydrochloride in pharmaceutical dosage 
forms or in biological fluids are reported. So far to our present knowledge, no validated 
stability indicating UPLC assay method for the determination of ticlopidine hydrochloride in 
pharmaceutical formulation was available in literature. Our work deals with the forced 
degradation of ticlopidine hydrochloride under stress condition like acid hydrolysis, base 
hydrolysis, and oxidation, thermal and photolytic stress. This work also deals with the 
validation of the developed method for the assay of ticlopidine hydrochloride from its dosage 
form (tablets). Hence, the method is recommended for routine quality control analysis and 
also stability sample analysis. 
 
The aim and scope of the proposed work are as under: 
 To developed suitable UPLC method for ticlopidine hydrochloride, 
 Forced degradation study of ticlopidine hydrochloride under stress condition, 
 To resolve all major impurities generated during the force degradation studies of 
ticlopidine hydrochloride, 
 Perform the validation for the developed method. 
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4. EXPERIMENTAL 
4.1 Materials  
Detail of materials for methods developed for Ticlopidine hydrochloride is mentioned 
in the section 1, page number 43. 
 
4.2 Instrumentation 
The LC system of Waters Acquity UPLC with PDA was used for this entire study and 
chromatographic separation was achieved on Zorbax SB-C18 (50 mm X 4.6mm 1.8µm) 
column as stationary phase with binary gradient mode.  
 
4.3 Mobile phase Preparation 
The mobile phase consisted of methanol – 0.01M ammonium acetate buffer pH 5.0 
(80: 20, v/v). To prepare the buffer solution, 0.7708 g ammonium acetate were weighed and 
dissolve in 1000 ml HPLC grade water and then adjusted to pH 5.0 with glacial acetic acid. 
Mobile phase was filtered through a 0.22 μm nylon membrane (Millipore Pvt. Ltd. Benglore, 
India) and degassed in an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai). 
4.4 Diluent Preparation  
Methanol used as a diluent. 
4.5 Standard Preparation  
Detail of standard preparation for methods developed for Ticlopidine hydrochloride is 
mentioned in the section 1, page number 43. 
 
4.6 Test Preparation  
 Twenty tablets were weighed and the average weight of tablet was determined. From 
these, five tablets were weighed and transfer into a 500 ml volumetric flask. About 50 ml 
methanol was added and sonicated for a minimum 30 min. with intermittent shaking. Then 
content was brought back to room temperature and diluted to volume with methanol. The 
sample was filtered through 0.22μm nylon syringe filter. The concentration obtained was 250 
μg/ml of ticlopidine hydrochloride.  
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4.7 Chromatographic Conditions  
Chromatographic analysis was performed on Zorbax SB-C18 (50 mm X 4.6mm 
1.8µm) column. The mobile phase consisted of methanol – 0.01M ammonium acetate buffer 
pH 5.0 (80: 20, v/v). The flow rate of the mobile phase was adjusted to 0.8 ml/min and the 
injection volume was 4.0 μl. Detection was performed at 235nm. 
 
5. RESULT AND DISCUSSION 
5.1 Development and Optimization of the UPLC Method 
Proper selection of the methods depends upon the nature of the sample (ionic or 
ionisable or neutral molecule) its molecular weight and solubility. Ticlopidine hydrochloride 
is dissolved in polar solvent hence RP-UPLC was selected to estimate them. To develop a 
rugged and suitable UPLC method for the quantitative determination of ticlopidine 
hydrochloride, the analytical condition were selected after testing the different parameters 
such as diluents, buffer, buffer concentration, organic solvent for mobile phase and mobile 
phase composition and other chromatographic conditions. Our preliminary trials using 
different composition of mobile phases consisting of water with methanol or acetonitrile, did 
not give good peak shape.  
The mobile phase consisted of methanol – 0.01M ammonium acetate buffer pH 5.0 
(80: 20, v/v). To prepare the buffer solution, 0.7708 g ammonium acetate were weighed and 
dissolve in 1000 ml HPLC grade water and then adjusted to pH 5.0 with glacial acetic acid. 
Mobile phase was filtered through a 0.20 μm nylon membrane (Millipore Pvt. Ltd. Benglore, 
India) and degassed in an ultrasonic bath (Spincotech Pvt. Ltd., Mumbai).  
By using 10 mM Ammonium acetate buffer in 1000 ml of buffer, adjusted to pH 5.0 
with glacial acetic acid and keeping mobile phase composition as methanol-ammonium 
acetate buffer (80: 20, v/v), best peak shape was obtained. For the selection of organic 
constituent of mobile phase, methanol was chosen to reduce the longer retention time and to 
attain good peak shape. Figure 2 and Figure 3 represent the chromatograms of standard and 
test preparation respectively. 
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Figure 2: Chromatogram of standard preparation 
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Figure 3: Chromatogram of test preparation 
 
5.2 Degradation Study 
The degradation samples were prepared by transferring powdered tablets, equivalent 
to 250 mg ticlopidine hydrochloride into a 250 ml round bottom flask. Then prepared 
samples were employed for acidic, alkaline and oxidant media and also for thermal and 
photolytic conditions. After the degradation treatments were completed, the stress content 
solutions were allowed to equilibrate to room temperature and diluted with mobile phase to 
attain 250 μg/ml concentrations. Specific conditions were described as follows. 
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5.2.1 Acidic condition  
Acidic degradation study was performed by heating the drug content in 0.1 N HCl at 
80° C for 2.0 hours and mixture was neutralized. Ticlopidine hydrochloride was found 
slightly degrade in acidic condition. (Figure 4) 
 
 
 
 
 
 
 
Figure 4: Chromatogram of acidic forced degradation study 
 
5.2.2 Alkaline condition 
Alkaline degradation study was performed by heating the drug content in 1 M NaOH 
at 80° C for 2 hours and mixture was neutralized. In alkali degradation, it was found that 
around 5-6 % of the drug degraded. (Figure 5) 
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Figure 5: Chromatogram of alkali forced degradation study 
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5.2.3 Oxidative condition 
Oxidation degradation study was performed by heating the drug content in 3% v/v 
H2O2 at 80° C for 1 hour. Major degradation was found in oxidative condition that product 
was degraded up to 7-8 %. The major impurity peaks was found at 3.49min.  (Figure 6) 
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Figure 6: Chromatogram of oxidative forced degradation study 
 
5.2.4 Thermal condition 
Thermal degradation was performed by exposing solid drug at 80° C for 72 hours.  
Ticlopidine hydrochloride is found to be stable under thermal degradation condition. There is 
no degradation observed in above specific thermal condition. Ticlopidine hydrochloride was 
found to be stable in thermal condition.   (Figure 7) 
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Figure 7: Chromatogram of thermal degradation study 
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5.2.5 Photolytic condition 
Photolytic degradation study was performed by exposing the drug content in UV-light 
for 72 hours. In photolytic degradation, it was found that around 4-5% of the drug degraded. 
(Figure 8) 
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Figure 8: Chromatogram of UV-light degradation study 
 
5.3 Method Validation 
5.3.1 Specificity 
The specificity of the method was determined by checking the interference of placebo 
with analyte and the proposed method was eluted by checking the peak purity of ticlopidine 
hydrochloride during the force degradation study. The peak purity of the ticlopidine 
hydrochloride was found satisfactory (0.9999) under different stress condition. There was no 
interference of any peak of degradation product with drug peak. 
 
5.3.2 Linearity 
Five points calibration curve were obtained in a concentration range from 62.5-375 
μg/ml for ticlopidine hydrochloride. The response of the drug was found to be linear in the 
investigation concentration range and the linear regression equation was y =7165671.78378x-
34207.26 with correlation coefficient 0.9999. (Figure 9) Chromatogram obtain during 
linearity study were shown in figure 10-14. 
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Figure 9: Linearity curve for ticlopidine hydrochloride 
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Figure 10: Linearity study chromatogram of level-1 (25%) 
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Figure 11: Linearity study chromatogram of level-2 (50%) 
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Figure 12: Linearity study chromatogram of level-3 (75%) 
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Figure 13: Linearity study chromatogram of level-4 (100%) 
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Figure 14: Linearity study chromatogram of level-5 (150%) 
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5.3.3 Precision 
The result of repeatability and intermediate precision study are shown in Table 1. The 
developed method was found to be precise as the %RSD values for the repeatability and 
intermediate precision studies were < 1.31 % and < 0.77 %, respectively, which confirm that 
method was precise. 
Table 1: Evaluation data of precision study 
Set Intraday (n = 6) Interday (n = 6) 
1 101.4 100.2 
2 98.8 99.3 
3 101.6 98.3 
4 99.4 99.7 
5 101.5 100.3 
6 99.2 100.2 
Mean 100.3 99.7 
Standard deviation 1.31 0.77 
% RSD 1.31 0.77 
 
5.3.4 Accuracy 
The HPLC area responses for accuracy determination are depicted in Table 2. The 
result shown that best recoveries (98.37-101.22 %) of the spiked drug were obtained at each 
added concentration, indicating that the method was accurate. Chromatogram obtain during 
accuracy study were shown in figure 15-17. 
 
Table 2: Evaluation data of accuracy study 
Level (%) 
 
Amount added 
concentration
 a
 
(mg/ml) 
Amount found 
concentration
 a
 
(mg/ml) 
% Recovery % RSD 
50 0.12267 0.12067 98.37 0.27 
100 0.25133 0.24995 99.45 0.22 
150 0.37133 0.37586 101.22 0.87 
a
 Each value corresponds to the mean of three determinations 
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Figure 15: Accuracy study chromatogram of level-1 (50%) 
3
.0
5
6
A
U
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
Minutes
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00
 
Figure 16: Accuracy study chromatogram of level-2 (100%) 
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Figure 17: Accuracy study chromatogram of level-3 (150%) 
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5.3.5 Solution stability study  
Table 3 shows the results obtain in the solution stability study at different time 
intervals for test preparation. It was concluded that the test preparation solution was found 
stable up to 48 h at 2 - 5˚ C and ambient temperature, as during this time the result was not 
decrease below the minimum percentage. 
Table 3: Evaluation data of solution stability study 
 
Intervals 
% Assay for Test 
Preparation Solution 
Stored at 2-5 ˚C 
% Assay for Test Preparation 
Solution Stored at Ambient 
Temperature 
Initial 100.2 101.0 
12 h 101.1 101.7 
24 h 98.5 99.8 
36 h 99.6 99.3 
48 h 98.6 98.4 
 
 
5.3.6 Robustness 
The result of robustness study of the developed assay method was established in 
Table 4. The result shown that during all variance conditions, assay value of the test 
preparation solution was not affected and it was in accordance with that of actual. System 
suitability parameters were also found satisfactory; hence the analytical method would be 
concluded as robust. Chromatogram obtain during robustness study were shown in figure  18-
24. 
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Table 4: Evaluation data of robustness study 
 
Robust conditions % Assay 
System Suitability Parameters 
Theoretical Plates Asymmetry 
Flow 0.9 ml/min 98.2 10244 1.08 
Flow 1.1 ml/min 98.8 10365 1.18 
Buffer pH 4.8 100.3 10400 1.10 
Buffer pH 5.2 100.5 10388 1.20 
Buffer-ACN (78: 22,v/v) 98.4 10354 1.09 
Buffer-ACN (82: 18,v/v) 100.7 10300 1.15 
Column change 99.7 10270 1.12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Standard chromatogram (0.9 ml/min flow rate) 
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Figure 21: Standard chromatogram (1.1 ml/min flow rate) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Standard chromatogram (Buffer-ACN (78: 22,v/v) 
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Figure 23: Standard chromatogram (Buffer-ACN (82: 18, v/v) 
   
 
 
 
 
 
 
 
 
 
 
 
 Figure 24: Standard chromatogram (pH 5.2) 
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Figure 25: Standard chromatogram (pH 4.8) 
 
3
.0
9
1
A
U
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
Minutes
0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00
 
Figure 26: Standard chromatogram (Column change) 
 
5.3.7 System suitability 
A system suitability test of the chromatographic system was performed before each 
validation run. Five replicate injections of standard preparation were injected and asymmetry, 
theoretical plate and % RSD of peak area were determined for same. Acceptance criteria for 
system suitability, Asymmetry not more than 2.0, theoretical plate not less then 10000 and % 
RSD of peak area not more then 2.0, were full fill during all validation parameter.  
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6. Calculation and data 
 
Calculation formula used: 
 
     
1. Calculation formula for % assay of ticlopidine hydrochloride 
 
 
WeightTest
Weight
AreaMean
AreaTestMean
Assay
500
100
Standard
Standard
%  
 
Standard
5
50
ofPotency
ClaimLable
WeightTestMean
 
 
 
2. Relative standard deviation 
 
100
sMeasurmentofValueMean
sMeasurmentofDeviationStandard
RSD%  
 
 
3. Recovery 
 
100
AddedAmount
foundAmount
erycovRe%  
 
 
4. Amount found  
 
ionConcentratStandard
AreaStandardMean
AreaTestMean
)ml/mg(FoundAmount  
 
 
5. Amount added 
 
Volume
Weight
)ml/mg(AddedAmount  
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Specificity Study for Analytical Method Validation of Ticlopidine hydrochloride Tablets 
 
Standard Weight (mg) 25.0     
Standard Dilution 100 1 1   
Standard Potency 100 %     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration 
(mg/ml) 
0.250     
      
Replicate 1 2 3 4 5 
Standard Area 1763648 1754781 1778451 1780452 1764578 
Mean Standard Area 1768382     
Stdev. 10827.49     
% RSD 0.61     
 
 
Replicate Test Area 
1 1757812 
2 1774132 
Mean Test Area 1765972 
Test Weight (mg) 1429.1 
Label claim (mg) 250 
Mean Test Weight (mg) 288.8 
% Assay 100.9 
 
Calculation: 
 
Prototype calculation for one set: 
 
1.1429
500
100
0.25
1768382
1765972
% Assay 100
250
8.288
5
50
 
 
              
     = 100.9 % 
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Linearity Study for Analytical Method Validation of Ticlopidine hydrochloride Tablets 
 
 
 
 
 
 
 
 
 
 
 
Standard Weight (mg) 50    
Standard Dilution 100 5 10  
Standard Potency 100.0 %    
Factor 1 298.50    
Factor 2 298.50     
Standard Concentration (mg/ml) 0.250     
Concentration of Linearity Stock 
Solution (mg/ml) 
0.50     
      
Replicate 1 2 3 4 5 
Standard Area 1763648 1754780 1778451 1780452 1764578 
Mean Standard Area 1768382     
Stdev 9684.40     
% RSD 0.55     
Concentration Level 
(%) 
Volume of 
Linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final Concentration 
(mg/ml) 
Mean Area 
25 1.25 10 0.0625 419803 
50 2.50 10 0.1250 852520 
75 3.75 10 0.1875 1306782 
100 5.00 10 0.2500 1763648 
150 7.50 10 0.3750 2651884 
  Correlation co-efficient 1.0000 
  Slope 7165671.78 
  Intercept -34207.26 
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Precision Study for Analytical Method Validation of Ticlopidine hydrochloride Tablets 
 
 
Standard Weight (mg) 25.2     
Standard Dilution 100 1 1   
Standard Potency 100.0 %     
Label Claim (mg) 250     
Mean Test Weight (mg) 288.8     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration (mg/ml) 0.252     
      
Replicate 1 2 3 4 5 
Standard Area 1762145 1760181 1777011 1764552 1767858 
Mean Standard Area 1766349     
Stdev. 6612.53     
% RSD 0.37     
 
 
 
Description Mean area Wt. (mg) % Assay 
Set 1 1770974 1439.1 101.4 
Set 2 1733422 1445.1 98.8 
Set 3 1800995 1460.1 101.6 
Set 4 1763122 1461.1 99.4 
Set 5 1765622 1434.1 101.5 
Set 6 1720972 1430.1 99.2 
  Mean 100.3 
  Stdev 1.31 
  % RSD 1.31 
    
 
 
Calculation: 
 
Prototype calculation for one set: 
 
1.1439
500
100
2.25
1766349
1770974
% Assay 100
250
8.288
5
50
 
 
     
= 101.4 % 
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Intermediate precision study for Analytical Method Validation of Ticlopidine 
hydrochloride tablet 
 
 
Standard Weight (mg) 25.5     
Standard Dilution 100 1 1   
Standard Potency 100.0 %     
Label Claim (mg) 250     
Mean Test weight (mg) 288.8     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration (mg/ml) 0.255     
      
Replicate 1 2 3 4 5 
Standard Area 1766744 1760234 1767810 1775127 1760129 
Mean Standard Area 1766009     
Stdev. 6221.87     
% RSD 0.35     
 
 
 
Description Mean area Wt. (mg) % Assay 
Set 1 1748515 1455.0 100.2 
Set 2 1726194 1450.4 99.3 
Set 3 1689348 1432.8 98.3 
Set 4 1743122 1458.6 99.7 
Set 5 1752764 1457.1 100.3 
Set 6 1742274 1450.7 100.2 
  Mean 99.7 
  Stdev 0.77 
  % RSD 0.77 
    
 
 
Calculation: 
 
Prototype calculation for one set: 
 
0.1455
500
100
5.25
1766009
1748515
% Assay 100
250
8.288
5
50
 
 
 
    = 99.7 % 
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Comparison for Precision and Intermediate Precision Study for Analytical Method 
Validation for Ticlopidine hydrochloride Tablets 
 
 
 Set %Assay 
Precision study 
1 101.4 
2 98.8 
3 101.6 
4 99.4 
5 101.5 
6 99.2 
Intermediate precision study 
1 100.2 
2 99.3 
3 98.3 
4 99.7 
5 100.3 
6 100.2 
 Mean 100.0 
 Stdev 1.08 
 % RSD 0.50 
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Accuracy study for Analytical Method Validation of Ticlopidine hydrochloride tablets 
 
Standard Weight (mg) 25.0     
Standard Dilution 100 1 1   
Standard Potency 100.0 %     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration 
(mg/ml) 
0.250     
      
Replicate 1 2 3 4 5 
Standard Area 1764878 1762447 1770454 1767971 1759432 
Mean Standard Area 1765036     
Stdev 4361.81     
% RSD 0.25     
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Accuracy Study for Analytical Method Validation of Ticlopidine hydrochloride Tablets 
 
 
Recovery 
Level 
Set 
No. 
Mean 
area 
Wight 
(mg) 
Volume 
(ml) 
Value added Value found % 
Recovery 
Mean % 
Recovery 
Std 
Dev 
% 
RSD Concentration(mg/ml) Concentration(mg/ml) 
50% 
Set 1 849258 12.2 100 0.12200 0.12029 98.60 
98.37 0.26 0.27 Set 2 854809 12.3 100 0.12300 0.12108 98.44 
Set 3 851701 12.3 100 0.12300 0.12064 98.08 
100% 
Set 1 1765987 25.1 100 0.25100 0.25013 99.65 
99.45 0.22 0.22 Set 2 1769950 25.2 100 0.25200 0.2507 99.48 
Set 3 1758115 25.1 100 0.25100 0.24902 99.21 
150% 
Set 1 2673601 37.2 100 0.37200 0.37869 101.80 
101.22 0.88 0.87 Set 2 2624547 37.1 100 0.37100 0.37174 100.20 
Set 3 2662654 37.1 100 0.37100 0.37714 101.65 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
100
12200.0
12029.0
covRe% ery  = 98.60 % 
 
2500.0
1765036
849258
)/( mlmgFoundAmount  = 0.12029mg/ml 
 
100
2.12
)/( mlmgAddedAmount  = 0.12200 mg/ml 
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Solution Stability Study for Analytical Method Validation of Ticlopidine hydrochloride 
Tablets 
 
System suitability of standard preparation for solution stability 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1764798 1768744 1759564 1766465 1764664 
2 1746457 1751214 1757858 1764544 1764679 
3 1770464 1770566 1761646 1757879 1779796 
4 1767745 1746434 1745529 1758976 1767943 
5 1769545 1760464 1758134 1763464 1764643 
Mean 1763802 1759484 1756546 1762266 1768345 
Stdev 9934.19 10585.53 6339.08 3685.31 6557.08 
%RSD 0.56 0.60 0.36 0.21 0.37 
 
 
Solution stability for standard preparation at 2 -8°C 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1764798 1764798 1764798 1764798 
2 1746457 1746457 1746457 1746457 
3 1770464 1770464 1770464 1770464 
4 1767745 1767745 1767745 1767745 
5 1769545 1769545 1769545 1769545 
1 1755449 1745464 1765842 1779855 
2 1758979 1779791 1746464 1774544 
Mean 1761920 1763466 1761616 1767630 
Stdev 8784.28 12818.57 10536.31 10529.97 
%RSD 0.50 0.73 0.60 0.60 
 
 
Solution stability for standard preparation at room temperature 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1764798 1764798 1764798 1764798 
2 1746457 1746457 1746457 1746457 
3 1770464 1770464 1770464 1770464 
4 1767745 1767745 1767745 1767745 
5 1769545 1769545 1769545 1769545 
1 1767412 1744794 1779742 1766494 
2 1769454 1746136 1744646 1764641 
Mean 1765125 1758563 1763342 1764306 
Stdev 8440.75 12083.00 13001.99 8174.38 
%RSD 0.48 0.69 0.74 0.46 
UPLC…   Part-B 
 
 
 
197 
 
 
 
Solution stability for test preparation at room temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1764798 1768744 1759564 1766465 1764664 
2 1746457 1751214 1757858 1764544 1764679 
3 1770464 1770566 1761646 1757879 1779796 
4 1767745 1746434 1745529 1758976 1767943 
5 1769545 1760464 1758134 1763464 1764643 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 1767412 1764797 1746461 1749779 1748944 
2 1769454 1774654 1746491 1738974 1746574 
Mean 1768433 1769725 1746476 1744376 1747759 
% Assay 101.0 101.7 99.8 99.3 98.4 
Standard weight (mg) 25.2 25.3 25.1 25.1 24.9 
Test weight (mg) 1439.1 1445.1 1460.1 1434.6 1430.0 
% Difference 
compare to that of 
Initial 
 -0.7 1.2 1.7 2.6 
 
Calculation: 
Prototype calculation for one set: 
1.1445
500
100
3.25
1768433
1769725
% Assay 100
250
8.288
5
50
 = 101.7 % 
Solution stability for test preparation at 2 -8°C 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 1764798 7518815 7609269 7683945 7622877 
2 1746457 7623545 7631760 7713623 7712111 
3 1770464 7597709 7661026 7699542 7713724 
4 1767745 7600418 7666737 7685978 7731233 
5 1769545 7605695 7635902 7685993 7739825 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 1767412 1746972 1758546 1765842 1758975 
2 1769454 1797956 1760464 1746464 1757891 
Mean 1768433 1772464 1759505 1756153 1758433 
% Assay 100.2 101.1 98.5 99.6 98.6 
Standard weight (mg) 25 25.1 24.6 25 24.8 
Test weight (mg) 1439.1 1445.1 1460.1 1434.6 1430.0 
% Difference compare 
to that of Initial 
 -0.9 1.7 0.6 1.6 
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Robustness Study for Analytical Method Validation of Ticlopidine hydrochloride Tablets 
 
 
Flow Rate at 
0.9ml/min 
Flow Rate at 
1.1ml/min 
Buffer-ACN 
63: 37 
Buffer- ACN 
67: 33 
Buffer pH 3.7 Buffer pH 3.3 
Column 
Change 
Replicate Standard Area Standard Area Standard Area Standard Area Standard Area Standard Area Standard Area 
1 1766744 1756454 1755664 1707461 1744648 1768756 1756454 
2 1760234 1779841 1756545 1756554 1735976 1763644 1764645 
3 1767810 1754564 1764641 1704680 1764556 1764544 1746541 
4 1775127 1756456 1746544 1735645 1765941 1770056 1775647 
5 1760129 1756464 1778975 1745564 1760564 1746461 1764562 
Mean 1766009 1760756 1760474 1729981 1754337 1762692 1761570 
Stdev 6221.87 10700.43 12168.29 23066.89 13312.21 9470.77 10823.75 
% RSD 0.35 0.61 0.69 1.33 0.76 0.54 0.61 
Replicate Test Area Test Area Test Area Test Area Test Area Test Area Test Area 
1 1684512 1695322 1754641 1765417 1678945 1746456 1721454 
2 1694184 1694564 1746545 1764642 1675814 1747446 1734852 
Mean 1689348 1694943 1750593 1765030 1677380 1746951 1728153 
Standard 
Weight (mg) 
25.5 25.5 25.4 24.6 25.5 25.4 25.4 
Test Weight 
(mg) 
1435.2 1435.2 1440.2 1442.2 1430.5 1444.2 1444.2 
Label Claim 
(mg) 
250 250 250 250 250 250 250 
Mean Test 
Weight (mg) 
288.8 288.8 288.8 288.8 288.8 288.8 288.8 
% Assay 98.2 98.8 101.3 100.5 98.4 100.7 99.7 
Calculation: 
Prototype calculation for one set: 
1.1435
500
100
5.25
1766009
1689348
% Assay 100
250
8.288
5
50
  = 98.2 
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1. INTRODUCTION 
Introduction of Ticlopidine hydrochloride is mentioned in the section 1, page 
number 32. 
 
1.1 SPECTROSCOPY  METHODS [1,2] 
It is the branch of science dealing with the study of interaction between 
electromagnetic radiation and matter. It is a most powerful tool available for the study of 
atomic and molecular structure/s and is used in the analyses of wide range of samples. 
Optical spectroscopy includes the region on electromagnetic spectrum between 100 Å and 
400 μm. The regions of electromagnetic spectrum are: 
 
Region Wavelength 
Far (or vacuum)ultraviolet 10-200 nm 
Near ultraviolet 200-400 nm 
Visible 400-750 nm 
Near infrared 0.75- 2.2 µm 
Mid infrared 2.5-50 µm 
Far infrared 50-1000 µm 
    
 
1.2 Ultraviolet-Visible spectrophotometry [3] 
  UV-Visible spectrophotometry is one of the most frequently employed technique       
in pharmaceutical analysis. It involves measuring the amount of ultraviolet or visible 
radiation absorbed by a substance in solution. Instrument which measure the ratio, or 
function of ratio, of the intensity of two beams of light in the U.V.visible region are called 
ultraviolet-visible spectrophotometers.  
  In qualitative analysis, organic compounds can be identified by use of 
spectrophotometer, if any recorded data is available, and quantitative spectrophotometric 
analysis is used to ascertain the quantity of molecular species absorbing the radiation. 
Spectrophotometric technique is simple, rapid, moderately specific and applicable to  
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small quantities of compounds. The fundamental law that governs the quantitative 
spectrophotometric analysis is the Beer -Lambert law. 
1.2.1 Beer’s law  
 It states that the intensity of a beam of parallel monochromatic radiation decreases 
exponentially with the number of absorbing molecules. In other words, absorbance is 
proportional to the concentration. 
1.2.2 Lambert’s law 
 It states that the intensity of a beam of parallel monochromatic radiation decreases 
exponentially as it passes through a medium of homogeneous thickness. 
A combination of these two laws yields the Beer-Lambert law. 
1.2.3 Beer-Lambert law 
 When beam of light is passed through a transparent cell containing a solution of 
an  absorbing substance , reduction of the intensity of light may occur.    
Mathematically, Beer-Lambert law is expressed as 
                               A = a b c 
                              Where, A = absorbance or optical density  
                                           a = absorptivity or extinction coefficient  
                                           b = path length of radiation through sample (cm) 
                                           c = concentration of solute in solution. 
Both b and   a are constant so a is directly proportional to the concentration c 
When c is in gm/100 ml, then the conctant is called A (1%, 1cm) 
 
 Quantification of medicinal substance using spectrophotometer may   carried out 
by preparing solution in transparent solvent and measuring it’s absorbance at suitable 
wavelength. The wavelength normally selected is wavelength of maximum absorption   (λ 
max), where small error in setting the wavelength scale have little effect on measured 
absorbance. Ideally, concentration should be adjusted to give an absorbance of  
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approximately, 0.9, around which the accuracy and precision of the measurements are 
optimal. 
The assay of single component sample, which contains other absorbing 
substances, is then calculated from the measured absorbance by using one of three 
principal procedures. They are, use of standard absorptivity value, calibration graph and 
single or double point standardization. 
In standard absorptive value method, the use of standard A (1%, 1cm) or E values 
are used in order to determine its absorptivity. It is advantageous in situations where it is 
difficult or expensive to obtain a sample of the reference substance. In calibration graph 
method, the absorbances of a number of standard solutions of the reference substance at 
concentrations encompassing the sample concentrations are measured and a calibration 
graph is constructed. The concentration of the analyte in the sample solution is read from 
the graph as the concentration corresponding to the absorbance of the solution. The single 
point standardization procedure involves the measurement of the absorbance of a sample 
solution and of a standard solution of the reference substance. The concentration of the 
substances in the sample is calculated from the proportional relationship that exists 
between absorbance and concentration. 
     Atest x Cstd 
                  Ctest       = 
          Astd 
Where Ctest and Cstd are the concentrations in the sample and standard  
solutions respectively and Atest and Astd are the absorbances of the sample         
and standard solutions respectively. 
For assay of substance/s in multi component samples by spectrophotometer; the following 
methods are being used routinely, which includes
13
; 
 Simultaneous equation method 
 Derivative spectrophotometric method 
 Absorbance ratio method ( Q-Absorbance method) 
 Difference spectrophotometry 
 Solvent extraction method 
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2. LITERATURE REVIEW 
Literature review for methods developed for Ticlopidine Hydrochloride is 
mentioned in the section 1, page number 39. 
 
3. AIM OF PRESENT WORK 
As per discussion in the literature review, reflectance near-infrared and fourier 
transform raman spectroscopy, gas Chromatographic, colorimetric, voltammetric and 
HPLC methods for the determination of ticlopidine hydrochloride in pharmaceutical 
dosage forms or in biological fluids are reported. reflectance near-infrared and fourier 
transform raman spectroscopy, gas chromatographic, colorimetric, voltammetric methods 
simply used for estimation of ticlopidine hydrochloride from pharmaceutical formulation 
and HPLC methods applied to the pharmacokinetic studies of ticlopidine hydrochloride. 
So far to our present knowledge, no validated spectrophotometric assay method for the 
determination of ticlopidine hydrochloride in pharmaceutical formulation was available in 
literature. Our work deals with the forced degradation of ticlopidine hydrochloride under 
stress condition like acid hydrolysis, base hydrolysis, and oxidation, thermal and 
photolytic stress. This work also deals with the validation of the developed method for the 
assay of ticlopidine hydrochloride from its dosage form (tablets). Hence, the method is 
recommended for routine quality control analysis and also stability sample analysis. 
 
The aim and scope of the proposed work are as under: 
 To developed suitable spectrophotometric method for ticlopidine hydrochloride. 
 Forced degradation study of ticlopidine hydrochloride under stress condition 
 To resolve all major impurities generated during the force degradation studies of 
ticlopidine hydrochloride. 
 Perform the validation for the developed method. 
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4. EXPERIMENTAL 
4.1 Materials 
 Ticlopidine hydrochloride standard of was provided by Aarti Drugs Ltd., Boisar 
(India). Ticlopidine hydrochloride tablets containing 233mg ticlopidine hydrochloride 
and the inactive ingredient used in drug matrix were obtained from market. Analytical 
grade methanol and water were obtained from Spectrochem Pvt. Ltd., Mumbai (India). 
 
4.2 Diluent Preparation  
 Methanol and Water (70:30, v/v) used as a diluents. 
 
4.3 Standard Preparation 
 A ticlopidine hydrochloride standard stock solution containing 100μg/ml was 
prepared in a 100 ml volumetric flask by dissolving 10.00 mg of ticlopidine 
hydrochloride and then diluted to volume with methanol as diluents. 
Further 10 ml of this stock solution in 50 ml volumetric flask and make up to mark 
with diluents. (Final concentration of standard solution is 40μg/ml) 
 
4.4 Test Preparation 
Twenty tablets were weighed and the average weight of tablet was determined. 
From these, five tablets were weighed and transfer into a 500 ml volumetric flask. About 
50 ml diluents was added and sonicated for a minimum 30 min. with intermittent shaking. 
Then content was brought back to room temperature and diluted to volume with 
methanol. The sample was filtered through 0.45μm nylon syringe filter. The 
concentration obtained was 2500 μg/ml of ticlopidine hydrochloride.  
Further take 0.8 ml this filtrate solution in 50 ml volumetric flask and make up to 
mark with diluents. The concentration obtained was 40 μg/ml of ticlopidine 
hydrochloride.  
 
4.5 Instrumentation 
UV-Visible double beam spectrophotometer with matched quartz cells (1cm) 
 Model: PharmaSpec1700 
 Make: Shimadzu, Kyoto, Japan. 
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5. RESULTS AND DISCUSSION 
5.1 Development and Optimization of the Spectrophotometric Method 
Proper wave length selection of the methods depends upon the nature of the 
sample and its solubility. To develop a rugged and suitable spectrophotometric method 
for the quantitative determination of ticlopidine hydrochloride, the analytical condition 
were selected after testing the different parameters such as diluents, buffer, buffer 
concentration, and other chromatographic conditions.  
Our preliminary trials using different composition of diluents consisting of water 
with buffer and methanol. By using diluent consisted of methanol – water (70: 30, v/v) 
best result was obtained and degassed in an ultrasonic bath (Spincotech Pvt. Ltd., 
Mumbai). Below figures represent the spectrums of blank, standard and test preparation 
respectively. 
 
5.1.1 Selection of Wavelength 
 Scan standard solution in UV spectrophotometer between 200 nm to 400 nm on 
spectrum mode, using diluents as a blank. 
 The spectrums are shown as under: 
 
Fig. 5.1.2: UV spectrum of Ticlopidine hydrochloride in Diluent (Blank) solution 
Spectrophotometric…   Part-C  
 
 
206 
 
 
 
Fig. 5.1.3: UV spectrum of Ticlopidine hydrochloride in Standard solution 
 
Fig. 5.1.3: UV spectrum of Ticlopidine hydrochloride in Sample solution 
 
Ticlopidine hydrochloride shows λ max at 233nm. The proposed analytical method 
is simple, accurate and reproducible. 
 
Spectrophotometric…   Part-C  
 
 
207 
 
5.2 Method Validation 
5.2.1 Specificity 
  The specificity of the method was determined by checking the interference of 
placebo with analyte. There was no interference is observed. 
 
5.2.2 Linearity 
Seven points calibration curve were obtained in a concentration range from 16-40 
μg/ml for ticlopidine hydrochloride. The response of the drug was found to be linear in 
the investigation concentration range and the linear regression equation was                                   
y =11.30580x+0.21412 with correlation coefficient 0.9972. (Figure 5.2.2) 
 
Linearity study for Ticlopidine HCl
y = 11.30580x + 0.21412
R
2
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Figure 5.2.2: Linearity curve for ticlopidine hydrochloride 
 
 
 
 
 
 
5.2.3 Precision 
  The result of repeatability and intermediate precision study are shown in Table 1. 
The developed method was found to be precise as the %RSD values for the repeatability 
and intermediate precision studies were < 0.98 % and < 0.79 %, respectively, which 
confirm that method was precise. 
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Table 1: Evaluation data of precision study 
Set Intraday (n = 6) Interday (n = 6) 
1 101.8 100.5 
2 101.2 99.0 
3 99.1 98.2 
4 101.3 98.6 
5 100.6 99.0 
6 101.5 99.3 
Mean 101.1 99.1 
Standard deviation 0.99 0.78 
% RSD 0.98 0.79 
 
 
5.2.4 Accuracy  
 The spectrophotometer absorbance responses for accuracy determination are 
depicted in Table 2. The result shown that best recoveries (98.82-100.61 %) of the spiked 
drug were obtained at each added concentration, indicating that the method was accurate.  
Table 2: Evaluation data of accuracy study 
 
Level (%) 
 
Amount Added 
Concentration
 a
 
(mg/ml) 
Amount Found 
Concentration
 a
 
(mg/ml) 
% Recovery % RSD 
50 0.01960 0.01953 99.65 1.82 
100 0.04040 0.03992 98.82 1.13 
150 0.06067 0.06104 100.61 0.20 
 
a
 Each value corresponds to the mean of three determinations 
 
 
Spectrophotometric…   Part-C  
 
 
209 
 
5.2.5 Solution stability study 
  Table 3 shows the results obtain in the solution stability study at different time 
intervals for test preparation. It was concluded that the test preparation solution was found 
stable up to 48 h at 2 - 5˚ C and ambient temperature, as during this time the result was 
not decrease below the minimum percentage. 
Table 3: Evaluation data of solution stability study 
 
Intervals 
% Assay for Test 
Preparation Solution 
Stored at 2-5 ˚C 
% Assay for Test Preparation 
Solution Stored at Ambient 
Temperature 
Initial 100.2 100.2 
12 h 98.7 98.7 
24 h 100.1 101.0 
36 h 100.8 100.5 
48 h 101.3 101.8 
 
5.2.6 Robustness 
  The result of robustness study of the developed assay method was established in 
Table 4. The result shown that during all variance conditions, assay value of the test 
preparation solution was not affected and it was in accordance with that of actual. System 
suitability parameters were also found satisfactory; hence the analytical method would be 
concluded as robust.  
 
Table 4: Evaluation data of robustness study 
 
Robust conditions % Assay 
Methanol: Water(78:22,v/v) 98.6 
Methanol: Water(78:22,v/v) 100.3 
Analyst change 100.4 
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5.2.7 System suitability 
  A system suitability test of the spectrophotometric system was performed before 
each validation run. Five replicate reading of standard preparation were taken and % RSD 
of standard reading were taken for same. Acceptance criteria for system suitability, % 
RSD of standard reading not more then 2.0%, were full fill during all validation 
parameter.  
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6. Calculation and data 
 
Calculation formula used: 
 
   
1. Calculation formula for % assay of ticlopidine hydrochloride 
 
 
25
10
100
Standard
Standard
%
Weight
AbsorbanceMean
AbsorbanceTestMean
Assay  
 
Standard
8.0
50500
ofPotency
ClaimLable
WeightTestMean
WeightTest
 
 
 
2. Relative standard deviation 
 
100
sMeasurmentofValueMean
sMeasurmentofDeviationStandard
RSD%  
 
 
3. Recovery 
 
100
AddedAmount
foundAmount
erycovRe%  
 
 
4. Amount found  
 
ionConcentratStandard
AreaStandardMean
AreaTestMean
)ml/mg(FoundAmount  
 
 
5. Amount added 
 
Volume
Weight
)ml/mg(AddedAmount  
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Specificity Study for Analytical Method Validation of Ticlopidine hydrochloride 
Tablets 
 
Standard Weight (mg) 9.4     
Standard Dilution 100 10 25   
Standard Potency 100 %     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration 
(mg/ml) 
0.0376     
      
Replicate 1 2 3 4 5 
Standard Area 1.011 1.011 1.01 1.012 1.012 
Mean Standard Area 1.011     
Stdev. 0.0008     
% RSD 0.08     
 
 
Replicate Test Area 
1 1.096 
2 1.097 
Mean Test Area 1.097 
Test Weight (mg) 1456.1 
Label claim (mg) 250 
Mean Test Weight (mg) 288.8 
% Assay 101.1 
 
 
Calculation: 
 
Prototype calculation for one set: 
 
25
10
100
4.9
011.1
1.096
% Assay 100
250
8.288
8.0
50
1.1456
500
 
 
              
     = 101.1 % 
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Linearity Study for Analytical Method Validation of Ticlopidine hydrochloride 
Tablets 
 
 
 
 
 
 
 
 
 
 
Standard Weight (mg) 20      
Standard Dilution 100 10 25   
Standard Potency 100.0 %     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration (mg/ml) 0.040     
Concentration of Linearity Stock 
Solution (mg/ml) 
0.100     
      
Replicate 1 2 3 4 5 
Standard Area 0.953 0956 0.958 0.959 0958 
Mean Standard Area 0.957     
Stdev 0.0021     
% RSD 0.22     
Concentration Level 
(%) 
Volume of 
Linearity stock 
solution taken 
(ml) 
Diluted to 
(ml) 
Final Concentration 
(mg/ml) 
Mean Area 
40 4.0 25 0.016 0.410 
60 6.0 25 0.024 0.480 
80 8.0 25 0.032 0.560 
100 10.0 25 0.040 0.658 
120 12.0 25 0.048 0.756 
140 14.0 25 0.056 0.850 
160 16.0 25 0.064 0.946 
  Correlation co-efficient 0.9972 
  Slope 11.30580 
  Intercept 0.21 
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Precision Study for Analytical Method Validation of Ticlopidine hydrochloride 
Tablets 
 
 
Standard Weight (mg) 9.5     
Standard Dilution 100 10 25   
Standard Potency 100.0 %     
Label Claim (mg) 250     
Mean Test Weight (mg) 290.9     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration (mg/ml) 0.038     
      
Replicate 1 2 3 4 5 
Standard Area 1.012 1.016 1.018 1.019 1.022 
Mean Standard Area 1.017     
Stdev. 0.0037     
% RSD 0.37     
 
 
 
Description Mean area Test Weight (mg) % Assay 
Set 1 1.097 292.6 101.8 
Set 2 1.074 288.4 101.2 
Set 3 1.052 288.3 99.1 
Set 4 1.083 290.4 101.3 
Set 5 1.113 297.5 101.6 
Set 6 1.078 288.4 101.5 
  Mean 101.1 
  Stdev 0.99 
  % RSD 0.98 
 
Calculation: 
 
Prototype calculation for one set: 
 
25
10
100
5.9
017.1
1.097
% Assay 100
250
9.290
8.0
50
6.292
100
 
     
    = 101.8 % 
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Intermediate precision study for Analytical Method Validation of Ticlopidine 
hydrochloride tablet 
 
 
Standard Weight (mg) 10.5     
Standard Dilution 100 10 25   
Standard Potency 100.0 %     
Label Claim (mg) 250     
Mean Test weight (mg) 288.8     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration (mg/ml) 0.042     
      
Replicate 1 2 3 4 5 
Standard Area 1.087 1.088 1.089 1.088 1.089 
Mean Standard Area 1.088     
Stdev. 286.5     
% RSD 0.79     
 
 
 
Description Mean area Test Weight (mg) % Assay 
Set 1 1.057 290.6 100.5 
Set 2 1.033 288.3 99.0 
Set 3 1.011 284.4 98.2 
Set 4 1.014 284.2 98.6 
Set 5 1.015 283.4 99.0 
Set 6 1.035 288.3 99.3 
  Mean 99.1 
  Stdev 0.78 
  % RSD 0.79 
    
 
Calculation: 
 
Prototype calculation for one set: 
 
25
10
100
5.10
088.1
1.057
% Assay 100
250
5.286
8.0
50
6.290
100
    = 100.5 % 
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Comparison for Precision and Intermediate Precision Study for Analytical Method 
Validation for Ticlopidine hydrochloride Tablets 
 
 
 Set %Assay 
Precision study 
1 101.8 
2 101.2 
3 99.1 
4 101.3 
5 101.6 
6 101.5 
Intermediate precision study 
1 100.5 
2 99.0 
3 98.2 
4 98.6 
5 99.0 
6 99.3 
 Mean 100.1 
 Stdev 1.3426 
 % RSD 1.34 
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Accuracy study for Analytical Method Validation of Ticlopidine hydrochloride 
tablets 
 
Standard Weight (mg) 10.0     
Standard Dilution 100 10 25   
Standard Potency 100.0 %     
Factor 1 298.50     
Factor 2 298.50     
Standard Concentration 
(mg/ml) 
0.040     
      
Replicate 1 2 3 4 5 
Standard Area 0.953 0.954 0.953 0.955 0.953 
Mean Standard Area 0.954     
Stdev 0.0008     
% RSD 0.09     
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Accuracy Study for Analytical Method Validation of Ticlopidine hydrochloride Tablets 
 
Recovery 
Level 
Set No. 
Mean 
area 
Wt. 
(mg) 
Volume 
(ml) 
Value added Value found % 
Recovery 
Mean % 
Recovery 
Std 
Dev 
% 
RSD Concentration(mg/ml) Concentration(mg/ml) 
50% 
Set 1 0.464 4.9 100 0.01960 0.01946 99.29 
99.65 1.81 1.82 Set 2 0.465 4.8 100 0.01920 0.01951 101.61 
Set 3 0.468 5.0 100 0.02000 0.01961 98.05 
100% 
Set 1 0.949 10.1 100 0.04040 0.03981 98.54 
98.82 1.12 1.13 Set 2 0.952 10.2 100 0.04080 0.03993 97.87 
Set 3 0.954 10.0 100 0.04000 0.04002 100.05 
150% 
Set 1 1.451 15.1 100 0.06040 0.06086 100.76 
100.61 0.20 0.20 Set 2 1.455 15.2 100 0.06080 0.06103 100.38 
Set 3 1.460 15.2 100 0.06080 0.06122 100.69 
 
Calculation: 
 
Prototype calculation for one set: 
 
100
01960.0
01946.0
covRe% ery  = 99.29 % 
 
0400.0
953.0
464.0
)/( mlmgFoundAmount  = 0.01946 mg/ml 
 
25
10
100
9.4
)/( mlmgAddedAmount  = 0.01960 mg/ml 
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Solution Stability Study for Analytical Method Validation of Ticlopidine 
hydrochloride Tablets 
 
 
 
System suitability of standard preparation for solution stability 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 0.9 1.094 1.08 1.075 1.081 
2 0.9 1.096 1.083 1.072 1.083 
3 0.901 1.097 1.084 1.073 1.084 
4 0.902 1.096 1.083 1.071 1.086 
5 0.904 1.097 1.083 1.07 1.08 
Mean 0.901 1.096 1.083 1.072 1.083 
Stdev 0.0017 0.0012 0.0015 0.0019 0.0024 
%RSD 0.19 0.11 0.14 0.18 0.22 
 
 
 
 
Solution stability for standard preparation at 2 -8°C 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1.094 1.08 1.079 1.068 
2 1.096 1.083 1.081 1.083 
3 1.097 1.084 1.075 1.08 
4 1.096 1.083 1.081 1.078 
5 1.097 1.083 1.08 1.079 
1 1.071 1.064 1.064 1.054 
2 1.073 1.067 1.063 1.052 
Mean 1.089 1.078 1.075 1.071 
Stdev 0.0118 0.0085 0.0079 0.0129 
%RSD 1.08 0.79 0.74 1.20 
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Calculation: 
Prototype calculation for one set: 
 
25
10
100
3.10
904.0
1.059
% Assay 100
250
9.290
8.0
50
6.292
100
 
 
        = 98.7 % 
Solution stability for standard preparation at room temperature 
 
After 12 hours After 24 hours After 36 hours After 48 hours 
Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area 
1 1.094 1.08 1.075 1.081 
2 1.096 1.083 1.072 1.083 
3 1.097 1.084 1.076 1.082 
4 1.096 1.083 1.079 1.078 
5 1.097 1.083 1.074 1.08 
1 1.062 1.074 1.052 1.054 
2 1.063 1.072 1.054 1.06 
Mean 1.086 1.080 1.069 1.074 
Stdev 0.0164 0.0049 0.0111 0.0118 
%RSD 1.51 0.45 1.03 1.10 
Solution stability for test preparation at room temperature 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 0.900 1.094 1.08 1.065 1.075 
2 0.900 1.096 1.083 1.068 1.074 
3 0.901 1.097 1.084 1.064 1.071 
4 0.902 1.096 1.083 1.069 1.073 
5 0.904 1.097 1.083 1.07 1.074 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 0.910 1.058 1.071 1.072 1.060 
2 0.912 1.06 1.069 1.07 1.058 
Mean 0.911 1.059 1.070 1.071 1.059 
% Assay 100.2 98.7 101.0 100.5 101.8 
Standard weight 
(mg) 
10 10.3 10.32 10.1 10.4 
Test weight (mg) 292.6 288.4 288.3 290.4 295.7 
% Difference 
compare to that of 
Initial 
 1.5 -0.7 -0.3 -1.5 
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Solution stability for test preparation at 2 -8°C 
 Initial 
After 12 
hours 
After 24 
hours 
After 36 
hours 
After 48 
hours 
 Standard Standard Standard Standard Standard 
Replicate Peak area Peak area Peak area Peak area Peak area 
1 0.900 1.094 1.08 1.073 1.065 
2 0.900 1.096 1.083 1.076 1.066 
3 0.901 1.097 1.084 1.072 1.068 
4 0.902 1.096 1.083 1.071 1.069 
5 0.904 1.097 1.083 1.071 1.072 
Replicate Test Area Test Area Test Area Test Area Test Area 
1 0.910 1.058 1.072 1.07 1.071 
2 0.912 1.060 1.070 1.068 1.069 
Mean 0.911 1.059 1.071 1.069 1.070 
% Assay 100.2 98.7 100.1 100.8 101.3 
Standard weight (mg) 10 10.3 10.2 10.2 10.2 
Test weight (mg) 292.6 288.4 288.3 290.4 295.7 
% Difference compare 
to that of Initial 
 1.5 0.2 -0.6 -1.1 
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Robustness Study for Analytical Method Validation of Ticlopidine hydrochloride Tablets 
 
 
 
Methanol: Water (72:18) Methanol: Water (72:18) Analyst Change 
Replicate Standard Area Standard Area Standard Area 
1 1.081 0.983 0.975 
2 1.08 0.983 0.976 
3 1.082 0.984 0.97 
4 1.082 0.985 0.972 
5 1.08 0.984 0.975 
Mean 1.081 0.984 0.974 
Stdev 0.00 0.00 0.0025 
% RSD 0.09 0.09 0.26 
Replicate Test Area Test Area Test Area 
1 1.026 0.977 0.977 
2 1.025 0.978 0.978 
Mean 1.026 0.978 0.978 
Standard Weight (mg) 10.4 10.1 
10.0 
Test Weight (mg) 1444.2 1444.2 
1444.2 
Label Claim (mg) 250 250 
250 
Mean Test Weight (mg) 288.8 288.8 
288.8 
% Assay 98.6 100.3 100.4 
 
Calculation: Prototype calculation for one set: 
25
10
100
4.10
081.1
1.026
% Assay 100
250
8.288
8.0
50
2.1444
500
 = 98.6 % 
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